Microbiocidal oxadiazole derivatives

ABSTRACT

Compounds of the formula (I) wherein the substituents are as defined in claim  1 , useful as pesticides, especially as fungicides.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a 371 National Stage application of InternationalApplication No. PCT/EP2017/063451, filed Jun. 2, 2017, which claimspriority to European Patent Application No. 16172974.4 filed Jun. 3,2016, the entire contents of which applications are hereby incorporatedby reference.

The present invention relates to microbiocidal oxadiazole derivatives,e.g., as active ingredients, which have microbiocidal activity, inparticular, fungicidal activity. The invention also relates toagrochemical compositions which comprise at least one of the oxadiazolederivatives, to processes of preparation of these compounds and to usesof the oxadiazole derivatives or compositions in agriculture orhorticulture for controlling or preventing infestation of plants,harvested food crops, seeds or non-living materials by phytopathogenicmicroorganisms, preferably fungi.

WO 2015/185485 describes the use of substituted oxadiazoles forcombating phytopathogenic fungi.

According to the present invention, there is provided a compound offormula (I):

wherein

n is 0, 1 or 2;

A¹ represents N or CR¹, wherein R¹ is hydrogen, halogen, methyl, ethyl,difluoromethyl, trifluoromethyl, methoxy, ethoxy, or difluoromethoxy;

A² represents N or CR², wherein R² is hydrogen, halogen, methyl, ethyl,difluoromethyl, trifluoromethyl, methoxy, ethoxy, or difluoromethoxy;

A³ represents N or CR³, wherein R³ is hydrogen or halogen; and

A⁴ represents N or CR⁴, wherein R⁴ is hydrogen or halogen;

wherein no more than two of A¹ to A⁴ are N;

R⁵ is hydrogen, C₁₋₄alkyl, C₃₋₆cycloalkyl or C₁₋₄alkoxy;

R⁶ and R⁷ are independently selected from hydrogen, cyano, C₁₋₄alkyl,C₁₋₄haloalkyl, C₃₋₆cycloalkyl and C₁₋₄alkoxy;

R⁸ represents hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,C₁₋₆haloalkyl, C₃₋₈cycloalkyl or phenyl;

R⁹ represents hydrogen, C₁₋₁₂alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,C₁₋₄haloalkyl, C₂₋₄haloalkenyl, hydroxyC₁₋₄alkyl, cyanoC₁₋₄alkyl,C₁₋₄alkoxyC₁₋₄alkyl, hydroxycarbonylC₁₋₄alkyl,C₁₋₄alkoxycarbonylC₁₋₄alkyl, aminoC₁₋₄alkyl, C₃₋₈cycloalkyl,C₃₋₈cycloalkylC₁₋₃alkyl, phenyl, phenylC₁₋₄alkyl, heterocyclyl orheterocyclylC₁₋₄alkyl wherein the heterocyclyl moiety is a 4- to6-membered non-aromatic ring which comprises 1, 2 or 3 heteroatomsindividually selected from N, O and S, and wherein C₃₋₈cycloalkyl,phenyl and heterocyclyl moieties are optionally substituted by 1, 2, or3 substituents, which may be the same or different, selected from R¹⁰,or 1, 2, 3, 4 or 5 substituents, which may be the same or different,selected from R¹¹;

R¹⁰ represents cyano, nitro, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,C₁₋₆haloalkyl, C₁₋₆alkoxy, C₁₋₆haloalkoxy, C₁₋₆alkylthio,C₁₋₄alkoxycarbonylC₁₋₄alkyl, hydroxycarbonylC₁₋₄alkyl, orC₃₋₈cycloalkyl; and

R¹¹ represents halogen;

or

a salt or an N-oxide thereof.

Surprisingly, it has been found that the novel compounds of formula (I)have, for practical purposes, a very advantageous level of biologicalactivity for protecting plants against diseases that are caused byfungi.

According to a second aspect of the invention, there is provided anagrochemical composition comprising a fungicidally effective amount of acompound of formula (I). Such an agricultural composition may furthercomprise at least one additional active ingredient and/or anagrochemically-acceptable diluent or carrier.

According to a third aspect of the invention, there is provided a methodof controlling or preventing infestation of useful plants byphytopathogenic microorganisms, wherein a fungicidally effective amountof a compound of formula (I), or a composition comprising this compoundas active ingredient, is applied to the plants, to parts thereof or thelocus thereof.

According to a fourth aspect of the invention, there is provided the useof a compound of formula (I) as a fungicide. According to thisparticular aspect of the invention, the use may exclude methods for thetreatment of the human or animal body by surgery or therapy.

As used herein, the term “halogen” or “halo” refers to fluorine(fluoro), chlorine (chloro), bromine (bromo) or iodine (iodo),preferably fluorine, chlorine or bromine.

As used herein, cyano means a —CN group.

As used herein, hydroxy means an —OH group.

As used herein, nitro means an —NO₂ group.

As used herein, the term “C₁₋₆alkyl” refers to a straight or branchedhydrocarbon chain radical consisting solely of carbon and hydrogenatoms, containing no unsaturation, having from one to six carbon atoms,and which is attached to the rest of the molecule by a single bond.C₁₋₁₂alkyl and C₁₋₄alkyl are to be construed accordingly. Examples ofC₁₋₆alkyl include, but are not limited to, methyl, ethyl, n-propyl,1-methylethyl (iso-propyl), n-butyl, and 1-dimethylethyl (t-butyl). A“C₁₋₆alkylene” group refers to the corresponding definition of C₁₋₆alkyl(and C₁₋₁₂alkyl, C₁₋₄alkyl and C₁₋₃alkyl), except that such radical isattached to the rest of the molecule by two single bonds. Examples ofC₁₋₆alkylene, include, but are not limited to, —CH₂—, —CH₂CH₂— and—(CH₂)₃—.

As used herein, the term “C₁₋₆alkoxy” refers to a radical of the formula—OR_(a) where R_(a) is a C₁₋₆alkyl radical as generally defined above.C₁₋₄alkoxy is to be construed accordingly. Examples of C₁₋₆alkoxyinclude, but are not limited to, methoxy, ethoxy, propoxy, iso-propoxy,t-butoxy.

As used herein, the term “C₁₋₆haloalkyl” refers to a C₁₋₆alkyl radicalas generally defined above substituted by one or more of the same ordifferent halogen atoms. C₁₋₄haloalkyl is to be construed accordingly.Examples of C₁₋₆haloalkyl include, but are not limited to fluoromethyl,fluoroethyl, difluoromethyl, trifluoromethyl, and 2,2,2-trifluoroethyl.

As used herein, the term “C₁₋₆haloalkoxy” refers to a C₁₋₆alkoxy groupas defined above substituted by one or more of the same or differenthalogen atoms. C₁₋₄haloalkoxy is to be construed accordingly. Examplesof C₁₋₆haloalkoxy include, but are not limited to, fluoromethoxy,difluoromethoxy, fluoroethoxy, trifluoromethoxy, and2,2,2-trifluoroethoxy.

As used herein, the term “C₂₋₆alkenyl” refers to a straight or branchedhydrocarbon chain radical group consisting solely of carbon and hydrogenatoms, containing at least one double bond that can be of either the(E)- or (Z)-configuration, having from two to six carbon atoms, which isattached to the rest of the molecule by a single bond. C₂₋₄alkenyl is tobe construed accordingly. Examples of C₂-C₆alkenyl include, but are notlimited to, prop-1-enyl, allyl (prop-2-enyl), and but-1-enyl.

As used herein, the term “C₂₋₄haloalkenyl” refers to a C₂₋₄alkenylradical as generally defined above substituted by one or more of thesame or different halogen atoms.

As used herein, the term “C₂₋₆alkynyl” refers to a straight or branchedhydrocarbon chain radical group consisting solely of carbon and hydrogenatoms, containing at least one triple bond, having from two to sixcarbon atoms, and which is attached to the rest of the molecule by asingle bond. The term “C₂₋₄alkynyl” is to be construed accordingly.Examples of C₂₋₆alkynyl include, but are not limited to, prop-1-ynyl,propargyl (prop-2-ynyl), and but-1-ynyl.

As used herein, the term “C₁₋₄alkoxyC₁₋₄alkyl” refers to radical of theformula R_(b)—O—R_(a)— where R_(b) is a C₁₋₄alkyl radical as generallydefined above, and R_(a) is a C₁₋₄alkylene radical as generally definedabove.

As used herein, the term “hydroxyC₁₋₆alkyl” refers to a C₁₋₆alkylradical as generally defined above substituted by one or more hydroxylgroups. HydroxyC₁₋₄alkyl is to be construed accordingly.

As used herein, the term “cyanoC₁₋₆alkyl” refers to refers to aC₁₋₆alkyl radical as generally defined above substituted by one or morecyano groups. CyanoC₁₋₄alkyl is to be construed accordingly.

As used herein, the term “hydroxycarbonylC₁₋₆alkyl” refers to a radicalof the formula —R_(a)C(O)OH where R_(a) is a C₁₋₆alkylene radical asgenerally defined above. The terms “hydroxycarbonylC₁₋₄alkyl” and“hydroxycarbonylC₁₋₂alkyl” are to be construed accordingly. Examples ofhydroxycarbonylC₁₋₆alkyl include, but are not limited to,hydroxycarbonylmethyl.

As used herein, the term “C₁₋₄alkoxycarbonyl” refers to a radical of theformula —C(O)OR_(a) where R_(a) is a C₁₋₄alkyl radical as generallydefined above.

As used herein, the term “C₁₋₄alkoxycarbonylC₁₋₄alkyl” refers to aradical of the formula —R_(b)C(O)OR_(a) where R_(a) is a C₁₋₄alkylradical as generally defined above and R_(b) is a C₁₋₄alkylene radicalas defined above.

As used herein, the term “C₁₋₆alkylthio” refers to a radical of theformula —SR_(a) where R_(a) is a C₁₋₆alkyl radical as generally definedabove. C₁₋₄alkylthio is to be construed accordingly.

As used herein, the term “aminoC₁₋₄alkyl” refers to a radical of theformula —R_(a)NH₂, where R_(a) is a C₁₋₄alkylene radical as definedabove. The term “aminoC₁₋₂alkyl” is to be construed accordingly.Examples of aminoC₁₋₄alkyl include, but are not limited to, aminoethyl.

As used herein, the term “C₃₋₈cycloalkyl” refers to a stable, monocyclicring radical which is saturated or partially unsaturated and contains 3to 8 carbon atoms. C₃₋₆cycloalkyl is to be construed accordingly.Examples of C₃₋₈cycloalkyl include, but are not limited to, cyclopropyl,cyclobutyl, cyclopentyl and cyclohexyl.

As used herein, the term “C₃₋₈cycloalkylC₁₋₃alkyl” refers to aC₃₋₈cycloalkyl ring as defined above attached to the rest of themolecule by a C₁₋₃alkylene radical as defined above. The terms“C₃₋₆cycloalkylC₁₋₃alkyl” and “C₃₋₄cycloalkylC₁₋₂alkyl” are to beconstrued accordingly. Examples of C₃₋₈cycloalkylC₁₋₃alkyl include, butare not limited to cyclopropyl-methyl, cyclobutyl-ethyl, andcyclopentyl-propyl.

As used herein, the term “phenylC₁₋₄alkyl” refers to a phenyl ringattached to the rest of the molecule by a C₁₋₄alkylene radical asdefined above. Examples of phenylC₁₋₄alkyl include, but are not limitedto, benzyl.

As used herein, the term “heterocyclyl” or “heterocyclic” refers to astable, 4- to 6-, and preferably a 5- or 6-membered non-aromaticmonocyclic ring radical which comprises 1, 2, or 3 heteroatomsindividually selected from nitrogen, oxygen and sulfur. The heterocyclylradical may be bonded to the rest of the molecule via a carbon atom orheteroatom. Examples of heterocyclyl include, but are not limited to,pyrrolinyl, pyrrolidyl, tetrahydrofuranyl, tetrahydrothienyl,tetrahydrothiopyranyl, piperidyl, piperazinyl, oxetanyl,tetrahydropyranyl, dioxolanyl, morpholinyl, δ-lactamyl, andperhydroazepinyl.

As used herein, the term “heterocyclylC₁₋₄alkyl” refers to aheterocyclic ring as defined above which is attached to the rest of themolecule by a C₁₋₄alkylene radical as defined above.

The presence of one or more possible asymmetric carbon atoms in acompound of formula (I) means that the compounds may occur in chiralisomeric forms, i.e., enantiomeric or diastereomeric forms. Alsoatropisomers may occur as a result of restricted rotation about a singlebond. Formula (I) is intended to include all those possible isomericforms and mixtures thereof. The present invention includes all thosepossible isomeric forms and mixtures thereof for a compound of formula(I). Likewise, formula (I) is intended to include all possible tautomers(including lactam-lactim tautomerism and keto-enol tautomerism) wherepresent. The present invention includes all possible tautomeric formsfor a compound of formula (I).

In each case, the compounds of formula (I) according to the inventionare in free form, in oxidized form as an N-oxide, in covalently hydratedform, or in salt form, e.g., an agronomically usable or agrochemicallyacceptable salt form.

N-oxides are oxidized forms of tertiary amines or oxidized forms ofnitrogen containing heteroaromatic compounds. They are described forinstance in the book “Heterocyclic N-oxides” by A. Albini and S. Pietra,CRC Press, Boca Raton 1991.

The following list provides definitions, including preferreddefinitions, for substituents n, A¹, A², A³, A⁴, R¹, R², R³, R⁴, R⁵, R⁶,R⁷, R⁸, R⁹, R¹⁰ and R¹¹, with reference to the compounds of formula (I)according to the invention. For any one of these substituents, any ofthe definitions given below may be combined with any definition of anyother substituent given below or elsewhere in this document.

n represents 0, 1 or 2. In some embodiments of the invention, n is 0. Inother embodiments of the invention, n is 1. Preferably, n represents 1or 2.

A¹ represents N or CR¹, wherein R¹ is hydrogen, halogen, methyl, ethyl,difluoromethyl, trifluoromethyl, methoxy, ethoxy, or difluoromethoxy.Preferably, A¹ is CR¹ and R¹ is hydrogen or halogen. More preferably, A¹is CR¹ and R¹ is hydrogen or fluoro.

A² represents N or CR², wherein R² is hydrogen, halogen, methyl, ethyl,difluoromethyl, trifluoromethyl, methoxy, ethoxy, or difluoromethoxy.Preferably, A² is CR² and R² is hydrogen.

A³ represents N or CR³, wherein R³ is hydrogen or halogen. Preferably,A³ is CR³ and R³ is hydrogen or halogen. More preferably, A³ is CR³ andR³ is hydrogen or fluoro.

A⁴ represents N or CR⁴, wherein R⁴ is hydrogen or halogen. Preferably,A² is CR⁴ and R⁴ is hydrogen.

In accordance with the compounds of the invention, no more than two ofA¹ to A⁴ are N.

Preferably, A¹ to A⁴ are all C—H, A² to A⁴ are all C—H and A¹ is CR¹wherein R¹ is fluoro, or A¹, A³ and A⁴ are all C—H and A² is CR² whereinR³ is fluoro, or A¹, A² and A⁴ are all C—H and A³ is CR³ wherein R³ isfluoro. Most preferably, A¹ to A⁴ are all C—H.

R⁵ is hydrogen, C₁₋₄alkyl, C₃₋₆cycloalkyl or C₁₋₄alkoxy. Preferably, R⁵is hydrogen, C₁₋₄alkyl, or C₃₋₆cycloalkyl. More preferably, hydrogen,methyl or cyclopropyl. More preferably still, R⁵ is hydrogen.

R⁶ and R⁷ are independently selected from hydrogen, cyano, C₁₋₄alkyl,C₁₋₄haloalkyl, C₃₋₆cycloalkyl and C₁₋₄alkoxy. Preferably, R⁶ and R⁷ areindependently selected from hydrogen, C₁₋₄alkyl and C₁₋₄alkoxy. Morepreferably, R⁶ and R⁷ are independently selected from hydrogen, methyland methoxy. Even more preferably, at least one of R⁶ and R⁷ is hydrogenand the other is selected from hydrogen, methyl and methoxy, preferablyhydrogen and methyl. In some embodiments of the invention, R⁶ and R⁷ areboth methyl. In a preferred embodiment of the invention, R⁶ and R⁷ areboth hydrogen.

R⁸ represents hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,C₁₋₆haloalkyl, C₃₋₈cycloalkyl or phenyl. Preferably, R⁸ is hydrogen orC₁₋₄alkyl. More preferably, R⁸ is hydrogen or methyl. Most preferably,R⁸ is hydrogen.

R⁹ represents hydrogen, C₁₋₁₂alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,C₁₋₄haloalkyl, C₂₋₄haloalkenyl, hydroxyC₁₋₄alkyl, cyanoC₁₋₄alkyl,C₁₋₄alkoxyC₁₋₄alkyl, hydroxycarbonylC₁₋₄alkyl,C₁₋₄alkoxycarbonylC₁₋₄alkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkylC₁₋₃alkyl,phenyl, phenylC₁₋₄alkyl, heterocyclyl or heterocyclylC₁₋₄alkyl, whereinthe heterocyclyl moiety is a 4- to 6-membered non-aromatic ring whichcomprises 1, 2 or 3 heteroatoms individually selected from N, O and S,and wherein C₃₋₈cycloalkyl, phenyl and heterocyclyl moieties areoptionally substituted by 1, 2, or 3 substituents, which may be the sameor different, selected from R¹⁰, or 1, 2, 3, 4 or 5 substituents, whichmay be the same or different, selected from R¹¹.

Preferably, R⁹ is hydrogen, C₁₋₁₂alkyl (e.g., C₁₋₆alkyl), C₁₋₄haloalkyl,hydroxyC₁₋₄alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₂₋₄haloalkenyl,C₁₋₄alkoxycarbonylC₁₋₄alkyl, C₃₋₈cycloalkylC₁₋₃alkyl, phenyl, benzyl,oxetanyl, tetrahydrofuranyl or tetrahydropyranyl, wherein phenylmoieties are optionally substituted by 1, 2 or 3 substituents, which maybe the same or different, selected from R¹⁰, or 1, 2, 3, 4 or 5substituents, which may be the same or different, selected from R¹¹.More preferably, R⁹ is hydrogen, C₁₋₆alkyl, C₁₋₄haloalkyl, C₂₋₆alkenyl,C₂₋₆alkynyl, or C₃₋₈cycloalkylC₁₋₃alkyl. Even more preferably, R⁹ isC₁₋₄alkyl, C₁₋₃haloalkyl, or C₃₋₆cycloalkylC₁₋₃alkyl, in particularmethyl, ethyl, isopropyl, t-butyl, 2,2,2-trifluoroethyl orcyclopropylmethyl.

R¹⁰ represents cyano, nitro, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,C₁₋₆haloalkyl, C₁₋₆alkoxy, C₁₋₆haloalkoxy, C₁₋₆alkylthio,C₁₋₄alkoxycarbonylC₁₋₄alkyl, or C₃₋₈cycloalkyl. Preferably, R¹⁰represents cyano, nitro, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl,C₁₋₄haloalkyl, C₁₋₄alkoxy, C₁₋₄haloalkoxy, C₁₋₄alkylthio,C₁₋₄alkoxycarbonylC₁₋₂alkyl, or C₃₋₆cycloalkyl. More preferably, R¹⁰represents nitro, methyl, methoxy, methoxycarbonylmethyl ortrifluoromethyl.

R¹¹ represents halogen. Preferably, R¹¹ is selected from fluoro, chloroand bromo.

Preferably, the compound according to formula (I) is selected from acompound 1.1 to 1.171 listed in Table T1 (below).

Preferably, in a compound according to formula (I) of the invention, nis 0 or 1;

-   -   A¹ to A⁴ are all C—H, A² to A⁴ are all C—H and A¹ is CR¹ wherein        R¹ is fluoro, or A¹, A² and A⁴ are all C—H and A³ is CR³ wherein        R³ is fluoro;    -   R⁵ is hydrogen or methyl;    -   R⁶ and R⁷ are independently selected from hydrogen, methyl and        methoxy;    -   R⁸ is hydrogen or methyl;    -   R⁹ is hydrogen, C₁₋₁₂alkyl, C₁₋₄haloalkyl, hydroxyC₁₋₄alkyl,        C₂₋₆alkenyl, C₂₋₆alkynyl, C₂₋₄haloalkenyl,        C₁₋₄alkoxycarbonylC₁₋₄alkyl, phenyl, benzyl, oxetanyl,        tetrahydrofuranyl or tetrahydropyranyl, wherein phenyl moieties        are optionally substituted by 1, 2 or 3 substituents, which may        be the same or different, selected from R¹⁰, or 1, 2, 3, 4 or 5        substituents, which may be the same or different, selected from        R¹¹.    -   R¹⁰ represents nitro, methyl, methoxy, methoxycarbonylmethyl or        trifluoromethyl;    -   R¹¹ represents halogen.

More preferably, n is 0 or 1;

-   -   A¹ to A⁴ are all C—H, A² to A⁴ are all C—H and A¹ is CR¹ wherein        R¹ is fluoro, or A¹, A² and A⁴ are all C—H and A³ is CR³ wherein        R³ is fluoro;    -   R⁵ is hydrogen;    -   R⁶ is hydrogen;    -   R⁷ is hydrogen, methyl or methoxy;    -   R⁸ is hydrogen or methyl;    -   R⁹ is hydrogen, C₁₋₁₂alkyl, C₁₋₄haloalkyl, hydroxyC₁₋₄alkyl,        C₂₋₆alkenyl, C₂₋₆alkynyl, C₂₋₄haloalkenyl,        C₁₋₄alkoxycarbonylC₁₋₄alkyl, phenyl, benzyl, oxetanyl,        tetrahydrofuranyl or tetrahydropyranyl, wherein phenyl moieties        are optionally substituted by 1, 2 or 3 substituents, which may        be the same or different, selected from R¹⁰, or 1, 2, 3, 4 or 5        substituents, which may be the same or different, selected from        R¹¹;    -   R¹⁰ represents nitro, methyl, methoxy, methoxycarbonylmethyl or        trifluoromethyl;    -   R¹¹ represents halogen.

Even more preferably, n is 0 or 1;

-   -   A¹ to A⁴ are all C—H, A² to A⁴ are all C—H and A¹ is CR¹ wherein        R¹ is fluoro, or A¹, A² and A⁴ are all C—H and A³ is CR³ wherein        R³ is fluoro;    -   R⁵ is hydrogen;    -   R⁶ is hydrogen;    -   R⁷ is hydrogen, methyl or methoxy;    -   R⁸ is hydrogen or methyl;    -   R⁹ is hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl or C₂₋₆alkynyl.

Still more preferably, n is 0 or 1;

-   -   A¹ to A⁴ are all C—H, A² to A⁴ are all C—H and A¹ is CR¹ wherein        R¹ is fluoro, or A¹, A² and A⁴ are all C—H and A³ is CR³ wherein        R³ is fluoro;    -   R⁵ is hydrogen;    -   R⁶ is hydrogen;    -   R⁷ is hydrogen, methyl or methoxy;    -   R⁸ is hydrogen or methyl;    -   R⁹ is hydrogen, methyl, ethyl or propyn-3-yl.    -   In a particularly preferred set of embodiments, in a compound        according to formula (I) of the invention, n is 1 or 2;    -   A¹ to A⁴ are all C—H;    -   R⁵ is hydrogen, methyl or cyclopropyl;    -   R⁶ is hydrogen;    -   R⁷ is hydrogen or methyl;    -   R⁸ is hydrogen;    -   R⁹ is methyl, ethyl, isopropyl, t-butyl, 2,2,2-trifluoroethyl or        cyclopropylmethyl.

Preferably, the compound of formula (I) according to the invention isselected from a compound 1.1 to 1.171 described in Table T1 (below).

The compounds of the present invention may be enantiomers of thecompound of formula (I) (e.g., when n=1) as represented by formula (Ia)or formula (Ib), wherein R⁶ and R⁷ are different.

Likewise, the compounds of the present invention may be diastereomers ofthe compound of formula (I) when n is 2, and wherein at each of the twocarbon positions bound to R⁶ and R⁷, R⁶ and R⁷ are different.

The compounds of the present invention may also be geometrical isomers((E) or (Z)) of the compound of formula (I) as represented by a formula(Ic) or a formula (Id).

It is understood that when in aqueous media, the compounds of formula(I) according to the invention may be present in a reversibleequilibrium with the corresponding covalently hydrated forms (i.e., thecompounds of formula (I-I) and formula (I-II) as shown below), which mayexist in tautomeric form as the compounds of formula (I-Ia) and formula(I-IIa), at the CF₃-oxadiazole motif. This dynamic equilibrium may beimportant for the biological activity of the compounds of formula (I),at the CF₃-oxadiazole motif. This dynamic equilibrium may be importantfor the biological activity of the compounds of formula (I). Thedesignations of n, A¹, A², A³, A⁴, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹,R¹⁰ and R¹¹, with reference to the compounds of formula (I) of thepresent invention apply generally to the compounds of formula (I-I) andformula (I-II), as do the specific disclosures of combinations of n, A¹,A², A³, A⁴, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰ and R¹¹, asrepresented by the compounds described in Tables 1.1 to 1.18, below, orthe compounds 1.1 to 1.171 described in Table T1 (below).

Compounds of the present invention can be made as shown in the followingschemes, in which, unless otherwise stated, the definition of eachvariable is as defined above for a compound of formula (I).

The compounds of formula (I) can be obtained by an amide couplingtransformation with compounds of formula (A) and compounds of formula(B) by activating the carboxylic acid function of the compounds offormula (A), a process that usually takes place by converting the —OH ofthe carboxylic acid into a good leaving group, such as a chloride group,for example by using (COCl)₂ or SOCl₂, prior to treatment with thecompounds of formula (B), preferably in a suitable solvent (e.g.,dimethylformamide, dichloromethane or tetrahydrofuran), preferably at atemperature of between 25° C. and 100° C., and optionally in thepresence of a base such as triethylamine or N,N-diisopropylethylamine,or under conditions described in the literature for an amide coupling.This is shown in Scheme 1 below. For examples, see Valeur, E.; Bradley,M. Chem. Soc. Rev. (2009), 38, 606 and Chinchilla, R., Najera, C. Chem.Soc. Rev. (2011), 40, 5084. Compounds of formula (A) can be made byknown methods from known compounds or are commercially available. Forexamples, see: Liu, K. et al. J. Med. Chem. (2008), 51, 7843 and WO2013/008162 A1. Compounds of formula (B) are known compounds or arecommercially available. For examples, see: Liu, K. et al. J. Med. Chem.(2008), 51, 7843 and WO 2009/030467 A1 and DE3306197.

Alternatively, compounds of formula (I) can be prepared from compoundsof formula (C) by treatment with trifluoroacetic anhydride,trifluoroacetyl fluoride or trifluoroacetyl chloride, in a suitablesolvent, such as tetrahydrofuran, at a temperature between 0° C. and 25°C. For related examples, see Kitamura, S. et al. Chem. Pharm. Bull.(2001), 49, 268. This is shown in Scheme 2.

Compounds of formula (C) can be prepared from compounds of formula (D)by treating them with a hydroxylamine hydrochloride salt in the presenceof a base, such as sodium carbonate, in a suitable solvent, such asmethanol, at a temperature between 0° C. and 100° C. For relatedexamples, see Kitamura, S. et al. Chem. Pharm. Bull. (2001), 49, 268.This is shown in Scheme 3.

Compounds of formula (D) can be made by known methods from knowncompounds. For examples, see: Chobanian, H. R. et al Tet. Lett. (2006),47, 3303; or Makovec, F. et al J. Med. Chem. (1992), 35, 3633.

Alternatively, compounds of formula (I) can be prepared from compoundsof formula (E) by treating them with compounds of formula (K) in thepresence of a base in a suitable solvent at a temperature between 0° C.and 50° C. This is shown in Scheme 4.

The compounds of formula (E) may be prepared by oxidizing thecorresponding alcohols of formula (F). Advantageous oxidation procedurescan be based on sulphur based oxidation agents (in the literaturereferred to, for example, as Swern-oxidation orPfizer-Moffat-oxidation), metal based oxidation agents or hydrogenperoxide in the presence of metal catalysts, such as Na₂WO₄ (c.f., e.g.,R. Noyori, Bull. Chem. Soc. Jpn. 1999, 72, 2287-2306). This is shown inScheme 5.

The compounds of formula (F) can be obtained by an amide couplingtransformation with compounds of formula (A) and compounds of formula(G) by activating the carboxylic acid function of the compounds offormula (A) as described in scheme 1. This is shown in Scheme 6.

The compounds of formula (E) can also be obtained by an amide couplingtransformation with compounds of formula (A) and compounds of formula(H) by activating the carboxylic acid function of the compounds offormula (A) as described in scheme 1. This is shown in Scheme 7.

Compounds of formula (Ie) where n is 0 can be obtained from compounds offormula (i) by treating them with a compound of formula (K) in thepresence of a base, such as triethylamine or N,N-diisopropylethylamine,in a suitable solvent, such as dichloromethane, preferably at atemperature of between 0° C. and 40° C. For related examples, seePetitjean, A. et al. Organic Letters (2011), Vol. 13, No. 19, 5160. Thisis shown in Scheme 8.

Compounds of formula (i) can be obtained from compounds of formula (L)by reacting them with N,N-dimethylformamide dimethylacetal (DMF-DMA), ina suitable solvent, such as benzene, toluene or the like, preferably ata temperature of between 50° C. and 140° C. whilst the methanolby-product is distilled off. For related examples, see Petitjean, A. etal. Organic Letters (2011), Vol. 13, No. 19, 5160. This is shown inScheme 9.

The compounds of formula (L) can be made by an amide couplingtransformation with compounds of formula (A) and ammonia by activatingthe carboxylic acid function of the compounds of formula (A) asdescribed in Scheme 1. This is shown in Scheme 10.

As already indicated, surprisingly, it has now been found that the novelcompounds of formula (I) of the present invention have, for practicalpurposes, a very advantageous level of biological activity forprotecting plants against diseases that are caused by fungi.

The compounds of formula (I) can be used in the agricultural sector andrelated fields of use, e.g., as active ingredients for controlling plantpests or on non-living materials for the control of spoilagemicroorganisms or organisms potentially harmful to man. The novelcompounds are distinguished by excellent activity at low rates ofapplication, by being well tolerated by plants and by beingenvironmentally safe. They have very useful curative, preventive andsystemic properties and can be used for protecting numerous cultivatedplants. The compounds of formula (I) can be used to inhibit or destroythe pests that occur on plants or parts of plants (fruit, blossoms,leaves, stems, tubers, roots) of different crops of useful plants, whileat the same time protecting also those parts of the plants that growlater, e.g., from phytopathogenic microorganisms.

The present invention further relates to a method for controlling orpreventing infestation of plants or plant propagation material and/orharvested food crops susceptible to microbial attack by treating plantsor plant propagation material and/or harvested food crops wherein aneffective amount a compound of formula (I) is applied to the plants, toparts thereof or the locus thereof.

It is also possible to use compounds of formula (I) as fungicide. Theterm “fungicide” as used herein means a compound that controls,modifies, or prevents the growth of fungi. The term “fungicidallyeffective amount” where used means the quantity of such a compound orcombination of such compounds that is capable of producing an effect onthe growth of fungi. Controlling or modifying effects include alldeviation from natural development, such as killing, retardation and thelike, and prevention includes barrier or other defensive formation in oron a plant to prevent fungal infection.

It may also be possible to use compounds of formula (I) as dressingagents for the treatment of plant propagation material, e.g., seed, suchas fruits, tubers or grains, or plant cuttings, for the protectionagainst fungal infections as well as against phytopathogenic fungioccurring in the soil. The propagation material can be treated with acomposition comprising a compound of formula (I) before planting: seed,for example, can be dressed before being sown. The active compounds offormula (I) can also be applied to grains (coating), either byimpregnating the seeds in a liquid formulation or by coating them with asolid formulation. The composition can also be applied to the plantingsite when the propagation material is being planted, for example, to theseed furrow during sowing. The invention relates also to such methods oftreating plant propagation material and to the plant propagationmaterial so treated.

Furthermore, the compounds of formula (I) can be used for controllingfungi in related areas, for example in the protection of technicalmaterials, including wood and wood related technical products, in foodstorage, in hygiene management.

In addition, the invention could be used to protect non-living materialsfrom fungal attack, e.g. lumber, wall boards and paint.

The compounds of formula (I) are for example, effective against fungiand fungal vectors of disease as well as phytopathogenic bacteria andviruses. These fungi and fungal vectors of disease as well asphytopathogenic bacteria and viruses are for example:

Absidia corymbifera, Alternaria spp, Aphanomyces spp, Ascochyta spp,Aspergillus spp. including A. flavus, A. fumigatus, A. nidulans, A.niger, A. terrus, Aureobasidium spp. including A. pullulans, Blastomycesdermatitidis, Blumeria graminis, Bremia lactucae, Botryosphaeria spp.including B. dothidea, B. obtusa, Botrytis spp. including B. cinerea,Candida spp. including C. albicans, C. glabrata, C. krusei, C.lusitaniae, C. parapsilosis, C. tropicalis, Cephaloascus fragrans,Ceratocystis spp, Cercospora spp. including C. arachidicola,Cercosporidium personatum, Cladosporium spp, Claviceps purpurea,Coccidioides immitis, Cochliobolus spp, Colletotrichum spp. including C.musae, Cryptococcus neoformans, Diaporthe spp, Didymella spp, Drechsleraspp, Elsinoe spp, Epidermophyton spp, Erwinia amylovora, Erysiphe spp.including E. cichoracearum, Eutypa lata, Fusarium spp. including F.culmorum, F. graminearum, F. langsethiae, F. moniliforme, F. oxysporum,F. proliferatum, F. subglutinans, F. solani, Gaeumannomyces graminis,Gibberella fujikuroi, Gloeodes pomigena, Gloeosporium musarum,Glomerella cingulate, Guignardia bidwellii, Gymnosporangiumjuniperi-virginianae, Helminthosporium spp, Hemileia spp, Histoplasmaspp. including H. capsulatum, Laetisaria fuciformis, Leptographiumlindbergi, Leveillula taurica, Lophodermium seditiosum, Microdochiumnivale, Microsporum spp, Monilinia spp, Mucor spp, Mycosphaerella spp.including M. graminicola, M. pomi, Oncobasidium theobromaeon, Ophiostomapiceae, Paracoccidioides spp, Penicillium spp. including P. digitatum,P. italicum, Petriellidium spp, Peronosclerospora spp. Including P.maydis, P. philippinensis and P. sorghi, Peronospora spp, Phaeosphaerianodorum, Phakopsora pachyrhizi, Phellinus igniarus, Phialophora spp,Phoma spp, Phomopsis viticola, Phytophthora spp. including P. infestans,Plasmopara spp. including P. halstedii, P. viticola, Pleospora spp.,Podosphaera spp. including P. leucotricha, Polymyxa graminis, Polymyxabetae, Pseudocercosporella herpotrichoides, Pseudomonas spp,Pseudoperonospora spp. including P. cubensis, P. humuli, Pseudopezizatracheiphila, Puccinia Spp. including P. hordei, P. recondita, P.striiformis, P. triticina, Pyrenopeziza spp, Pyrenophora spp,Pyricularia spp. including P. oryzae, Pythium spp. including P. ultimum,Ramularia spp, Rhizoctonia spp, Rhizomucor pusillus, Rhizopus arrhizus,Rhynchosporium spp, Scedosporium spp. including S. apiospermum and S.prolificans, Schizothyrium pomi, Sclerotinia spp, Sclerotium spp,Septoria spp, including S. nodorum, S. tritici, Sphaerotheca macularis,Sphaerotheca fusca (Sphaerotheca fuliginea), Sporothorix spp,Stagonospora nodorum, Stemphylium spp., Stereum hirsutum, Thanatephoruscucumeris, Thielaviopsis basicola, Tilletia spp, Trichoderma spp.including T. harzianum, T. pseudokoningii, T. viride, Trichophyton spp,Typhula spp, Uncinula necator, Urocystis spp, Ustilago spp, Venturiaspp. including V. inaequalis, Verticillium spp, and Xanthomonas spp.

The compounds of formula (I) may be used for example on turf,ornamentals, such as flowers, shrubs, broad-leaved trees or evergreens,for example conifers, as well as for tree injection, pest management andthe like.

Within the scope of present invention, target crops and/or useful plantsto be protected typically comprise perennial and annual crops, such asberry plants for example blackberries, blueberries, cranberries,raspberries and strawberries; cereals for example barley, maize (corn),millet, oats, rice, rye, sorghum triticale and wheat; fibre plants forexample cotton, flax, hemp, jute and sisal; field crops for examplesugar and fodder beet, coffee, hops, mustard, oilseed rape (canola),poppy, sugar cane, sunflower, tea and tobacco; fruit trees for exampleapple, apricot, avocado, banana, cherry, citrus, nectarine, peach, pearand plum; grasses for example Bermuda grass, bluegrass, bentgrass,centipede grass, fescue, ryegrass, St. Augustine grass and Zoysia grass;herbs such as basil, borage, chives, coriander, lavender, lovage, mint,oregano, parsley, rosemary, sage and thyme; legumes for example beans,lentils, peas and soya beans; nuts for example almond, cashew, groundnut, hazelnut, peanut, pecan, pistachio and walnut; palms for exampleoil palm; ornamentals for example flowers, shrubs and trees; othertrees, for example cacao, coconut, olive and rubber; vegetables forexample asparagus, aubergine, broccoli, cabbage, carrot, cucumber,garlic, lettuce, marrow, melon, okra, onion, pepper, potato, pumpkin,rhubarb, spinach and tomato; and vines for example grapes.

The term “useful plants” is to be understood as also including usefulplants that have been rendered tolerant to herbicides like bromoxynil orclasses of herbicides (such as, for example, HPPD inhibitors, ALSinhibitors, for example primisulfuron, prosulfuron and trifloxysulfuron,EPSPS (5-enol-pyrovyl-shikimate-3-phosphate-synthase) inhibitors, GS(glutamine synthetase) inhibitors or PPO (protoporphyrinogen-oxidase)inhibitors) as a result of conventional methods of breeding or geneticengineering. An example of a crop that has been rendered tolerant toimidazolinones, e.g. imazamox, by conventional methods of breeding(mutagenesis) is Clearfield® summer rape (Canola). Examples of cropsthat have been rendered tolerant to herbicides or classes of herbicidesby genetic engineering methods include glyphosate- andglufosinate-resistant maize varieties commercially available under thetrade names RoundupReady®, Herculex I® and LibertyLink®.

The term “useful plants” is to be understood as also including usefulplants which have been so transformed by the use of recombinant DNAtechniques that they are capable of synthesising one or more selectivelyacting toxins, such as are known, for example, from toxin-producingbacteria, especially those of the genus Bacillus.

Examples of such plants are: YieldGard® (maize variety that expresses aCryIA(b) toxin); YieldGard Rootworm® (maize variety that expresses aCryIIIB(b1) toxin); YieldGard Plus® (maize variety that expresses aCryIA(b) and a CryIIIB(b1) toxin); Starlink® (maize variety thatexpresses a Cry9(c) toxin); Herculex I® (maize variety that expresses aCryIF(a2) toxin and the enzyme phosphinothricine N-acetyltransferase(PAT) to achieve tolerance to the herbicide glufosinate ammonium);NuCOTN 33B® (cotton variety that expresses a CryIA(c) toxin); BollgardI® (cotton variety that expresses a CryIA(c) toxin); Bollgard II®(cotton variety that expresses a CryIA(c) and a CryIlA(b) toxin);VIPCOT® (cotton variety that expresses a VIP toxin); NewLeaf® (potatovariety that expresses a CryIIIA toxin); NatureGard® Agrisure® GTAdvantage (GA21 glyphosate-tolerant trait), Agrisure® CB Advantage (Bt11corn borer (CB) trait), Agrisure® RW (corn rootworm trait) andProtecta®.

The term “crops” is to be understood as including also crop plants whichhave been so transformed by the use of recombinant DNA techniques thatthey are capable of synthesising one or more selectively acting toxins,such as are known, for example, from toxin-producing bacteria,especially those of the genus Bacillus.

Toxins that can be expressed by such transgenic plants include, forexample, insecticidal proteins from Bacillus cereus or Bacilluspopilliae; or insecticidal proteins from Bacillus thuringiensis, such asδ-endotoxins, e.g. Cry1Ab, Cry1Ac, Cry1F, Cry1Fa2, Cry2Ab, Cry3A,Cry3Bb1 or Cry9C, or vegetative insecticidal proteins (Vip), e.g. Vip1,Vip2, Vip3 or Vip3A; or insecticidal proteins of bacteria colonisingnematodes, for example Photorhabdus spp. or Xenorhabdus spp., such asPhotorhabdus luminescens, Xenorhabdus nematophilus; toxins produced byanimals, such as scorpion toxins, arachnid toxins, wasp toxins and otherinsect-specific neurotoxins; toxins produced by fungi, such asStreptomycetes toxins, plant lectins, such as pea lectins, barleylectins or snowdrop lectins; agglutinins; proteinase inhibitors, such astrypsin inhibitors, serine protease inhibitors, patatin, cystatin,papain inhibitors; ribosome-inactivating proteins (RIP), such as ricin,maize-RIP, abrin, luffin, saporin or bryodin; steroid metabolismenzymes, such as 3-hydroxysteroidoxidase,ecdysteroid-UDP-glycosyl-transferase, cholesterol oxidases, ecdysoneinhibitors, HMG-COA-reductase, ion channel blockers, such as blockers ofsodium or calcium channels, juvenile hormone esterase, diuretic hormonereceptors, stilbene synthase, bibenzyl synthase, chitinases andglucanases.

Further, in the context of the present invention there are to beunderstood by δ-endotoxins, for example Cry1Ab, Cry1Ac, Cry1F, Cry1Fa2,Cry2Ab, Cry3A, Cry3Bb1 or Cry9C, or vegetative insecticidal proteins(Vip), for example Vip1, Vip2, Vip3 or Vip3A, expressly also hybridtoxins, truncated toxins and modified toxins. Hybrid toxins are producedrecombinantly by a new combination of different domains of thoseproteins (see, for example, WO 02/15701). Truncated toxins, for examplea truncated Cry1Ab, are known. In the case of modified toxins, one ormore amino acids of the naturally occurring toxin are replaced. In suchamino acid replacements, preferably non-naturally present proteaserecognition sequences are inserted into the toxin, such as, for example,in the case of Cry3A055, a cathepsin-G-recognition sequence is insertedinto a Cry3A toxin (see WO 03/018810).

Examples of such toxins or transgenic plants capable of synthesisingsuch toxins are disclosed, for example, in EP-A-0 374 753, WO93/07278,WO95/34656, EP-A-0 427 529, EP-A-451 878 and WO 03/052073.

The processes for the preparation of such transgenic plants aregenerally known to the person skilled in the art and are described, forexample, in the publications mentioned above. Cry1-type deoxyribonucleicacids and their preparation are known, for example, from WO 95/34656,EP-A-0 367 474, EP-A-0 401 979 and WO 90/13651.

The toxin contained in the transgenic plants imparts to the plantstolerance to harmful insects. Such insects can occur in any taxonomicgroup of insects, but are especially commonly found in the beetles(Coleoptera), two-winged insects (Diptera) and butterflies(Lepidoptera).

Transgenic plants containing one or more genes that code for aninsecticidal resistance and express one or more toxins are known andsome of them are commercially available. Examples of such plants are:YieldGard® (maize variety that expresses a Cry1Ab toxin); YieldGardRootworm® (maize variety that expresses a Cry3Bb1 toxin); YieldGardPlus® (maize variety that expresses a Cry1Ab and a Cry3Bb1 toxin);Starlink® (maize variety that expresses a Cry9C toxin); Herculex I®(maize variety that expresses a Cry1Fa2 toxin and the enzymephosphinothricine N-acetyltransferase (PAT) to achieve tolerance to theherbicide glufosinate ammonium); NuCOTN 33B® (cotton variety thatexpresses a Cry1Ac toxin); Bollgard I® (cotton variety that expresses aCry1Ac toxin); Bollgard II® (cotton variety that expresses a Cry1Ac anda Cry2Ab toxin); VipCot® (cotton variety that expresses a Vip3A and aCry1Ab toxin); NewLeaf® (potato variety that expresses a Cry3A toxin);NatureGard®, Agrisure® GT Advantage (GA21 glyphosate-tolerant trait),Agrisure® CB Advantage (Bt11 corn borer (CB) trait) and Protecta®.

Further examples of such transgenic crops are:

1. Bt11 Maize from Syngenta Seeds SAS, Chemin de l'Hobit 27, F-31 790St. Sauveur, France, registration number C/FR/96/05/10. Geneticallymodified Zea mays which has been rendered resistant to attack by theEuropean corn borer (Ostrinia nubilalis and Sesamia nonagrioides) bytransgenic expression of a truncated Cry1Ab toxin. Bt11 maize alsotransgenically expresses the enzyme PAT to achieve tolerance to theherbicide glufosinate ammonium.2. Bt176 Maize from Syngenta Seeds SAS, Chemin de l'Hobit 27, F-31 790St. Sauveur, France, registration number C/FR/96/05/10. Geneticallymodified Zea mays which has been rendered resistant to attack by theEuropean corn borer (Ostrinia nubilalis and Sesamia nonagrioides) bytransgenic expression of a Cry1Ab toxin. Bt176 maize also transgenicallyexpresses the enzyme PAT to achieve tolerance to the herbicideglufosinate ammonium.3. MIR604 Maize from Syngenta Seeds SAS, Chemin de l'Hobit 27, F-31 790St. Sauveur, France, registration number C/FR/96/05/10. Maize which hasbeen rendered insect-resistant by transgenic expression of a modifiedCry3A toxin. This toxin is Cry3A055 modified by insertion of acathepsin-G-protease recognition sequence. The preparation of suchtransgenic maize plants is described in WO 03/018810.4. MON 863 Maize from Monsanto Europe S.A. 270-272 Avenue de Tervuren,B-1150 Brussels, Belgium, registration number C/DE/02/9. MON 863expresses a Cry3Bb1 toxin and has resistance to certain Coleopterainsects.5. IPC 531 Cotton from Monsanto Europe S.A. 270-272 Avenue de Tervuren,B-1150 Brussels, Belgium, registration number C/ES/96/02.6. 1507 Maize from Pioneer Overseas Corporation, Avenue Tedesco, 7B-1160 Brussels, Belgium, registration number C/NL/00/10. Geneticallymodified maize for the expression of the protein Cry1F for achievingresistance to certain Lepidoptera insects and of the PAT protein forachieving tolerance to the herbicide glufosinate ammonium.7. NK603×MON 810 Maize from Monsanto Europe S.A. 270-272 Avenue deTervuren, B-1150 Brussels, Belgium, registration number C/GB/02/M3/03.Consists of conventionally bred hybrid maize varieties by crossing thegenetically modified varieties NK603 and MON 810. NK603×MON 810 Maizetransgenically expresses the protein CP4 EPSPS, obtained fromAgrobacterium sp. strain CP4, which imparts tolerance to the herbicideRoundup® (contains glyphosate), and also a Cry1Ab toxin obtained fromBacillus thuringiensis subsp. kurstaki which brings about tolerance tocertain Lepidoptera, include the European corn borer.

The term “locus” as used herein means fields in or on which plants aregrowing, or where seeds of cultivated plants are sown, or where seedwill be placed into the soil. It includes soil, seeds, and seedlings, aswell as established vegetation.

The term “plants” refers to all physical parts of a plant, includingseeds, seedlings, saplings, roots, tubers, stems, stalks, foliage, andfruits.

The term “plant propagation material” is understood to denote generativeparts of the plant, such as seeds, which can be used for themultiplication of the latter, and vegetative material, such as cuttingsor tubers, for example potatoes. There can be mentioned for exampleseeds (in the strict sense), roots, fruits, tubers, bulbs, rhizomes andparts of plants. Germinated plants and young plants which are to betransplanted after germination or after emergence from the soil, mayalso be mentioned. These young plants can be protected beforetransplantation by a total or partial treatment by immersion. Preferably“plant propagation material” is understood to denote seeds.

The compounds of formula I may be used in unmodified form or,preferably, together with the adjuvants conventionally employed in theart of formulation. To this end they may be conveniently formulated inknown manner to emulsifiable concentrates, coatable pastes, directlysprayable or dilutable solutions or suspensions, dilute emulsions,wettable powders, soluble powders, dusts, granulates, and alsoencapsulations e.g. in polymeric substances. As with the type of thecompositions, the methods of application, such as spraying, atomising,dusting, scattering, coating or pouring, are chosen in accordance withthe intended objectives and the prevailing circumstances. Thecompositions may also contain further adjuvants such as stabilizers,antifoams, viscosity regulators, binders or tackifiers as well asfertilizers, micronutrient donors or other formulations for obtainingspecial effects.

Suitable carriers and adjuvants, e.g. for agricultural use, can be solidor liquid and are substances useful in formulation technology, e.g.natural or regenerated mineral substances, solvents, dispersants,wetting agents, tackifiers, thickeners, binders or fertilizers. Suchcarriers are for example described in WO 97/33890.

Suspension concentrates are aqueous formulations in which finely dividedsolid particles of the active compound are suspended. Such formulationsinclude anti-settling agents and dispersing agents and may furtherinclude a wetting agent to enhance activity as well an anti-foam and acrystal growth inhibitor. In use, these concentrates are diluted inwater and normally applied as a spray to the area to be treated. Theamount of active ingredient may range from 0.5% to 95% of theconcentrate.

Wettable powders are in the form of finely divided particles whichdisperse readily in water or other liquid carriers. The particlescontain the active ingredient retained in a solid matrix. Typical solidmatrices include fuller's earth, kaolin clays, silicas and other readilywet organic or inorganic solids. Wettable powders normally contain from5% to 95% of the active ingredient plus a small amount of wetting,dispersing or emulsifying agent.

Emulsifiable concentrates are homogeneous liquid compositionsdispersible in water or other liquid and may consist entirely of theactive compound with a liquid or solid emulsifying agent, or may alsocontain a liquid carrier, such as xylene, heavy aromatic naphthas,isophorone and other non-volatile organic solvents. In use, theseconcentrates are dispersed in water or other liquid and normally appliedas a spray to the area to be treated. The amount of active ingredientmay range from 0.5% to 95% of the concentrate.

Granular formulations include both extrudates and relatively coarseparticles and are usually applied without dilution to the area in whichtreatment is required. Typical carriers for granular formulationsinclude sand, fuller's earth, attapulgite clay, bentonite clays,montmorillonite clay, vermiculite, perlite, calcium carbonate, brick,pumice, pyrophyllite, kaolin, dolomite, plaster, wood flour, ground corncobs, ground peanut hulls, sugars, sodium chloride, sodium sulphate,sodium silicate, sodium borate, magnesia, mica, iron oxide, zinc oxide,titanium oxide, antimony oxide, cryolite, gypsum, diatomaceous earth,calcium sulphate and other organic or inorganic materials which absorbor which can be coated with the active compound. Granular formulationsnormally contain 5% to 25% of active ingredients which may includesurface-active agents such as heavy aromatic naphthas, kerosene andother petroleum fractions, or vegetable oils; and/or stickers such asdextrins, glue or synthetic resins.

Dusts are free-flowing admixtures of the active ingredient with finelydivided solids such as talc, clays, flours and other organic andinorganic solids which act as dispersants and carriers.

Microcapsules are typically droplets or granules of the activeingredient enclosed in an inert porous shell which allows escape of theenclosed material to the surroundings at controlled rates. Encapsulateddroplets are typically 1 to 50 microns in diameter. The enclosed liquidtypically constitutes 50% to 95% of the weight of the capsule and mayinclude solvent in addition to the active compound. Encapsulatedgranules are generally porous granules with porous membranes sealing thegranule pore openings, retaining the active species in liquid forminside the granule pores. Granules typically range from 1 millimetre to1 centimetre and preferably 1 to 2 millimetres in diameter. Granules areformed by extrusion, agglomeration or prilling, or are naturallyoccurring. Examples of such materials are vermiculite, sintered clay,kaolin, attapulgite clay, sawdust and granular carbon. Shell or membranematerials include natural and synthetic rubbers, cellulosic materials,styrene-butadiene copolymers, polyacrylonitriles, polyacrylates,polyesters, polyamides, polyureas, polyurethanes and starch xanthates.

Other useful formulations for agrochemical applications include simplesolutions of the active ingredient in a solvent in which it iscompletely soluble at the desired concentration, such as acetone,alkylated naphthalenes, xylene and other organic solvents. Pressurisedsprayers, wherein the active ingredient is dispersed in finely-dividedform as a result of vaporisation of a low boiling dispersant solventcarrier, may also be used.

Suitable agricultural adjuvants and carriers that are useful informulating the compositions of the invention in the formulation typesdescribed above are well known to those skilled in the art.

Liquid carriers that can be employed include, for example, water,toluene, xylene, petroleum naphtha, crop oil, acetone, methyl ethylketone, cyclohexanone, acetic anhydride, acetonitrile, acetophenone,amyl acetate, 2-butanone, chlorobenzene, cyclohexane, cyclohexanol,alkyl acetates, diacetonalcohol, 1,2-dichloropropane, diethanolamine,p-diethylbenzene, diethylene glycol, diethylene glycol abietate,diethylene glycol butyl ether, diethylene glycol ethyl ether, diethyleneglycol methyl ether, N,N-dimethyl formamide, dimethyl sulfoxide,1,4-dioxane, dipropylene glycol, dipropylene glycol methyl ether,dipropylene glycol dibenzoate, diproxitol, alkyl pyrrolidinone, ethylacetate, 2-ethyl hexanol, ethylene carbonate, 1,1,1-trichloroethane,2-heptanone, alpha pinene, d-limonene, ethylene glycol, ethylene glycolbutyl ether, ethylene glycol methyl ether, gamma-butyrolactone,glycerol, glycerol diacetate, glycerol monoacetate, glycerol triacetate,hexadecane, hexylene glycol, isoamyl acetate, isobornyl acetate,isooctane, isophorone, isopropyl benzene, isopropyl myristate, lacticacid, laurylamine, mesityl oxide, methoxy-propanol, methyl isoamylketone, methyl isobutyl ketone, methyl laurate, methyl octanoate, methyloleate, methylene chloride, m-xylene, n-hexane, n-octylamine,octadecanoic acid, octyl amine acetate, oleic acid, oleylamine,o-xylene, phenol, polyethylene glycol (PEG400), propionic acid,propylene glycol, propylene glycol monomethyl ether, p-xylene, toluene,triethyl phosphate, triethylene glycol, xylene sulfonic acid, paraffin,mineral oil, trichloroethylene, perchloroethylene, ethyl acetate, amylacetate, butyl acetate, methanol, ethanol, isopropanol, and highermolecular weight alcohols such as amyl alcohol, tetrahydrofurfuanrylalcohol, hexanol, octanol, etc., ethylene glycol, propylene glycol,glycerine and N-methyl-2-pyrrolidinone. Water is generally the carrierof choice for the dilution of concentrates.

Suitable solid carriers include, for example, talc, titanium dioxide,pyrophyllite clay, silica, attapulgite clay, kieselguhr, chalk,diatomaxeous earth, lime, calcium carbonate, bentonite clay, fuller'searth, cotton seed hulls, wheat flour, soybean flour, pumice, woodflour, walnut shell flour and lignin.

A broad range of surface-active agents are advantageously employed inboth said liquid and solid compositions, especially those designed to bediluted with carrier before application. These agents, when used,normally comprise from 0.1% to 15% by weight of the formulation. Theycan be anionic, cationic, non-ionic or polymeric in character and can beemployed as emulsifying agents, wetting agents, suspending agents or forother purposes. Typical surface active agents include salts of alkylsulfates, such as diethanolammonium lauryl sulphate; alkylarylsulfonatesalts, such as calcium dodecylbenzenesulfonate; alkylphenol-alkyleneoxide addition products, such as nonylphenol-C.sub. 18 ethoxylate;alcohol-alkylene oxide addition products, such as tridecylalcohol-C.sub. 16 ethoxylate; soaps, such as sodium stearate;alkylnaphthalenesulfonate salts, such as sodiumdibutylnaphthalenesulfonate; dialkyl esters of sulfosuccinate salts,such as sodium di(2-ethylhexyl) sulfosuccinate; sorbitol esters, such assorbitol oleate; quaternary amines, such as lauryl trimethylammoniumchloride; polyethylene glycol esters of fatty acids, such aspolyethylene glycol stearate; block copolymers of ethylene oxide andpropylene oxide; and salts of mono and dialkyl phosphate esters.

Other adjuvants commonly utilized in agricultural compositions includecrystallisation inhibitors, viscosity modifiers, suspending agents,spray droplet modifiers, pigments, antioxidants, foaming agents,anti-foaming agents, light-blocking agents, compatibilizing agents,antifoam agents, sequestering agents, neutralising agents and buffers,corrosion inhibitors, dyes, odorants, spreading agents, penetrationaids, micronutrients, emollients, lubricants and sticking agents.

In addition, further, other biocidally active ingredients orcompositions may be combined with the compositions of the invention andused in the methods of the invention and applied simultaneously orsequentially with the compositions of the invention. When appliedsimultaneously, these further active ingredients may be formulatedtogether with the compositions of the invention or mixed in, forexample, the spray tank. These further biocidally active ingredients maybe fungicides, herbicides, insecticides, bactericides, acaricides,nematicides and/or plant growth regulators.

Pesticidal agents are referred to herein using their common name areknown, for example, from “The Pesticide Manual”, 15th Ed., British CropProtection Council 2009.

In addition, the compositions of the invention may also be applied withone or more systemically acquired resistance inducers (“SAR” inducer).SAR inducers are known and described in, for example, U.S. Pat. No.6,919,298 and include, for example, salicylates and the commercial SARinducer acibenzolar-S-methyl.

The compounds of formula (I) are normally used in the form ofagrochemical compositions and can be applied to the crop area or plantto be treated, simultaneously or in succession with further compounds.These further compounds can be e.g. fertilizers or micronutrient donorsor other preparations, which influence the growth of plants. They canalso be selective herbicides or non-selective herbicides as well asinsecticides, fungicides, bactericides, nematicides, molluscicides ormixtures of several of these preparations, if desired together withfurther carriers, surfactants or application promoting adjuvantscustomarily employed in the art of formulation.

The compounds of formula (I) may be used in the form of (fungicidal)compositions for controlling or protecting against phytopathogenicmicroorganisms, comprising as active ingredient at least one compound offormula (I) or of at least one preferred individual compound as definedherein, in free form or in agrochemically usable salt form, and at leastone of the above-mentioned adjuvants.

The invention therefore provides a composition, preferably a fungicidalcomposition, comprising at least one compound formula (I) anagriculturally acceptable carrier and optionally an adjuvant. Anagricultural acceptable carrier is for example a carrier that issuitable for agricultural use. Agricultural carriers are well known inthe art. Preferably said composition may comprise at least one or morepesticidally-active compounds, for example an additional fungicidalactive ingredient in addition to the compound of formula (I).

The compound of formula (I) may be the sole active ingredient of acomposition or it may be admixed with one or more additional activeingredients such as a pesticide, fungicide, synergist, herbicide orplant growth regulator where appropriate. An additional activeingredient may, in some cases, result in unexpected synergisticactivities.

Examples of suitable additional active ingredients include thefollowing: acycloamino acid fungicides, aliphatic nitrogen fungicides,amide fungicides, anilide fungicides, antibiotic fungicides, aromaticfungicides, arsenical fungicides, aryl phenyl ketone fungicides,benzamide fungicides, benzanilide fungicides, benzimidazole fungicides,benzothiazole fungicides, botanical fungicides, bridged diphenylfungicides, carbamate fungicides, carbanilate fungicides, conazolefungicides, copper fungicides, dicarboximide fungicides, dinitrophenolfungicides, dithiocarbamate fungicides, dithiolane fungicides, furamidefungicides, furanilide fungicides, hydrazide fungicides, imidazolefungicides, mercury fungicides, morpholine fungicides, organophosphorousfungicides, organotin fungicides, oxathiin fungicides, oxazolefungicides, phenylsulfamide fungicides, polysulfide fungicides, pyrazolefungicides, pyridine fungicides, pyrimidine fungicides, pyrrolefungicides, quaternary ammonium fungicides, quinoline fungicides,quinone fungicides, quinoxaline fungicides, strobilurin fungicides,sulfonanilide fungicides, thiadiazole fungicides, thiazole fungicides,thiazolidine fungicides, thiocarbamate fungicides, thiophene fungicides,triazine fungicides, triazole fungicides, triazolopyrimidine fungicides,urea fungicides, valinamide fungicides, and zinc fungicides.

Examples of suitable additional active ingredients also include thefollowing: 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid(9-dichloromethylene-1,2,3,4-tetrahydro-1,4-methano-naphthalen-5-yl)-amide,3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acidmethoxy-[1-methyl-2-(2,4,6-trichlorophenyl)-ethyl]-amide,1-methyl-3-difluoromethyl-1H-pyrazole-4-carboxylic acid(2-dichloromethylene-3-ethyl-1-methyl-indan-4-yl)-amide (1072957-71-1),1-methyl-3-difluoromethyl-1H-pyrazole-4-carboxylic acid(4′-methylsulfanyl-biphenyl-2-yl)-amide,1-methyl-3-difluoromethyl-4H-pyrazole-4-carboxylic acid[2-(2,4-dichloro-phenyl)-2-methoxy-1-methyl-ethyl]-amide,(5-Chloro-2,4-dimethyl-pyridin-3-yl)-(2,3,4-trimethoxy-6-methyl-phenyl)-methanone,(5-Bromo-4-chloro-2-methoxy-pyridin-3-yl)-(2,3,4-trimethoxy-6-methyl-phenyl)-methanone,2-{2-[(E)-3-(2,6-Dichloro-phenyl)-1-methyl-prop-2-en-(E)-ylideneaminooxymethyl]-phenyl}-2-[(Z)-methoxyimino]-N-methyl-acetamide,3-[5-(4-Chloro-phenyl)-2,3-dimethyl-isoxazolid in-3-yl]-pyridine,(E)-N-methyl-2-[2-(2, 5-dimethylphenoxymethyl)phenyl]-2-methoxy-iminoacetamide, 4-bromo-2-cyano-N,N-dimethyl-6-trifluoromethylbenzimidazole-1-sulphonamide,a-[N-(3-chloro-2, 6-xylyl)-2-methoxyacetamido]-y-butyrolactone,4-chloro-2-cyano-N, -dimethyl-5-p-tolylimidazole-1-sulfonamide,N-allyl-4, 5,-dimethyl-2-trimethylsilylthiophene-3-carboxamide,N-(I-cyano-1,2-dimethylpropyl)-2-(2, 4-dichlorophenoxy) propionamide,N-(2-methoxy-5-pyridyl)-cyclopropane carboxamide,(.+−.)-cis-1-(4-chlorophenyl)-2-(1H-1,2,4-triazol-1-yl)-cycloheptanol,2-(1-tert-butyl)-1-(2-chlorophenyl)-3-(1,2,4-triazol-1-yl)-propan-2-ol,2′,6′-dibromo-2-methyl-4-trifluoromethoxy-4′-trifluoromethyl-1,3-thiazole-5-carboxanilide,1-imidazolyl-1-(4′-chlorophenoxy)-3,3-dimethylbutan-2-one, methyl(E)-2-[2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl]3-methoxyacrylate,methyl(E)-2-[2-[6-(2-thioamidophenoxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate,methyl(E)-2-[2-[6-(2-fluorophenoxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate,methyl(E)-2-[2-[6-(2,6-difluorophenoxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate,methyl (E)-2-[2-[3-(pyrimidin-2-yloxy)phenoxy]phenyl]-3-methoxyacrylate,methyl(E)-2-[2-[3-(5-methylpyrimidin-2-yloxy)-phenoxy]phenyl]-3-methoxyacrylate,methyl(E)-2-[2-[3-(phenyl-sulphonyloxy)phenoxy]phenyl-3-methoxyacrylate,methyl (E)-2-[2-[3-(4-nitrophenoxy)phenoxy]phenyl]-3-methoxyacrylate,methyl (E)-2-[2-phenoxyphenyl]-3-methoxyacrylate, methyl(E)-2-[2-(3,5-dimethyl-benzoyl)pyrrol-1-yl]-3-methoxyacrylate, methyl(E)-2-[2-(3-methoxyphenoxy)phenyl]-3-methoxyacrylate, methyl(E)-2-[2-(2-phenylethen-1-yl)-phenyl]-3-methoxyacrylate, methyl(E)-2-[2-(3,5-dichlorophenoxy)pyridin-3-yl]-3-methoxyacrylate, methyl(E)-2-(2-(3-(1,1,2,2-tetrafluoroethoxy)phenoxy)phenyl)-3-methoxyacrylate,methyl(E)-2-(2-[3-(alpha-hydroxybenzyl)phenoxy]phenyl)-3-methoxyacrylate,methyl (E)-2-(2-(4-phenoxypyridin-2-yloxy)phenyl)-3-methoxyacrylate,methyl (E)-2-[2-(3-n-propyloxy-phenoxy)phenyl]3-methoxyacrylate, methyl(E)-2-[2-(3-isopropyloxyphenoxy)phenyl]-3-methoxyacrylate, methyl(E)-2-[2-[3-(2-fluorophenoxy)phenoxy]phenyl]-3-methoxyacrylate, methyl(E)-2-[2-(3-ethoxyphenoxy)phenyl]-3-methoxyacrylate, methyl(E)-2-[2-(4-tert-butyl-pyridin-2-yloxy)phenyl]-3-methoxyacrylate, methyl(E)-2-[2-[3-(3-cyanophenoxy)phenoxy]phenyl]-3-methoxyacrylate, methyl(E)-2-[2-[(3-methyl-pyridin-2-yloxymethyl)phenyl]-3-methoxyacrylate,methyl(E)-2-[2-[6-(2-methyl-phenoxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate,methyl(E)-2-[2-(5-bromo-pyridin-2-yloxymethyl)phenyl]-3-methoxyacrylate,methyl(E)-2-[2-(3-(3-iodopyridin-2-yloxy)phenoxy)phenyl]-3-methoxyacrylate,methyl(E)-2-[2-[6-(2-chloropyridin-3-yloxy)pyrimidin-4-yloxy]phenyl]-3-methoxyacrylate,methyl (E),(E)-2-[2-(5,6-dimethylpyrazin-2-ylmethyloximinomethyl)phenyl]-3-methoxyacrylate, methyl(E)-2-{2-[6-(6-methylpyridin-2-yloxy)pyrimidin-4-yloxy]phenyl}-3-methoxy-acrylate,methyl(E),(E)-2-{2-(3-methoxyphenyl)methyloximinomethyl]-phenyl}-3-methoxyacrylate,methyl(E)-2-{2-(6-(2-azidophenoxy)-pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate,methyl(E),(E)-2-{2-[6-phenylpyrimidin-4-yl)-methyloximinomethyl]phenyl}-3-methoxyacrylate,methyl(E),(E)-2-{2-[(4-chlorophenyl)-methyloximinomethyl]-phenyl}-3-methoxyacrylate,methyl(E)-2-{2-[6-(2-n-propylphenoxy)-1,3,5-triazin-4-yloxy]phenyl}-3-methoxyacrylate,methyl(E),(E)-2-{2-[(3-nitrophenyl)methyloximinomethyl]phenyl}-3-methoxyacrylate,3-chloro-7-(2-aza-2,7,7-trimethyl-oct-3-en-5-ine),2,6-dichloro-N-(4-trifluoromethylbenzyl)-benzamide,3-iodo-2-propinylalcohol, 4-chlorophenyl-3-iodopropargyl formal,3-bromo-2,3-diiodo-2-propenyl ethylcarbamate, 2,3,3-triiodoallylalcohol, 3-bromo-2,3-diiodo-2-propenyl alcohol, 3-iodo-2-propinyln-butylcarbamate, 3-iodo-2-propinyl n-hexylcarbamate, 3-iodo-2-propinylcyclohexyl-carbamate, 3-iodo-2-propinyl phenylcarbamate; phenolderivatives, such as tribromophenol, tetrachlorophenol,3-methyl-4-chlorophenol, 3,5-dimethyl-4-chlorophenol, phenoxyethanol,dichlorophene, o-phenylphenol, m-phenylphenol, p-phenylphenol,2-benzyl-4-chlorophenol, 5-hydroxy-2(5H)-furanone;4,5-dichlorodithiazolinone, 4,5-benzodithiazolinone,4,5-trimethylenedithiazolinone, 4,5-dichloro-(3H)-1,2-dithiol-3-one,3,5-dimethyl-tetrahydro-1,3,5-thiadiazine-2-thione,N-(2-p-chlorobenzoylethyl)-hexaminium chloride, acibenzolar, acypetacs,alanycarb, albendazole, aldimorph, allicin, allyl alcohol, ametoctradin,amisulbrom, amobam, ampropylfos, anilazine, asomate, aureofungin,azaconazole, azafendin, azithiram, azoxystrobin, barium polysulfide,benalaxyl, benalaxyl-M, benodanil, benomyl, benquinox, bentaluron,benthiavalicarb, benthiazole, benzalkonium chloride, benzamacril,benzamorf, benzohydroxamic acid, benzovindiflupyr, berberine,bethoxazin, biloxazol, binapacryl, biphenyl, bitertanol, bithionol,bixafen, blasticidin-S, boscalid, bromothalonil, bromuconazole,bupirimate, buthiobate, butylamine calcium polysulfide, captafol,captan, carbamorph, carbendazim, carbendazim chlorhydrate, carboxin,carpropamid, carvone, CGA41396, CGA41397, chinomethionate, chitosan,chlobenthiazone, chloraniformethan, chloranil, chlorfenazole, chloroneb,chloropicrin, chlorothalonil, chlorozolinate, chlozolinate, climbazole,clotrimazole, clozylacon, copper containing compounds such as copperacetate, copper carbonate, copper hydroxide, copper naphthenate, copperoleate, copper oxychloride, copper oxyquinolate, copper silicate, coppersulphate, copper tallate, copper zinc chromate and Bordeaux mixture,cresol, cufraneb, cuprobam, cuprous oxide, cyazofamid, cyclafuramid,cycloheximide, cyflufenamid, cymoxanil, cypendazole, cyproconazole,cyprodinil, dazomet, debacarb, decafentin, dehydroacetic acid,di-2-pyridyl disulphide 1, 1′-dioxide, dichlofluanid, diclomezine,dichlone, dicloran, dichlorophen, dichlozoline, diclobutrazol,diclocymet, diethofencarb, difenoconazole, difenzoquat, diflumetorim,O-di-iso-propyl-S-benzyl thiophosphate, dimefluazole, dimetachlone,dimetconazole, dimethomorph, dimethirimol, diniconazole, diniconazole-M,dinobuton, dinocap, dinocton, dinopenton, dinosulfon, dinoterbon,diphenylamine, dipyrithione, disulfiram, ditalimfos, dithianon,dithioether, dodecyl dimethyl ammonium chloride, dodemorph, dodicin,dodine, doguadine, drazoxolon, edifenphos, enestroburin, epoxiconazole,etaconazole, etem, ethaboxam, ethirimol, ethoxyquin, ethilicin, ethyl(Z)—N-benzyl-N([methyl (methyl-thioethylideneamino-oxycarbonyl) amino]thio)-ß-alaninate, etridiazole, famoxadone, fenamidone, fenaminosulf,fenapanil, fenarimol, fenbuconazole, fenfuram, fenhexamid, fenitropan,fenoxanil, fenpiclonil, fenpicoxamid, fenpropidin, fenpropimorph,fenpyrazamine, fentin acetate, fentin hydroxide, ferbam, ferimzone,fluazinam, fludioxonil, flumetover, flumorph, flupicolide, fluopyram,fluoroimide, fluotrimazole, fluoxastrobin, fluquinconazole, flusilazole,flusulfamide, flutanil, flutolanil, flutriafol, fluxapyroxad, folpet,formaldehyde, fosetyl, fuberidazole, furalaxyl, furametpyr, furcarbanil,furconazole, furfural, furmecyclox, furophanate, glyodin, griseofulvin,guazatine, halacrinate, hexachlorobenzene, hexachlorobutadiene,hexachlorophene, hexaconazole, hexylthiofos, hydrargaphen,hydroxyisoxazole, hymexazole, imazalil, imazalil sulphate,imibenconazole, iminoctadine, iminoctadine triacetate, inezin, iodocarb,ipconazole, ipfentrifluconazole, iprobenfos, iprodione, iprovalicarb,isopropanyl butyl carbamate, isoprothiolane, isopyrazam, isotianil,isovaledione, izopamfos, kasugamycin, kresoxim-methyl, LY186054,LY211795, LY248908, mancozeb, mandipropamid, maneb, mebenil,mecarbinzid, mefenoxam, mefentrifluconazole, mepanipyrim, mepronil,mercuric chloride, mercurous chloride, meptyldinocap, metalaxyl,metalaxyl-M, metam, metazoxolon, metconazole, methasulfocarb,methfuroxam, methyl bromide, methyl iodide, methyl isothiocyanate,metiram, metiram-zinc, metominostrobin, metrafenone, metsulfovax,milneb, moroxydine, myclobutanil, myclozolin, nabam, natamycin,neoasozin, nickel dimethyldithiocarbamate, nitrostyrene,nitrothal-iso-propyl, nuarimol, octhilinone, ofurace, organomercurycompounds, orysastrobin, osthol, oxadixyl, oxasulfuron, oxathiapiprolin,oxine-copper, oxolinic acid, oxpoconazole, oxycarboxin, parinol,pefurazoate, penconazole, pencycuron, penflufen, pentachlorophenol,penthiopyrad, phenamacril, phenazin oxide, phosdiphen, phosetyl-AI,phosphorus acids, phthalide, picoxystrobin, piperalin, polycarbamate,polyoxin D, polyoxrim, polyram, probenazole, prochloraz, procymidone,propamidine, propamocarb, propiconazole, propineb, propionic acid,proquinazid, prothiocarb, prothioconazole, pydiflumetofen, pyracarbolid,pyraclostrobin, pyrametrostrobin, pyraoxystrobin, pyrazophos,pyribencarb, pyridinitril, pyrifenox, pyrimethanil, pyriofenone,pyroquilon, pyroxychlor, pyroxyfur, pyrrolnitrin, quaternary ammoniumcompounds, quinacetol, quinazamid, quinconazole, quinomethionate,quinoxyfen, quintozene, rabenzazole, santonin, sedaxane, silthiofam,simeconazole, sipconazole, sodium pentachlorophenate, spiroxamine,streptomycin, sulphur, sultropen, tebuconazole, tebfloquin, tecloftalam,tecnazene, tecoram, tetraconazole, thiabendazole, thiadifluor,thicyofen, thifluzamide, 2-(thiocyanomethylthio) benzothiazole,thiophanate-methyl, thioquinox, thiram, tiadinil, timibenconazole,tioxymid, tolclofos-methyl, tolylfluanid, triadimefon, triadimenol,triamiphos, triarimol, triazbutil, triazoxide, tricyclazole, tridemorph,trifloxystrobin, triflumazole, triforine, triflumizole, triticonazole,uniconazole, urbacide, validamycin, valifenalate, vapam, vinclozolin,zarilamid, zineb, ziram, and zoxamide.

The compounds of the invention may also be used in combination withanthelmintic agents. Such anthelmintic agents include, compoundsselected from the macrocyclic lactone class of compounds such asivermectin, avermectin, abamectin, emamectin, eprinomectin, doramectin,selamectin, moxidectin, nemadectin and milbemycin derivatives asdescribed in EP-357460, EP-444964 and EP-594291. Additional anthelminticagents include semisynthetic and biosynthetic avermectin/milbemycinderivatives such as those described in U.S. Pat. No. 5,015,630,WO-9415944 and WO-9522552. Additional anthelmintic agents include thebenzimidazoles such as albendazole, cambendazole, fenbendazole,flubendazole, mebendazole, oxfendazole, oxibendazole, parbendazole, andother members of the class. Additional anthelmintic agents includeimidazothiazoles and tetrahydropyrimidines such as tetramisole,levamisole, pyrantel pamoate, oxantel or morantel. Additionalanthelmintic agents include flukicides, such as triclabendazole andclorsulon and the cestocides, such as praziquantel and epsiprantel.

The compounds of the invention may be used in combination withderivatives and analogues of the paraherquamide/marcfortine class ofanthelmintic agents, as well as the antiparasitic oxazolines such asthose disclosed in U.S. Pat. Nos. 5,478,855, 4,639,771 and DE-19520936.

The compounds of the invention may be used in combination withderivatives and analogues of the general class of dioxomorpholineantiparasitic agents as described in WO 96/15121 and also withanthelmintic active cyclic depsipeptides such as those described in WO96/11945, WO 93/19053, WO 93/25543, EP 0 626 375, EP 0 382 173, WO94/19334, EP 0 382 173, and EP 0 503 538.

The compounds of the invention may be used in combination with otherectoparasiticides; for example, fipronil; pyrethroids; organophosphates;insect growth regulators such as lufenuron; ecdysone agonists such astebufenozide and the like; neonicotinoids such as imidacloprid and thelike.

The compounds of the invention may be used in combination with terpenealkaloids, for example those described in International PatentApplication Publication Numbers WO 95/19363 or WO 04/72086, particularlythe compounds disclosed therein.

Other examples of such biologically active compounds that the compoundsof the invention may be used in combination with include but are notrestricted to the following:

Organophosphates: acephate, azamethiphos, azinphos-ethyl,azinphos-methyl, bromophos, bromophos-ethyl, cadusafos, chlorethoxyphos,chlorpyrifos, chlorfenvinphos, chlormephos, demeton, demeton-S-methyl,demeton-S-methyl sulphone, dialifos, diazinon, dichlorvos, dicrotophos,dimethoate, disulfoton, ethion, ethoprophos, etrimfos, famphur,fenamiphos, fenitrothion, fensulfothion, fenthion, flupyrazofos,fonofos, formothion, fosthiazate, heptenophos, isazophos, isothioate,isoxathion, malathion, methacriphos, methamidophos, methidathion,methyl-parathion, mevinphos, monocrotophos, naled, omethoate,oxydemeton-methyl, paraoxon, parathion, parathion-methyl, phenthoate,phosalone, phosfolan, phosphocarb, phosmet, phosphamidon, phorate,phoxim, pirimiphos, pirimiphos-methyl, profenofos, propaphos,proetamphos, prothiofos, pyraclofos, pyridapenthion, quinalphos,sulprophos, temephos, terbufos, tebupirimfos, tetrachlorvinphos,thimeton, triazophos, trichlorfon, vamidothion.

Carbamates: alanycarb, aldicarb, 2-sec-butylphenyl methylcarbamate,benfuracarb, carbaryl, carbofuran, carbosulfan, cloethocarb,ethiofencarb, fenoxycarb, fenthiocarb, furathiocarb, HCN-801,isoprocarb, indoxacarb, methiocarb, methomyl,5-methyl-m-cumenylbutyryl(methyl)carbamate, oxamyl, pirimicarb,propoxur, thiodicarb, thiofanox, triazamate, UC-51717.

Pyrethroids: acrinathin, allethrin, alphametrin, 5-benzyl-3-furylmethyl(E)-(1R)-cis-2,2-dimethyl-3-(2-oxothiolan-3-ylidenemethyl)cyclopropanecarboxylate,bifenthrin, beta-cyfluthrin, cyfluthrin, a-cypermethrin,beta-cypermethrin, bioallethrin, bioallethrin((S)-cyclopentylisomer),bioresmethrin, bifenthrin, NCI-85193, cycloprothrin, cyhalothrin,cythithrin, cyphenothrin, deltamethrin, empenthrin, esfenvalerate,ethofenprox, fenfluthrin, fenpropathrin, fenvalerate, flucythrinate,flumethrin, fluvalinate (D isomer), imiprothrin, cyhalothrin,lambda-cyhalothrin, permethrin, phenothrin, prallethrin, pyrethrins(natural products), resmethrin, tetramethrin, transfluthrin,theta-cypermethrin, silafluofen, t-fluvalinate, tefluthrin,tralomethrin, Zeta-cypermethrin.

Arthropod growth regulators: a) chitin synthesis inhibitors:benzoylureas: chlorfluazuron, diflubenzuron, fluazuron, flucycloxuron,flufenoxuron, hexaflumuron, lufenuron, novaluron, teflubenzuron,triflumuron, buprofezin, diofenolan, hexythiazox, etoxazole,chlorfentazine; b) ecdysone antagonists: halofenozide, methoxyfenozide,tebufenozide; c) juvenoids: pyriproxyfen, methoprene (includingS-methoprene), fenoxycarb; d) lipid biosynthesis inhibitors:spirodiclofen.

Other antiparasitics: acequinocyl, amitraz, AKD-1022, ANS-118,azadirachtin, Bacillus thuringiensis, bensultap, bifenazate, binapacryl,bromopropylate, BTG-504, BTG-505, camphechlor, cartap, chlorobenzilate,chlordimeform, chlorfenapyr, chromafenozide, clothianidine, cyromazine,diacloden, diafenthiuron, DBI-3204, dinactin,dihydroxymethyldihydroxypyrrolidine, dinobuton, dinocap, endosulfan,ethiprole, ethofenprox, fenazaquin, flumite, MTI-800, fenpyroximate,fluacrypyrim, flubenzimine, flubrocythrinate, flufenzine, flufenprox,fluproxyfen, halofenprox, hydramethylnon, IKI-220, kanemite, NC-196,neem guard, nidinorterfuran, nitenpyram, SD-35651, WL-108477, pirydaryl,propargite, protrifenbute, pymethrozine, pyridaben, pyrimidifen,NC-1111, R-195, RH-0345, RH-2485, RYI-210, S-1283, S-1833, SI-8601,silafluofen, silomadine, spinosad, tebufenpyrad, tetradifon,tetranactin, thiacloprid, thiocyclam, thiamethoxam, tolfenpyrad,triazamate, triethoxyspinosyn, trinactin, verbutin, vertalec, YI-5301.

Biological agents: Bacillus thuringiensis ssp aizawai, kurstaki,Bacillus thuringiensis delta endotoxin, baculovirus, entomopathogenicbacteria, virus and fungi.

Bactericides: chlortetracycline, oxytetracycline, streptomycin.

Other biological agents: enrofloxacin, febantel, penethamate, moloxicam,cefalexin, kanamycin, pimobendan, clenbuterol, omeprazole, tiamulin,benazepril, pyriprole, cefquinome, florfenicol, buserelin, cefovecin,tulathromycin, ceftiour, carprofen, metaflumizone, praziquarantel,triclabendazole.

The following mixtures of the compounds of formula (I) with activeingredients are preferred. The abbreviation “TX” means one compoundselected from the group consisting of the compounds described in: Tables1.1 to 1.18 or Table T1 (below). an adjuvant selected from the group ofsubstances consisting of petroleum oils (alternative name) (628)+TX,

an acaricide selected from the group of substances consisting of1,1-bis(4-chlorophenyl)-2-ethoxyethanol (IUPAC name) (910)+TX,2,4-dichlorophenyl benzenesulfonate (IUPAC/Chemical Abstracts name)(1059)+TX, 2-fluoro-N-methyl-N-1-naphthylacetamide (IUPAC name)(1295)+TX, 4-chlorophenyl phenyl sulfone (IUPAC name) (981)+TX,abamectin (1)+TX, acequinocyl (3)+TX, acetoprole [CCN]+TX, acrinathrin(9)+TX, aldicarb (16)+TX, aldoxycarb (863)+TX, alpha-cypermethrin(202)+TX, amidithion (870)+TX, amidoflumet [CCN]+TX, amidothioate(872)+TX, amiton (875)+TX, amiton hydrogen oxalate (875)+TX, amitraz(24)+TX, aramite (881)+TX, arsenous oxide (882)+TX, AVI 382 (compoundcode)+TX, AZ 60541 (compound code)+TX, azinphos-ethyl (44)+TX,azinphos-methyl (45)+TX, azobenzene (IUPAC name) (888)+TX, azocyclotin(46)+TX, azothoate (889)+TX, benomyl (62)+TX, benoxafos (alternativename) [CCN]+TX, benzoximate (71)+TX, benzyl benzoate (IUPAC name)[CCN]+TX, bifenazate (74)+TX, bifenthrin (76)+TX, binapacryl (907)+TX,brofenvalerate (alternative name)+TX, bromocyclen (918)+TX, bromophos(920)+TX, bromophos-ethyl (921)+TX, bromopropylate (94)+TX, buprofezin(99)+TX, butocarboxim (103)+TX, butoxycarboxim (104)+TX, butylpyridaben(alternative name)+TX, calcium polysulfide (IUPAC name) (111)+TX,camphechlor (941)+TX, carbanolate (943)+TX, carbaryl (115)+TX,carbofuran (118)+TX, carbophenothion (947)+TX, CGA 50′439 (developmentcode) (125)+TX, chinomethionat (126)+TX, chlorbenside (959)+TX,chlordimeform (964)+TX, chlordimeform hydrochloride (964)+TX,chlorfenapyr (130)+TX, chlorfenethol (968)+TX, chlorfenson (970)+TX,chlorfensulfide (971)+TX, chlorfenvinphos (131)+TX, chlorobenzilate(975)+TX, chloromebuform (977)+TX, chloromethiuron (978)+TX,chloropropylate (983)+TX, chlorpyrifos (145)+TX, chlorpyrifos-methyl(146)+TX, chlorthiophos (994)+TX, cinerin I (696)+TX, cinerin II(696)+TX, cinerins (696)+TX, clofentezine (158)+TX, closantel(alternative name) [CCN]+TX, coumaphos (174)+TX, crotamiton (alternativename) [CCN]+TX, crotoxyphos (1010)+TX, cufraneb (1013)+TX, cyanthoate(1020)+TX, cyflumetofen (CAS Reg. No.: 400882-07-7)+TX, cyhalothrin(196)+TX, cyhexatin (199)+TX, cypermethrin (201)+TX, DCPM (1032)+TX, DDT(219)+TX, demephion (1037)+TX, demephion-O (1037)+TX, demephion-S(1037)+TX, demeton (1038)+TX, demeton-methyl (224)+TX, demeton-O(1038)+TX, demeton-O-methyl (224)+TX, demeton-S (1038)+TX,demeton-S-methyl (224)+TX, demeton-S-methylsulfon (1039)+TX,diafenthiuron (226)+TX, dialifos (1042)+TX, diazinon (227)+TX,dichlofluanid (230)+TX, dichlorvos (236)+TX, dicliphos (alternativename)+TX, dicofol (242)+TX, dicrotophos (243)+TX, dienochlor (1071)+TX,dimefox (1081)+TX, dimethoate (262)+TX, dinactin (alternative name)(653)+TX, dinex (1089)+TX, dinex-diclexine (1089)+TX, dinobuton(269)+TX, dinocap (270)+TX, dinocap-4 [CCN]+TX, dinocap-6 [CCN]+TX,dinocton (1090)+TX, dinopenton (1092)+TX, dinosulfon (1097)+TX,dinoterbon (1098)+TX, dioxathion (1102)+TX, diphenyl sulfone (IUPACname) (1103)+TX, disulfiram (alternative name) [CCN]+TX, disulfoton(278)+TX, DNOC (282)+TX, dofenapyn (1113)+TX, doramectin (alternativename) [CCN]+TX, endosulfan (294)+TX, endothion (1121)+TX, EPN (297)+TX,eprinomectin (alternative name) [CCN]+TX, ethion (309)+TX,ethoate-methyl (1134)+TX, etoxazole (320)+TX, etrimfos (1142)+TX,fenazaflor (1147)+TX, fenazaquin (328)+TX, fenbutatin oxide (330)+TX,fenothiocarb (337)+TX, fenpropathrin (342)+TX, fenpyrad (alternativename)+TX, fenpyroximate (345)+TX, fenson (1157)+TX, fentrifanil(1161)+TX, fenvalerate (349)+TX, fipronil (354)+TX, fluacrypyrim(360)+TX, fluazuron (1166)+TX, flubenzimine (1167)+TX, flucycloxuron(366)+TX, flucythrinate (367)+TX, fluenetil (1169)+TX, flufenoxuron(370)+TX, flumethrin (372)+TX, fluorbenside (1174)+TX, fluvalinate(1184)+TX, FMC 1137 (development code) (1185)+TX, formetanate (405)+TX,formetanate hydrochloride (405)+TX, formothion (1192)+TX, formparanate(1193)+TX, gamma-HCH (430)+TX, glyodin (1205)+TX, halfenprox (424)+TX,heptenophos (432)+TX, hexadecyl cyclopropanecarboxylate (IUPAC/ChemicalAbstracts name) (1216)+TX, hexythiazox (441)+TX, iodomethane (IUPACname) (542)+TX, isocarbophos (alternative name) (473)+TX, isopropylO-(methoxyaminothiophosphoryl)salicylate (IUPAC name) (473)+TX,ivermectin (alternative name) [CCN]+TX, jasmolin I (696)+TX, jasmolin II(696)+TX, jodfenphos (1248)+TX, lindane (430)+TX, lufenuron (490)+TX,malathion (492)+TX, malonoben (1254)+TX, mecarbam (502)+TX, mephosfolan(1261)+TX, mesulfen (alternative name) [CCN]+TX, methacrifos (1266)+TX,methamidophos (527)+TX, methidathion (529)+TX, methiocarb (530)+TX,methomyl (531)+TX, methyl bromide (537)+TX, metolcarb (550)+TX,mevinphos (556)+TX, mexacarbate (1290)+TX, milbemectin (557)+TX,milbemycin oxime (alternative name) [CCN]+TX, mipafox (1293)+TX,monocrotophos (561)+TX, morphothion (1300)+TX, moxidectin (alternativename) [CCN]+TX, naled (567)+TX, NC-184 (compound code)+TX, NC-512(compound code)+TX, nifluridide (1309)+TX, nikkomycins (alternativename) [CCN]+TX, nitrilacarb (1313)+TX, nitrilacarb 1:1 zinc chloridecomplex (1313)+TX, NNI-0101 (compound code)+TX, NNI-0250 (compoundcode)+TX, omethoate (594)+TX, oxamyl (602)+TX, oxydeprofos (1324)+TX,oxydisulfoton (1325)+TX, pp′-DDT (219)+TX, parathion (615)+TX,permethrin (626)+TX, petroleum oils (alternative name) (628)+TX,phenkapton (1330)+TX, phenthoate (631)+TX, phorate (636)+TX, phosalone(637)+TX, phosfolan (1338)+TX, phosmet (638)+TX, phosphamidon (639)+TX,phoxim (642)+TX, pirimiphos-methyl (652)+TX, polychloroterpenes(traditional name) (1347)+TX, polynactins (alternative name) (653)+TX,proclonol (1350)+TX, profenofos (662)+TX, promacyl (1354)+TX, propargite(671)+TX, propetamphos (673)+TX, propoxur (678)+TX, prothidathion(1360)+TX, prothoate (1362)+TX, pyrethrin I (696)+TX, pyrethrin II(696)+TX, pyrethrins (696)+TX, pyridaben (699)+TX, pyridaphenthion(701)+TX, pyrimidifen (706)+TX, pyrimitate (1370)+TX, quinalphos(711)+TX, quintiofos (1381)+TX, R-1492 (development code) (1382)+TX,RA-17 (development code) (1383)+TX, rotenone (722)+TX, schradan(1389)+TX, sebufos (alternative name)+TX, selamectin (alternative name)[CCN]+TX, SI-0009 (compound code)+TX, sophamide (1402)+TX, spirodiclofen(738)+TX, spiromesifen (739)+TX, SSI-121 (development code) (1404)+TX,sulfiram (alternative name) [CCN]+TX, sulfluramid (750)+TX, sulfotep(753)+TX, sulfur (754)+TX, SZI-121 (development code) (757)+TX,tau-fluvalinate (398)+TX, tebufenpyrad (763)+TX, TEPP (1417)+TX, terbam(alternative name)+TX, tetrachlorvinphos (777)+TX, tetradifon (786)+TX,tetranactin (alternative name) (653)+TX, tetrasul (1425)+TX, thiafenox(alternative name)+TX, thiocarboxime (1431)+TX, thiofanox (800)+TX,thiometon (801)+TX, thioquinox (1436)+TX, thuringiensin (alternativename) [CCN]+TX, triamiphos (1441)+TX, triarathene (1443)+TX, triazophos(820)+TX, triazuron (alternative name)+TX, trichlorfon (824)+TX,trifenofos (1455)+TX, trinactin (alternative name) (653)+TX, vamidothion(847)+TX, vaniliprole [CCN] and YI-5302 (compound code)+TX,

an algicide selected from the group of substances consisting ofbethoxazin [CCN]+TX, copper dioctanoate (IUPAC name) (170)+TX, coppersulfate (172)+TX, cybutryne [CCN]+TX, dichlone (1052)+TX, dichlorophen(232)+TX, endothal (295)+TX, fentin (347)+TX, hydrated lime [CCN]+TX,nabam (566)+TX, quinoclamine (714)+TX, quinonamid (1379)+TX, simazine(730)+TX, triphenyltin acetate (IUPAC name) (347) and triphenyltinhydroxide (IUPAC name) (347)+TX,

an anthelmintic selected from the group of substances consisting ofabamectin (1)+TX, crufomate (1011)+TX, doramectin (alternative name)[CCN]+TX, emamectin (291)+TX, emamectin benzoate (291)+TX, eprinomectin(alternative name) [CCN]+TX, ivermectin (alternative name) [CCN]+TX,milbemycin oxime (alternative name) [CCN]+TX, moxidectin (alternativename) [CCN]+TX, piperazine [CCN]+TX, selamectin (alternative name)[CCN]+TX, spinosad (737) and thiophanate (1435)+TX,

an avicide selected from the group of substances consisting ofchloralose (127)+TX, endrin (1122)+TX, fenthion (346)+TX,pyridin-4-amine (IUPAC name) (23) and strychnine (745)+TX,

a bactericide selected from the group of substances consisting of1-hydroxy-1H-pyridine-2-thione (IUPAC name) (1222)+TX,4-(quinoxalin-2-ylamino)benzenesulfonamide (IUPAC name) (748)+TX,8-hydroxyquinoline sulfate (446)+TX, bronopol (97)+TX, copperdioctanoate (IUPAC name) (170)+TX, copper hydroxide (IUPAC name)(169)+TX, cresol [CCN]+TX, dichlorophen (232)+TX, dipyrithione(1105)+TX, dodicin (1112)+TX, fenaminosulf (1144)+TX, formaldehyde(404)+TX, hydrargaphen (alternative name) [CCN]+TX, kasugamycin(483)+TX, kasugamycin hydrochloride hydrate (483)+TX, nickelbis(dimethyldithiocarbamate) (IUPAC name) (1308)+TX, nitrapyrin(580)+TX, octhilinone (590)+TX, oxolinic acid (606)+TX, oxytetracycline(611)+TX, potassium hydroxyquinoline sulfate (446)+TX, probenazole(658)+TX, streptomycin (744)+TX, streptomycin sesquisulfate (744)+TX,tecloftalam (766)+TX, and thiomersal (alternative name) [CCN]+TX,

a biological agent selected from the group of substances consisting ofAdoxophyes orana GV (alternative name) (12)+TX, Agrobacteriumradiobacter (alternative name) (13)+TX, Amblyseius spp. (alternativename) (19)+TX, Anagrapha falcifera NPV (alternative name) (28)+TX,Anagrus atomus (alternative name) (29)+TX, Aphelinus abdominalis(alternative name) (33)+TX, Aphidius colemani (alternative name)(34)+TX, Aphidoletes aphidimyza (alternative name) (35)+TX, Autographacalifornica NPV (alternative name) (38)+TX, Bacillus firmus (alternativename) (48)+TX, Bacillus sphaericus Neide (scientific name) (49)+TX,Bacillus thuringiensis Berliner (scientific name) (51)+TX, Bacillusthuringiensis subsp. aizawai (scientific name) (51)+TX, Bacillusthuringiensis subsp. israelensis (scientific name) (51)+TX, Bacillusthuringiensis subsp. japonensis (scientific name) (51)+TX, Bacillusthuringiensis subsp. kurstaki (scientific name) (51)+TX, Bacillusthuringiensis subsp. tenebrionis (scientific name) (51)+TX, Beauveriabassiana (alternative name) (53)+TX, Beauveria brongniartii (alternativename) (54)+TX, Chrysoperla carnea (alternative name) (151)+TX,Cryptolaemus montrouzieri (alternative name) (178)+TX, Cydia pomonellaGV (alternative name) (191)+TX, Dacnusa sibirica (alternative name)(212)+TX, Diglyphus isaea (alternative name) (254)+TX, Encarsia formosa(scientific name) (293)+TX, Eretmocerus eremicus (alternative name)(300)+TX, Helicoverpa zea NPV (alternative name) (431)+TX,Heterorhabditis bacteriophora and H. megidis (alternative name)(433)+TX, Hippodamia convergens (alternative name) (442)+TX, Leptomastixdactylopii (alternative name) (488)+TX, Macrolophus caliginosus(alternative name) (491)+TX, Mamestra brassicae NPV (alternative name)(494)+TX, Metaphycus helvolus (alternative name) (522)+TX, Metarhiziumanisopliae var. acridum (scientific name) (523)+TX, Metarhiziumanisopliae var. anisopliae (scientific name) (523)+TX, Neodiprionsertifer NPV and N. lecontei NPV (alternative name) (575)+TX, Orius spp.(alternative name) (596)+TX, Paecilomyces fumosoroseus (alternativename) (613)+TX, Phytoseiulus persimilis (alternative name) (644)+TX,Spodoptera exigua multicapsid nuclear polyhedrosis virus (scientificname) (741)+TX, Steinernema bibionis (alternative name) (742)+TX,Steinernema carpocapsae (alternative name) (742)+TX, Steinernema feltiae(alternative name) (742)+TX, Steinernema glaseri (alternative name)(742)+TX, Steinernema riobrave (alternative name) (742)+TX, Steinernemariobravis (alternative name) (742)+TX, Steinernema scapterisci(alternative name) (742)+TX, Steinernema spp. (alternative name)(742)+TX, Trichogramma spp. (alternative name) (826)+TX, Typhlodromusoccidentalis (alternative name) (844) and Verticillium lecanii(alternative name) (848)+TX, Bacillus subtilis var. amyloliquefaciensStrain FZB24 (available from Novozymes Biologicals Inc., 5400 CorporateCircle, Salem, Va. 24153, U.S.A. and known under the trade nameTaegro®)+TX,

a soil sterilant selected from the group of substances consisting ofiodomethane (IUPAC name) (542) and methyl bromide (537)+TX,

a chemosterilant selected from the group of substances consisting ofapholate [CCN]+TX, bisazir (alternative name) [CCN]+TX, busulfan(alternative name) [CCN]+TX, diflubenzuron (250)+TX, dimatif(alternative name) [CCN]+TX, hemel [CCN]+TX, hempa [CCN]+TX, metepa[CCN]+TX, methiotepa [CCN]+TX, methyl apholate [CCN]+TX, morzid[CCN]+TX, penfluron (alternative name) [CCN]+TX, tepa [CCN]+TX,thiohempa (alternative name) [CCN]+TX, thiotepa (alternative name)[CCN]+TX, tretamine (alternative name) [CCN] and uredepa (alternativename) [CCN]+TX,

an insect pheromone selected from the group of substances consisting of(E)-dec-5-en-1-yl acetate with (E)-dec-5-en-1-ol (IUPAC name) (222)+TX,(E)-tridec-4-en-1-yl acetate (IUPAC name) (829)+TX,(E)-6-methylhept-2-en-4-ol (IUPAC name) (541)+TX,(E,Z)-tetradeca-4,10-dien-1-yl acetate (IUPAC name) (779)+TX,(Z)-dodec-7-en-1-yl acetate (IUPAC name) (285)+TX, (Z)-hexadec-11-enal(IUPAC name) (436)+TX, (Z)-hexadec-11-en-1-yl acetate (IUPAC name)(437)+TX, (Z)-hexadec-13-en-11-yn-1-yl acetate (IUPAC name) (438)+TX,(Z)-icos-13-en-10-one (IUPAC name) (448)+TX, (Z)-tetradec-7-en-1-al(IUPAC name) (782)+TX, (Z)-tetradec-9-en-1-ol (IUPAC name) (783)+TX,(Z)-tetradec-9-en-1-yl acetate (IUPAC name) (784)+TX,(7E,9Z)-dodeca-7,9-dien-1-yl acetate (IUPAC name) (283)+TX,(9Z,11E)-tetradeca-9,11-dien-1-yl acetate (IUPAC name) (780)+TX,(9Z,12E)-tetradeca-9,12-dien-1-yl acetate (IUPAC name) (781)+TX,14-methyloctadec-1-ene (IUPAC name) (545)+TX, 4-methylnonan-5-ol with4-methylnonan-5-one (IUPAC name) (544)+TX, alpha-multistriatin(alternative name) [CCN]+TX, brevicomin (alternative name) [CCN]+TX,codlelure (alternative name) [CCN]+TX, codlemone (alternative name)(167)+TX, cuelure (alternative name) (179)+TX, disparlure (277)+TX,dodec-8-en-1-yl acetate (IUPAC name) (286)+TX, dodec-9-en-1-yl acetate(IUPAC name) (287)+TX, dodeca-8+TX, 10-dien-1-yl acetate (IUPAC name)(284)+TX, dominicalure (alternative name) [CCN]+TX, ethyl4-methyloctanoate (IUPAC name) (317)+TX, eugenol (alternative name)[CCN]+TX, frontalin (alternative name) [CCN]+TX, gossyplure (alternativename) (420)+TX, grandlure (421)+TX, grandlure I (alternative name)(421)+TX, grandlure II (alternative name) (421)+TX, grandlure III(alternative name) (421)+TX, grandlure IV (alternative name) (421)+TX,hexalure [CCN]+TX, ipsdienol (alternative name) [CCN]+TX, ipsenol(alternative name) [CCN]+TX, japonilure (alternative name) (481)+TX,lineatin (alternative name) [CCN]+TX, litlure (alternative name)[CCN]+TX, looplure (alternative name) [CCN]+TX, medlure [CCN]+TX,megatomoic acid (alternative name) [CCN]+TX, methyl eugenol (alternativename) (540)+TX, muscalure (563)+TX, octadeca-2,13-dien-1-yl acetate(IUPAC name) (588)+TX, octadeca-3,13-dien-1-yl acetate (IUPAC name)(589)+TX, orfralure (alternative name) [CCN]+TX, oryctalure (alternativename) (317)+TX, ostramone (alternative name) [CCN]+TX, siglure [CCN]+TX,sordidin (alternative name) (736)+TX, sulcatol (alternative name)[CCN]+TX, tetradec-11-en-1-yl acetate (IUPAC name) (785)+TX, trimedlure(839)+TX, trimedlure A (alternative name) (839)+TX, trimedlure B₁(alternative name) (839)+TX, trimedlure B₂ (alternative name) (839)+TX,trimedlure C (alternative name) (839) and trunc-call (alternative name)[CCN]+TX,

an insect repellent selected from the group of substances consisting of2-(octylthio)ethanol (IUPAC name) (591)+TX, butopyronoxyl (933)+TX,butoxy(polypropylene glycol) (936)+TX, dibutyl adipate (IUPAC name)(1046)+TX, dibutyl phthalate (1047)+TX, dibutyl succinate (IUPAC name)(1048)+TX, diethyltoluamide [CCN]+TX, dimethyl carbate [CCN]+TX,dimethyl phthalate [CCN]+TX, ethyl hexanediol (1137)+TX, hexamide[CCN]+TX, methoquin-butyl (1276)+TX, methylneodecanamide [CCN]+TX,oxamate [CCN] and picaridin [CCN]+TX,

an insecticide selected from the group of substances consisting of1-dichloro-1-nitroethane (IUPAC/Chemical Abstracts name) (1058)+TX,1,1-dichloro-2,2-bis(4-ethylphenyl)ethane (IUPAC name) (1056), +TX,1,2-dichloropropane (IUPAC/Chemical Abstracts name) (1062)+TX,1,2-dichloropropane with 1,3-dichloropropene (IUPAC name) (1063)+TX,1-bromo-2-chloroethane (IUPAC/Chemical Abstracts name) (916)+TX,2,2,2-trichloro-1-(3,4-dichlorophenyl)ethyl acetate (IUPAC name)(1451)+TX, 2,2-dichlorovinyl 2-ethylsulfinylethyl methyl phosphate(IUPAC name) (1066)+TX, 2-(1,3-dithiolan-2-yl)phenyl dimethylcarbamate(IUPAC/Chemical Abstracts name) (1109)+TX, 2-(2-butoxyethoxy)ethylthiocyanate (IUPAC/Chemical Abstracts name) (935)+TX,2-(4,5-dimethyl-1,3-dioxolan-2-yl)phenyl methylcarbamate (IUPAC/ChemicalAbstracts name) (1084)+TX, 2-(4-chloro-3,5-xylyloxy)ethanol (IUPAC name)(986)+TX, 2-chlorovinyl diethyl phosphate (IUPAC name) (984)+TX,2-imidazolidone (IUPAC name) (1225)+TX, 2-isovalerylindan-1,3-dione(IUPAC name) (1246)+TX, 2-methyl(prop-2-ynyl)aminophenyl methylcarbamate(IUPAC name) (1284)+TX, 2-thiocyanatoethyl laurate (IUPAC name)(1433)+TX, 3-bromo-1-chloroprop-1-ene (IUPAC name) (917)+TX,3-methyl-1-phenylpyrazol-5-yl dimethylcarbamate (IUPAC name) (1283)+TX,4-methyl(prop-2-ynyl)amino-3,5-xylyl methylcarbamate (IUPAC name)(1285)+TX, 5,5-dimethyl-3-oxocyclohex-1-enyl dimethylcarbamate (IUPACname) (1085)+TX, abamectin (1)+TX, acephate (2)+TX, acetamiprid (4)+TX,acethion (alternative name) [CCN]+TX, acetoprole [CCN]+TX, acrinathrin(9)+TX, acrylonitrile (IUPAC name) (861)+TX, alanycarb (15)+TX, aldicarb(16)+TX, aldoxycarb (863)+TX, aldrin (864)+TX, allethrin (17)+TX,allosamidin (alternative name) [CCN]+TX, allyxycarb (866)+TX,alpha-cypermethrin (202)+TX, alpha-ecdysone (alternative name) [CCN]+TX,aluminium phosphide (640)+TX, amidithion (870)+TX, amidothioate(872)+TX, aminocarb (873)+TX, amiton (875)+TX, amiton hydrogen oxalate(875)+TX, amitraz (24)+TX, anabasine (877)+TX, athidathion (883)+TX, AVI382 (compound code)+TX, AZ 60541 (compound code)+TX, azadirachtin(alternative name) (41)+TX, azamethiphos (42)+TX, azinphos-ethyl(44)+TX, azinphos-methyl (45)+TX, azothoate (889)+TX, Bacillusthuringiensis delta endotoxins (alternative name) (52)+TX, bariumhexafluorosilicate (alternative name) [CCN]+TX, barium polysulfide(IUPAC/Chemical Abstracts name) (892)+TX, barthrin [CCN]+TX, Bayer22/190 (development code) (893)+TX, Bayer 22408 (development code)(894)+TX, bendiocarb (58)+TX, benfuracarb (60)+TX, bensultap (66)+TX,beta-cyfluthrin (194)+TX, beta-cypermethrin (203)+TX, bifenthrin(76)+TX, bioallethrin (78)+TX, bioallethrin S-cyclopentenyl isomer(alternative name) (79)+TX, bioethanomethrin [CCN]+TX, biopermethrin(908)+TX, bioresmethrin (80)+TX, bis(2-chloroethyl) ether (IUPAC name)(909)+TX, bistrifluron (83)+TX, borax (86)+TX, brofenvalerate(alternative name)+TX, bromfenvinfos (914)+TX, bromocyclen (918)+TX,bromo-DDT (alternative name) [CCN]+TX, bromophos (920)+TX,bromophos-ethyl (921)+TX, bufencarb (924)+TX, buprofezin (99)+TX,butacarb (926)+TX, butathiofos (927)+TX, butocarboxim (103)+TX, butonate(932)+TX, butoxycarboxim (104)+TX, butylpyridaben (alternative name)+TX,cadusafos (109)+TX, calcium arsenate [CCN]+TX, calcium cyanide (444)+TX,calcium polysulfide (IUPAC name) (111)+TX, camphechlor (941)+TX,carbanolate (943)+TX, carbaryl (115)+TX, carbofuran (118)+TX, carbondisulfide (IUPAC/Chemical Abstracts name) (945)+TX, carbon tetrachloride(IUPAC name) (946)+TX, carbophenothion (947)+TX, carbosulfan (119)+TX,cartap (123)+TX, cartap hydrochloride (123)+TX, cevadine (alternativename) (725)+TX, chlorbicyclen (960)+TX, chlordane (128)+TX, chlordecone(963)+TX, chlordimeform (964)+TX, chlordimeform hydrochloride (964)+TX,chlorethoxyfos (129)+TX, chlorfenapyr (130)+TX, chlorfenvinphos(131)+TX, chlorfluazuron (132)+TX, chlormephos (136)+TX, chloroform[CCN]+TX, chloropicrin (141)+TX, chlorphoxim (989)+TX, chlorprazophos(990)+TX, chlorpyrifos (145)+TX, chlorpyrifos-methyl (146)+TX,chlorthiophos (994)+TX, chromafenozide (150)+TX, cinerin I (696)+TX,cinerin II (696)+TX, cinerins (696)+TX, cis-resmethrin (alternativename)+TX, cismethrin (80)+TX, clocythrin (alternative name)+TX,cloethocarb (999)+TX, closantel (alternative name) [CCN]+TX,clothianidin (165)+TX, copper acetoarsenite [CCN]+TX, copper arsenate[CCN]+TX, copper oleate [CCN]+TX, coumaphos (174)+TX, coumithoate(1006)+TX, crotamiton (alternative name) [CCN]+TX, crotoxyphos(1010)+TX, crufomate (1011)+TX, cryolite (alternative name) (177)+TX, CS708 (development code) (1012)+TX, cyanofenphos (1019)+TX, cyanophos(184)+TX, cyanthoate (1020)+TX, cyclethrin [CCN]+TX, cycloprothrin(188)+TX, cyfluthrin (193)+TX, cyhalothrin (196)+TX, cypermethrin(201)+TX, cyphenothrin (206)+TX, cyromazine (209)+TX, cythioate(alternative name) [CCN]+TX, d-limonene (alternative name) [CCN]+TX,d-tetramethrin (alternative name) (788)+TX, DAEP (1031)+TX, dazomet(216)+TX, DDT (219)+TX, decarbofuran (1034)+TX, deltamethrin (223)+TX,demephion (1037)+TX, demephion-O (1037)+TX, demephion-S (1037)+TX,demeton (1038)+TX, demeton-methyl (224)+TX, demeton-O (1038)+TX,demeton-O-methyl (224)+TX, demeton-S (1038)+TX, demeton-S-methyl(224)+TX, demeton-S-methylsulphon (1039)+TX, diafenthiuron (226)+TX,dialifos (1042)+TX, diamidafos (1044)+TX, diazinon (227)+TX, dicapthon(1050)+TX, dichlofenthion (1051)+TX, dichlorvos (236)+TX, dicliphos(alternative name)+TX, dicresyl (alternative name) [CCN]+TX, dicrotophos(243)+TX, dicyclanil (244)+TX, dieldrin (1070)+TX, diethyl5-methylpyrazol-3-yl phosphate (IUPAC name) (1076)+TX, diflubenzuron(250)+TX, dilor (alternative name) [CCN]+TX, dimefluthrin [CCN]+TX,dimefox (1081)+TX, dimetan (1085)+TX, dimethoate (262)+TX, dimethrin(1083)+TX, dimethylvinphos (265)+TX, dimetilan (1086)+TX, dinex(1089)+TX, dinex-diclexine (1089)+TX, dinoprop (1093)+TX, dinosam(1094)+TX, dinoseb (1095)+TX, dinotefuran (271)+TX, diofenolan(1099)+TX, dioxabenzofos (1100)+TX, dioxacarb (1101)+TX, dioxathion(1102)+TX, disulfoton (278)+TX, dithicrofos (1108)+TX, DNOC (282)+TX,doramectin (alternative name) [CCN]+TX, DSP (1115)+TX, ecdysterone(alternative name) [CCN]+TX, EI 1642 (development code) (1118)+TX,emamectin (291)+TX, emamectin benzoate (291)+TX, EMPC (1120)+TX,empenthrin (292)+TX, endosulfan (294)+TX, endothion (1121)+TX, endrin(1122)+TX, EPBP (1123)+TX, EPN (297)+TX, epofenonane (1124)+TX,eprinomectin (alternative name) [CCN]+TX, esfenvalerate (302)+TX,etaphos (alternative name) [CCN]+TX, ethiofencarb (308)+TX, ethion(309)+TX, ethiprole (310)+TX, ethoate-methyl (1134)+TX, ethoprophos(312)+TX, ethyl formate (IUPAC name) [CCN]+TX, ethyl-DDD (alternativename) (1056)+TX, ethylene dibromide (316)+TX, ethylene dichloride(chemical name) (1136)+TX, ethylene oxide [CCN]+TX, etofenprox (319)+TX,etrimfos (1142)+TX, EXD (1143)+TX, famphur (323)+TX, fenamiphos(326)+TX, fenazaflor (1147)+TX, fenchlorphos (1148)+TX, fenethacarb(1149)+TX, fenfluthrin (1150)+TX, fenitrothion (335)+TX, fenobucarb(336)+TX, fenoxacrim (1153)+TX, fenoxycarb (340)+TX, fenpirithrin(1155)+TX, fenpropathrin (342)+TX, fenpyrad (alternative name)+TX,fensulfothion (1158)+TX, fenthion (346)+TX, fenthion-ethyl [CCN]+TX,fenvalerate (349)+TX, fipronil (354)+TX, flonicamid (358)+TX,flubendiamide (CAS. Reg. No.: 272451-65-7)+TX, flucofuron (1168)+TX,flucycloxuron (366)+TX, flucythrinate (367)+TX, fluenetil (1169)+TX,flufenerim [CCN]+TX, flufenoxuron (370)+TX, flufenprox (1171)+TX,flumethrin (372)+TX, fluvalinate (1184)+TX, FMC 1137 (development code)(1185)+TX, fonofos (1191)+TX, formetanate (405)+TX, formetanatehydrochloride (405)+TX, formothion (1192)+TX, formparanate (1193)+TX,fosmethilan (1194)+TX, fospirate (1195)+TX, fosthiazate (408)+TX,fosthietan (1196)+TX, furathiocarb (412)+TX, furethrin (1200)+TX,gamma-cyhalothrin (197)+TX, gamma-HCH (430)+TX, guazatine (422)+TX,guazatine acetates (422)+TX, GY-81 (development code) (423)+TX,halfenprox (424)+TX, halofenozide (425)+TX, HCH (430)+TX, HEOD(1070)+TX, heptachlor (1211)+TX, heptenophos (432)+TX, heterophos[CCN]+TX, hexaflumuron (439)+TX, HHDN (864)+TX, hydramethylnon (443)+TX,hydrogen cyanide (444)+TX, hydroprene (445)+TX, hyquincarb (1223)+TX,imidacloprid (458)+TX, imiprothrin (460)+TX, indoxacarb (465)+TX,iodomethane (IUPAC name) (542)+TX, IPSP (1229)+TX, isazofos (1231)+TX,isobenzan (1232)+TX, isocarbophos (alternative name) (473)+TX, isodrin(1235)+TX, isofenphos (1236)+TX, isolane (1237)+TX, isoprocarb (472)+TX,isopropyl O-(methoxy-aminothiophosphoryl)salicylate (IUPAC name)(473)+TX, isoprothiolane (474)+TX, isothioate (1244)+TX, isoxathion(480)+TX, ivermectin (alternative name) [CCN]+TX, jasmolin I (696)+TX,jasmolin II (696)+TX, jodfenphos (1248)+TX, juvenile hormone I(alternative name) [CCN]+TX, juvenile hormone II (alternative name)[CCN]+TX, juvenile hormone III (alternative name) [CCN]+TX, kelevan(1249)+TX, kinoprene (484)+TX, lambda-cyhalothrin (198)+TX, leadarsenate [CCN]+TX, lepimectin (CCN)+TX, leptophos (1250)+TX, lindane(430)+TX, lirimfos (1251)+TX, lufenuron (490)+TX, lythidathion(1253)+TX, m-cumenyl methylcarbamate (IUPAC name) (1014)+TX, magnesiumphosphide (IUPAC name) (640)+TX, malathion (492)+TX, malonoben(1254)+TX, mazidox (1255)+TX, mecarbam (502)+TX, mecarphon (1258)+TX,menazon (1260)+TX, mephosfolan (1261)+TX, mercurous chloride (513)+TX,mesulfenfos (1263)+TX, metaflumizone (CCN)+TX, metam (519)+TX,metam-potassium (alternative name) (519)+TX, metam-sodium (519)+TX,methacrifos (1266)+TX, methamidophos (527)+TX, methanesulfonyl fluoride(IUPAC/Chemical Abstracts name) (1268)+TX, methidathion (529)+TX,methiocarb (530)+TX, methocrotophos (1273)+TX, methomyl (531)+TX,methoprene (532)+TX, methoquin-butyl (1276)+TX, methothrin (alternativename) (533)+TX, methoxychlor (534)+TX, methoxyfenozide (535)+TX, methylbromide (537)+TX, methyl isothiocyanate (543)+TX, methylchloroform(alternative name) [CCN]+TX, methylene chloride [CCN]+TX, metofluthrin[CCN]+TX, metolcarb (550)+TX, metoxadiazone (1288)+TX, mevinphos(556)+TX, mexacarbate (1290)+TX, milbemectin (557)+TX, milbemycin oxime(alternative name) [CCN]+TX, mipafox (1293)+TX, mirex (1294)+TX,monocrotophos (561)+TX, morphothion (1300)+TX, moxidectin (alternativename) [CCN]+TX, naftalofos (alternative name) [CCN]+TX, naled (567)+TX,naphthalene (IUPAC/Chemical Abstracts name) (1303)+TX, NC-170(development code) (1306)+TX, NC-184 (compound code)+TX, nicotine(578)+TX, nicotine sulfate (578)+TX, nifluridide (1309)+TX, nitenpyram(579)+TX, nithiazine (1311)+TX, nitrilacarb (1313)+TX, nitrilacarb 1:1zinc chloride complex (1313)+TX, NNI-0101 (compound code)+TX, NNI-0250(compound code)+TX, nornicotine (traditional name) (1319)+TX, novaluron(585)+TX, noviflumuron (586)+TX, O-5-dichloro-4-iodophenyl O-ethylethylphosphonothioate (IUPAC name) (1057)+TX, O,O-diethylO-4-methyl-2-oxo-2H-chromen-7-yl phosphorothioate (IUPAC name)(1074)+TX, O,O-diethyl O-6-methyl-2-propylpyrimidin-4-ylphosphorothioate (IUPAC name) (1075)+TX, O,O,O′,O′-tetrapropyldithiopyrophosphate (IUPAC name) (1424)+TX, oleic acid (IUPAC name)(593)+TX, omethoate (594)+TX, oxamyl (602)+TX, oxydemeton-methyl(609)+TX, oxydeprofos (1324)+TX, oxydisulfoton (1325)+TX, pp′-DDT(219)+TX, para-dichlorobenzene [CCN]+TX, parathion (615)+TX,parathion-methyl (616)+TX, penfluron (alternative name) [CCN]+TX,pentachlorophenol (623)+TX, pentachlorophenyl laurate (IUPAC name)(623)+TX, permethrin (626)+TX, petroleum oils (alternative name)(628)+TX, PH 60-38 (development code) (1328)+TX, phenkapton (1330)+TX,phenothrin (630)+TX, phenthoate (631)+TX, phorate (636)+TX, phosalone(637)+TX, phosfolan (1338)+TX, phosmet (638)+TX, phosnichlor (1339)+TX,phosphamidon (639)+TX, phosphine (IUPAC name) (640)+TX, phoxim (642)+TX,phoxim-methyl (1340)+TX, pirimetaphos (1344)+TX, pirimicarb (651)+TX,pirimiphos-ethyl (1345)+TX, pirimiphos-methyl (652)+TX,polychlorodicyclopentadiene isomers (IUPAC name) (1346)+TX,polychloroterpenes (traditional name) (1347)+TX, potassium arsenite[CCN]+TX, potassium thiocyanate [CCN]+TX, prallethrin (655)+TX,precocene I (alternative name) [CCN]+TX, precocene II (alternative name)[CCN]+TX, precocene III (alternative name) [CCN]+TX, primidophos(1349)+TX, profenofos (662)+TX, profluthrin [CCN]+TX, promacyl(1354)+TX, promecarb (1355)+TX, propaphos (1356)+TX, propetamphos(673)+TX, propoxur (678)+TX, prothidathion (1360)+TX, prothiofos(686)+TX, prothoate (1362)+TX, protrifenbute [CCN]+TX, pymetrozine(688)+TX, pyraclofos (689)+TX, pyrazophos (693)+TX, pyresmethrin(1367)+TX, pyrethrin I (696)+TX, pyrethrin II (696)+TX, pyrethrins(696)+TX, pyridaben (699)+TX, pyridalyl (700)+TX, pyridaphenthion(701)+TX, pyrimidifen (706)+TX, pyrimitate (1370)+TX, pyriproxyfen(708)+TX, quassia (alternative name) [CCN]+TX, quinalphos (711)+TX,quinalphos-methyl (1376)+TX, quinothion (1380)+TX, quintiofos (1381)+TX,R-1492 (development code) (1382)+TX, rafoxanide (alternative name)[CCN]+TX, resmethrin (719)+TX, rotenone (722)+TX, RU 15525 (developmentcode) (723)+TX, RU 25475 (development code) (1386)+TX, ryania(alternative name) (1387)+TX, ryanodine (traditional name) (1387)+TX,sabadilla (alternative name) (725)+TX, schradan (1389)+TX, sebufos(alternative name)+TX, selamectin (alternative name) [CCN]+TX, SI-0009(compound code)+TX, SI-0205 (compound code)+TX, SI-0404 (compoundcode)+TX, SI-0405 (compound code)+TX, silafluofen (728)+TX, SN 72129(development code) (1397)+TX, sodium arsenite [CCN]+TX, sodium cyanide(444)+TX, sodium fluoride (IUPAC/Chemical Abstracts name) (1399)+TX,sodium hexafluorosilicate (1400)+TX, sodium pentachlorophenoxide(623)+TX, sodium selenate (IUPAC name) (1401)+TX, sodium thiocyanate[CCN]+TX, sophamide (1402)+TX, spinosad (737)+TX, spiromesifen (739)+TX,spirotetrmat (CCN)+TX, sulcofuron (746)+TX, sulcofuron-sodium (746)+TX,sulfluramid (750)+TX, sulfotep (753)+TX, sulfuryl fluoride (756)+TX,sulprofos (1408)+TX, tar oils (alternative name) (758)+TX,tau-fluvalinate (398)+TX, tazimcarb (1412)+TX, TDE (1414)+TX,tebufenozide (762)+TX, tebufenpyrad (763)+TX, tebupirimfos (764)+TX,teflubenzuron (768)+TX, tefluthrin (769)+TX, temephos (770)+TX, TEPP(1417)+TX, terallethrin (1418)+TX, terbam (alternative name)+TX,terbufos (773)+TX, tetrachloroethane [CCN]+TX, tetrachlorvinphos(777)+TX, tetramethrin (787)+TX, theta-cypermethrin (204)+TX,thiacloprid (791)+TX, thiafenox (alternative name)+TX, thiamethoxam(792)+TX, thicrofos (1428)+TX, thiocarboxime (1431)+TX, thiocyclam(798)+TX, thiocyclam hydrogen oxalate (798)+TX, thiodicarb (799)+TX,thiofanox (800)+TX, thiometon (801)+TX, thionazin (1434)+TX, thiosultap(803)+TX, thiosultap-sodium (803)+TX, thuringiensin (alternative name)[CCN]+TX, tolfenpyrad (809)+TX, tralomethrin (812)+TX, transfluthrin(813)+TX, transpermethrin (1440)+TX, triamiphos (1441)+TX, triazamate(818)+TX, triazophos (820)+TX, triazuron (alternative name)+TX,trichlorfon (824)+TX, trichlormetaphos-3 (alternative name) [CCN]+TX,trichloronat (1452)+TX, trifenofos (1455)+TX, triflumuron (835)+TX,trimethacarb (840)+TX, triprene (1459)+TX, vamidothion (847)+TX,vaniliprole [CCN]+TX, veratridine (alternative name) (725)+TX, veratrine(alternative name) (725)+TX, XMC (853)+TX, xylylcarb (854)+TX, YI-5302(compound code)+TX, zeta-cypermethrin (205)+TX, zetamethrin (alternativename)+TX, zinc phosphide (640)+TX, zolaprofos (1469) and ZXI 8901(development code) (858)+TX, cyantraniliprole [736994-63-19+TX,chlorantraniliprole [500008-45-7]+TX, cyenopyrafen [560121-52-0]+TX,cyflumetofen [400882-07-7]+TX, pyrifluquinazon [337458-27-2]+TX,spinetoram [187166-40-1+187166-15-0]+TX, spirotetramat [203313-25-1]+TX,sulfoxaflor [946578-00-3]+TX, flufiprole [704886-18-0]+TX, meperfluthrin[915288-13-0]+TX, tetramethylfluthrin [84937-88-2]+TX, triflumezopyrim(disclosed in WO 2012/092115)+TX,

a molluscicide selected from the group of substances consisting ofbis(tributyltin) oxide (IUPAC name) (913)+TX, bromoacetamide [CCN]+TX,calcium arsenate [CCN]+TX, cloethocarb (999)+TX, copper acetoarsenite[CCN]+TX, copper sulfate (172)+TX, fentin (347)+TX, ferric phosphate(IUPAC name) (352)+TX, metaldehyde (518)+TX, methiocarb (530)+TX,niclosamide (576)+TX, niclosamide-olamine (576)+TX, pentachlorophenol(623)+TX, sodium pentachlorophenoxide (623)+TX, tazimcarb (1412)+TX,thiodicarb (799)+TX, tributyltin oxide (913)+TX, trifenmorph (1454)+TX,trimethacarb (840)+TX, triphenyltin acetate (IUPAC name) (347) andtriphenyltin hydroxide (IUPAC name) (347)+TX, pyriprole[394730-71-3]+TX,

a nematicide selected from the group of substances consisting ofAKD-3088 (compound code)+TX, 1,2-dibromo-3-chloropropane (IUPAC/ChemicalAbstracts name) (1045)+TX, 1,2-dichloropropane (IUPAC/Chemical Abstractsname) (1062)+TX, 1,2-dichloropropane with 1,3-dichloropropene (IUPACname) (1063)+TX, 1,3-dichloropropene (233)+TX,3,4-dichlorotetrahydrothiophene 1,1-dioxide (IUPAC/Chemical Abstractsname) (1065)+TX, 3-(4-chlorophenyl)-5-methylrhodanine (IUPAC name)(980)+TX, 5-methyl-6-thioxo-1,3,5-thiadiazinan-3-ylacetic acid (IUPACname) (1286)+TX, 6-isopentenylaminopurine (alternative name) (210)+TX,abamectin (1)+TX, acetoprole [CCN]+TX, alanycarb (15)+TX, aldicarb(16)+TX, aldoxycarb (863)+TX, AZ 60541 (compound code)+TX, benclothiaz[CCN]+TX, benomyl (62)+TX, butylpyridaben (alternative name)+TX,cadusafos (109)+TX, carbofuran (118)+TX, carbon disulfide (945)+TX,carbosulfan (119)+TX, chloropicrin (141)+TX, chlorpyrifos (145)+TX,cloethocarb (999)+TX, cytokinins (alternative name) (210)+TX, dazomet(216)+TX, DBCP (1045)+TX, DCIP (218)+TX, diamidafos (1044)+TX,dichlofenthion (1051)+TX, dicliphos (alternative name)+TX, dimethoate(262)+TX, doramectin (alternative name) [CCN]+TX, emamectin (291)+TX,emamectin benzoate (291)+TX, eprinomectin (alternative name) [CCN]+TX,ethoprophos (312)+TX, ethylene dibromide (316)+TX, fenamiphos (326)+TX,fenpyrad (alternative name)+TX, fensulfothion (1158)+TX, fosthiazate(408)+TX, fosthietan (1196)+TX, furfural (alternative name) [CCN]+TX,GY-81 (development code) (423)+TX, heterophos [CCN]+TX, iodomethane(IUPAC name) (542)+TX, isamidofos (1230)+TX, isazofos (1231)+TX,ivermectin (alternative name) [CCN]+TX, kinetin (alternative name)(210)+TX, mecarphon (1258)+TX, metam (519)+TX, metam-potassium(alternative name) (519)+TX, metam-sodium (519)+TX, methyl bromide(537)+TX, methyl isothiocyanate (543)+TX, milbemycin oxime (alternativename) [CCN]+TX, moxidectin (alternative name) [CCN]+TX, Myrotheciumverrucaria composition (alternative name) (565)+TX, NC-184 (compoundcode)+TX, oxamyl (602)+TX, phorate (636)+TX, phosphamidon (639)+TX,phosphocarb [CCN]+TX, sebufos (alternative name)+TX, selamectin(alternative name) [CCN]+TX, spinosad (737)+TX, terbam (alternativename)+TX, terbufos (773)+TX, tetrachlorothiophene (IUPAC/ChemicalAbstracts name) (1422)+TX, thiafenox (alternative name)+TX, thionazin(1434)+TX, triazophos (820)+TX, triazuron (alternative name)+TX,xylenols [CCN]+TX, YI-5302 (compound code) and zeatin (alternative name)(210)+TX, fluensulfone [318290-98-1]+TX,

a nitrification inhibitor selected from the group of substancesconsisting of potassium ethylxanthate [CCN] and nitrapyrin (580)+TX,

a plant activator selected from the group of substances consisting ofacibenzolar (6)+TX, acibenzolar-S-methyl (6)+TX, probenazole (658) andReynoutria sachalinensis extract (alternative name) (720)+TX,

a rodenticide selected from the group of substances consisting of2-isovalerylindan-1,3-dione (IUPAC name) (1246)+TX,4-(quinoxalin-2-ylamino)benzenesulfonamide (IUPAC name) (748)+TX,alpha-chlorohydrin [CCN]+TX, aluminium phosphide (640)+TX, antu(880)+TX, arsenous oxide (882)+TX, barium carbonate (891)+TX,bisthiosemi (912)+TX, brodifacoum (89)+TX, bromadiolone (91)+TX,bromethalin (92)+TX, calcium cyanide (444)+TX, chloralose (127)+TX,chlorophacinone (140)+TX, cholecalciferol (alternative name) (850)+TX,coumachlor (1004)+TX, coumafuryl (1005)+TX, coumatetralyl (175)+TX,crimidine (1009)+TX, difenacoum (246)+TX, difethialone (249)+TX,diphacinone (273)+TX, ergocalciferol (301)+TX, flocoumafen (357)+TX,fluoroacetamide (379)+TX, flupropadine (1183)+TX, flupropadinehydrochloride (1183)+TX, gamma-HCH (430)+TX, HCH (430)+TX, hydrogencyanide (444)+TX, iodomethane (IUPAC name) (542)+TX, lindane (430)+TX,magnesium phosphide (IUPAC name) (640)+TX, methyl bromide (537)+TX,norbormide (1318)+TX, phosacetim (1336)+TX, phosphine (IUPAC name)(640)+TX, phosphorus [CCN]+TX, pindone (1341)+TX, potassium arsenite[CCN]+TX, pyrinuron (1371)+TX, scilliroside (1390)+TX, sodium arsenite[CCN]+TX, sodium cyanide (444)+TX, sodium fluoroacetate (735)+TX,strychnine (745)+TX, thallium sulfate [CCN]+TX, warfarin (851) and zincphosphide (640)+TX,

a synergist selected from the group of substances consisting of2-(2-butoxyethoxy)ethyl piperonylate (IUPAC name) (934)+TX,5-(1,3-benzodioxol-5-yl)-3-hexylcyclohex-2-enone (IUPAC name) (903)+TX,farnesol with nerolidol (alternative name) (324)+TX, MB-599 (developmentcode) (498)+TX, MGK 264 (development code) (296)+TX, piperonyl butoxide(649)+TX, piprotal (1343)+TX, propyl isomer (1358)+TX, S421 (developmentcode) (724)+TX, sesamex (1393)+TX, sesasmolin (1394) and sulfoxide(1406)+TX,

an animal repellent selected from the group of substances consisting ofanthraquinone (32)+TX, chloralose (127)+TX, copper naphthenate [CCN]+TX,copper oxychloride (171)+TX, diazinon (227)+TX, dicyclopentadiene(chemical name) (1069)+TX, guazatine (422)+TX, guazatine acetates(422)+TX, methiocarb (530)+TX, pyridin-4-amine (IUPAC name) (23)+TX,thiram (804)+TX, trimethacarb (840)+TX, zinc naphthenate [CCN] and ziram(856)+TX,

a virucide selected from the group of substances consisting of imanin(alternative name) [CCN] and ribavirin (alternative name) [CCN]+TX,

a wound protectant selected from the group of substances consisting ofmercuric oxide (512)+TX, octhilinone (590) and thiophanate-methyl(802)+TX,

and biologically active compounds selected from the group consisting ofametoctradin [865318-97-4]+TX, amisulbrom [348635-87-0]+TX, azaconazole[60207-31-0]+TX, benzovindiflupyr [1072957-71-1]+TX, bitertanol[70585-36-3]+TX, bixafen [581809-46-3]+TX, bromuconazole[116255-48-2]+TX, coumoxystrobin [850881-70-8]+TX, cyproconazole[94361-06-5]+TX, difenoconazole [119446-68-3]+TX, diniconazole[83657-24-3]+TX, enoxastrobin [238410-11-2]+TX, epoxiconazole[106325-08-0]+TX, fenbuconazole [114369-43-6]+TX, fenpyrazamine[473798-59-3]+TX, fluquinconazole [136426-54-5]+TX, flusilazole[85509-19-9]+TX, flutriafol [76674-21-0]+TX, fluxapyroxad[907204-31-3]+TX, fluopyram [658066-35-4]+TX, fenaminstrobin[366815-39-6]+TX, isofetamid [875915-78-9]+TX, hexaconazole[79983-71-4]+TX, imazalil [35554-44-0]+TX, imibenconazole[86598-92-7]+TX, ipconazole [125225-28-7]+TX, ipfentrifluconazole[1417782-08-1]+TX, isotianil [224049-04-1]+TX, mandestrobin[173662-97-0] (can be prepared according to the procedures described inWO 2010/093059)+TX, mefentrifluconazole [1417782-03-6]+TX, metconazole[125116-23-6]+TX, myclobutanil [88671-89-0]+TX, paclobutrazol[76738-62-0]+TX, pefurazoate [101903-30-4]+TX, penflufen[494793-67-8]+TX, penconazole [66246-88-6]+TX, prothioconazole[178928-70-6]+TX, pyrifenox [88283-41-4]+TX, prochloraz [67747-09-5]+TX,propiconazole [60207-90-1]+TX, simeconazole [149508-90-7]+TX,tebuconazole [107534-96-3]+TX, tetraconazole [112281-77-3]+TX,triadimefon [43121-43-3]+TX, triadimenol [55219-65-3]+TX, triflumizole[99387-89-0]+TX, triticonazole [131983-72-7]+TX, ancymidol[12771-68-5]+TX, fenarimol [60168-88-9]+TX, nuarimol [63284-71-9]+TX,bupirimate [41483-43-6]+TX, dimethirimol [5221-53-4]+TX, ethirimol[23947-60-6]+TX, dodemorph [1593-77-7]+TX, fenpropidin [67306-00-7]+TX,fenpropimorph [67564-91-4]+TX, spiroxamine [118134-30-8]+TX, tridemorph[81412-43-3]+TX, cyprodinil [121552-61-2]+TX, mepanipyrim[110235-47-7]+TX, pyrimethanil [53112-28-0]+TX, fenpiclonil[74738-17-3]+TX, fludioxonil [131341-86-1]+TX, fluindapyr[1383809-87-7]+TX, benalaxyl [71626-11-4]+TX, furalaxyl [57646-30-7]+TX,metalaxyl [57837-19-1]+TX, R-metalaxyl [70630-17-0]+TX, ofurace[58810-48-3]+TX, oxadixyl [77732-09-3]+TX, benomyl [17804-35-2]+TX,carbendazim [10605-21-7]+TX, debacarb [62732-91-6]+TX, fuberidazole[3878-19-1]+TX, thiabendazole [148-79-8]+TX, chlozolinate[84332-86-5]+TX, dichlozoline [24201-58-9]+TX, iprodione[36734-19-7]+TX, myclozoline [54864-61-8]+TX, procymidone[32809-16-8]+TX, vinclozoline [50471-44-8]+TX, boscalid[188425-85-6]+TX, carboxin [5234-68-4]+TX, fenfuram [24691-80-3]+TX,flutolanil [66332-96-5]+TX, flutianil [958647-10-4]+TX, mepronil[55814-41-0]+TX, oxycarboxin [5259-88-1]+TX, penthiopyrad[183675-82-3]+TX, thifluzamide [130000-40-7]+TX, guazatine[108173-90-6]+TX, dodine [2439-10-3] [112-65-2] (free base)+TX,iminoctadine [13516-27-3]+TX, azoxystrobin [131860-33-8]+TX,dimoxystrobin [149961-52-4]+TX, enestroburin {Proc. BCPC, Int. Congr.,Glasgow, 2003, 1, 93}+TX, fluoxastrobin [361377-29-9]+TX,kresoxim-methyl [143390-89-0]+TX, metominostrobin [133408-50-1]+TX,trifloxystrobin [141517-21-7]+TX, orysastrobin [248593-16-0]+TX,picoxystrobin [117428-22-5]+TX, pyraclostrobin [175013-18-0]+TX,pyraoxystrobin [862588-11-2]+TX, ferbam [14484-64-1]+TX, mancozeb[8018-01-7]+TX, maneb [12427-38-2]+TX, metiram [9006-42-2]+TX, propineb[12071-83-9]+TX, thiram [137-26-8]+TX, zineb [12122-67-7]+TX, ziram[137-30-4]+TX, captafol [2425-06-1]+TX, captan [133-06-2]+TX,dichlofluanid [1085-98-9]+TX, fluoroimide [41205-21-4]+TX, folpet[133-07-3]+TX, tolylfluanid [731-27-1]+TX, bordeaux mixture[8011-63-0]+TX, copperhydroxid [20427-59-2]+TX, copperoxychlorid[1332-40-7]+TX, coppersulfat [7758-98-7]+TX, copperoxid [1317-39-1]+TX,mancopper [53988-93-5]+TX, oxine-copper [10380-28-6]+TX, dinocap[131-72-6]+TX, nitrothal-isopropyl [10552-74-6]+TX, edifenphos[17109-49-8]+TX, iprobenphos [26087-47-8]+TX, isoprothiolane[50512-35-1]+TX, phosdiphen [36519-00-3]+TX, pyrazophos [13457-18-6]+TX,tolclofos-methyl [57018-04-9]+TX, acibenzolar-S-methyl [135158-54-2]+TX,anilazine [101-05-3]+TX, benthiavalicarb [413615-35-7]+TX, blasticidin-S[2079-00-7]+TX, chinomethionat [2439-01-2]+TX, chloroneb [2675-77-6]+TX,chlorothalonil [1897-45-6]+TX, cyflufenamid [180409-60-3]+TX, cymoxanil[57966-95-7]+TX, dichlone [117-80-6]+TX, diclocymet [139920-32-4]+TX,diclomezine [62865-36-5]+TX, dicloran [99-30-9]+TX, diethofencarb[87130-20-9]+TX, dimethomorph [110488-70-5]+TX, SYP-LI90 (Flumorph)[211867-47-9]+TX, dithianon [3347-22-6]+TX, ethaboxam [162650-77-3]+TX,etridiazole [2593-15-9]+TX, famoxadone [131807-57-3]+TX, fenamidone[161326-34-7]+TX, fenoxanil [115852-48-7]+TX, fentin [668-34-8]+TX,ferimzone [89269-64-7]+TX, fluazinam [79622-59-6]+TX, fluopicolide[239110-15-7]+TX, flusulfamide [106917-52-6]+TX, fenhexamid[126833-17-8]+TX, fosetyl-aluminium [39148-24-8]+TX, hymexazol[10004-44-1]+TX, iprovalicarb [140923-17-7]+TX, IKF-916 (Cyazofamid)[120116-88-3]+TX, kasugamycin [6980-18-3]+TX, methasulfocarb[66952-49-6]+TX, metrafenone [220899-03-6]+TX, pencycuron[66063-05-6]+TX, phthalide [27355-22-2]+TX, picarbutrazox[500207-04-5]+TX, polyoxins [11113-80-7]+TX, probenazole[27605-76-1]+TX, propamocarb [25606-41-1]+TX, proquinazid[189278-12-4]+TX, pydiflumetofen [1228284-64-7]+TX, pyrametostrobin[915410-70-7]+TX, pyroquilon [57369-32-1]+TX, pyriofenone[688046-61-9]+TX, pyribencarb [799247-52-2]+TX, pyrisoxazole[847749-37-5]+TX, quinoxyfen [124495-18-7]+TX, quintozene [82-68-8]+TX,sulfur [7704-34-9]+TX, Timorex Gold™ (plant extract containing tea treeoil from the Stockton Group)+TX, tebufloquin [376645-78-2]+TX, tiadinil[223580-51-6]+TX, triazoxide [72459-58-6]+TX, tolprocarb[911499-62-2]+TX, triclopyricarb [902760-40-1]+TX, tricyclazole[41814-78-2]+TX, triforine [26644-46-2]+TX, validamycin [37248-47-8]+TX,valifenalate [283159-90-0]+TX, zoxamide (RH7281) [156052-68-5]+TX,mandipropamid [374726-62-2]+TX, isopyrazam [881685-58-1]+TX,phenamacril+TX, sedaxane [874967-67-6]+TX, trinexapac-ethyl[95266-40-3]+TX, 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid(9-dichloromethylene-1,2,3,4-tetrahydro-1,4-methano-naphthalen-5-yl)-amide(disclosed in WO 2007/048556)+TX,3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid(3′,4′,5′-trifluoro-biphenyl-2-yl)-amide (disclosed in WO2006/087343)+TX,[(3S,4R,4aR,6S,6aS,12R,12aS,12bS)-3-[(cyclopropylcarbonyl)oxy]-1,3,4,4a,5,6,6a,12,12a,12b-decahydro-6,12-dihydroxy-4,6a,12b-trimethyl-11-oxo-9-(3-pyridinyl)-2H,11Hnaphtho[2,1-b]pyrano[3,4-e]pyran-4-yl]methyl-cyclopropanecarboxylate[915972-17-7]+TX and1,3,5-trimethyl-N-(2-methyl-1-oxopropyl)-N-[3-(2-methylpropyl)-4-[2,2,2-trifluoro-1-methoxy-1-(trifluoromethyl)ethyl]phenyl]-1H-pyrazole-4-carboxamide[926914-55-8]+TX,

or a biologically active compound selected from the group consisting ofN-[(5-chloro-2-isopropyl-phenyl)methyl]-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-pyrazole-4-carboxamide(can be prepared according to the procedures described in WO2010/130767)+TX,2,6-Dimethyl-1H,5H-[1,4]dithiino[2,3-c:5,6-c′]dipyrrole-1,3,5,7(2H,6H)-tetrone(can be prepared according to the procedures described in WO2011/138281)+TX,6-ethyl-5,7-dioxo-pyrrolo[4,5][1,4]dithiino[1,2-c]isothiazole-3-carbonitrile+TX,4-(2-bromo-4-fluoro-phenyl)-N-(2-chloro-6-fluoro-phenyl)-2,5-dimethyl-pyrazazol-3-amine(can be prepared according to the procedures described in WO2012/031061)+TX,3-(difluoromethyl)-N-(7-fluoro-1,1,3-trimethyl-indan-4-yl)-1-methyl-pyrazole-4-carboxamide(can be prepared according to the procedures described in WO2012/084812)+TX, CAS 850881-30-0+TX,3-(3,4-dichloro-1,2-thiazol-5-ylmethoxy)-1,2-benzothiazole 1,1-dioxide(can be prepared according to the procedures described in WO2007/129454)+TX,2-[2-[(2,5-dimethylphenoxy)methyl]phenyl]-2-methoxy-N-methyl-acetamide+TX,3-(4,4-difluoro-3,4-dihydro-3,3-dimethylisoquinolin-1-yl)quinolone (canbe prepared according to the procedures described in WO 2005/070917)+TX,2-[2-fluoro-6-[(8-fluoro-2-methyl-3-quinolyl)oxy]phenyl]propan-2-ol (canbe prepared according to the procedures described in WO 2011/081174)+TX,2-[2-[(7,8-difluoro-2-methyl-3-quinolyl)oxy]-6-fluoro-phenyl]propan-2-ol(can be prepared according to the procedures described in WO2011/081174)+TX, oxathiapiprolin+TX [1003318-67-9], tert-butylN-[6-[[[(1-methyltetrazol-5-yl)-phenyl-methylene]amino]oxymethyl]-2-pyridyl]carbamate+TX,N-[2-(3,4-difluorophenyl)phenyl]-3-(trifluoromethyl)pyrazine-2-carboxamide(can be prepared according to the procedures described in WO2007/072999)+TX,3-(difluoromethyl)-1-methyl-N-[(3R)-1,1,3-trimethylindan-4-yl]pyrazole-4-carboxamide(can be prepared according to the procedures described in WO2014/013842)+TX, 2,2,2-trifluoroethylN-[2-methyl-1-[[(4-methylbenzoyl)amino]methyl]propyl]carbamate+TX,(2RS)-2-[4-(4-chlorophenoxy)-α,α,α-trifluoro-o-tolyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol+TX,(2RS)-2-[4-(4-chlorophenoxy)-α,α,α-trifluoro-o-tolyl]-3-methyl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol+TX,2-(difluoromethyl)-N-[(3R)-3-ethyl-1,1-dimethyl-indan-4-yl]pyridine-3-carboxamide+TX,2-(difluoromethyl)-N-[3-ethyl-1,1-dimethyl-indan-4-yl]pyridine-3-carboxamide+TX,N′-(2,5-dimethyl-4-phenoxy-phenyl)-N-ethyl-N-methyl-formamidine+TX,N′-[4-(4,5-dichlorothiazol-2-yl)oxy-2,5-dimethyl-phenyl]-N-ethyl-N-methyl-formamidine(can be prepared according to the procedures described in WO2007/031513)+TX,[2-[3-[2-[1-[2-[3,5-bis(difluoromethyl)pyrazol-1-yl]acetyl]-4-piperidyl]thiazol-4-yl]-4,5-dihydroisoxazol-5-yl]-3-chloro-phenyl]methanesulfonate (can be prepared according to the procedures describedin WO 2012/025557)+TX, but-3-ynylN-[6-[[(Z)-[(1-methyltetrazol-5-yl)-phenyl-methylene]amino]oxymethyl]-2-pyridyl]carbamate(can be prepared according to the procedures described in WO2010/000841)+TX,2-[[3-(2-chlorophenyl)-2-(2,4-difluorophenyl)oxiran-2-yl]methyl]-4H-1,2,4-triazole-3-thione(can be prepared according to the procedures described in WO2010/146031)+TX, methylN-[[5-[4-(2,4-dimethylphenyl)triazol-2-yl]-2-methyl-phenyl]methyl]carbamate+TX,3-chloro-6-methyl-5-phenyl-4-(2,4,6-trifluorophenyl)pyridazine (can beprepared according to the procedures described in WO 2005/121104)+TX,2-[2-chloro-4-(4-chlorophenoxy)phenyl]-1-(1,2,4-triazol-1-yl)propan-2-ol(can be prepared according to the procedures described in WO2013/024082)+TX,3-chloro-4-(2,6-difluorophenyl)-6-methyl-5-phenyl-pyridazine (can beprepared according to the procedures described in WO 2012/020774)+TX,4-(2,6-difluorophenyl)-6-methyl-5-phenyl-pyridazine-3-carbonitrile (canbe prepared according to the procedures described in WO 2012/020774)+TX,(R)-3-(difluoromethyl)-1-methyl-N-[1,1,3-trimethylindan-4-yl]pyrazole-4-carboxamide(can be prepared according to the procedures described in WO2011/162397)+TX,3-(difluoromethyl)-N-(7-fluoro-1,1,3-trimethyl-indan-4-yl)-1-methyl-pyrazole-4-carboxamide(can be prepared according to the procedures described in WO2012/084812)+TX,1-[2-[[1-(4-chlorophenyl)pyrazol-3-yl]oxymethyl]-3-methyl-phenyl]-4-methyl-tetrazol-5-one(can be prepared according to the procedures described in WO2013/162072)+TX,1-methyl-4-[3-methyl-2-[[2-methyl-4-(3,4,5-trimethylpyrazol-1-yl)phenoxy]methyl]phenyl]tetrazol-5-one(can be prepared according to the procedures described in WO2014/051165)+TX,(Z,2E)-5-[1-(4-chlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino-N,3-dimethyl-pent-3-enamide+TX,(4-phenoxyphenyl)methyl 2-amino-6-methyl-pyridine-3-carboxylate+TX,N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methylpyrazole-4-carboxamide[1255734-28-1] (can be prepared according to the procedures described inWO 2010/130767)+TX,3-(difluoromethyl)-N-[(R)-2,3-dihydro-1,1,3-trimethyl-1H-inden-4-yl]-1-methylpyrazole-4-carboxamide[1352994-67-2]+TX,N′-(2,5-dimethyl-4-phenoxy-phenyl)-N-ethyl-N-methyl-formamidine+TX,N′-[4-(4,5-dichloro-thiazol-2-yloxy)-2,5-dimethyl-phenyl]-N-ethyl-N-methyl-formamidine+TX,N′-(2,5-dimethyl-4-phenoxy-phenyl)-N-ethyl-N-methyl-formamidine+TX,N′-[4-(4,5-dichloro-thiazol-2-yloxy)-2,5-dimethyl-phenyl]-N-ethyl-N-methyl-formamidine+TX,

(fenpicoxamid [517875-34-2])+TX (as described in WO 2003/035617),2-(difluoromethyl)-N-(1,1,3-trimethylindan-4-yl)pyridine-3-carboxamide+TX,2-(difluoromethyl)-N-(3-ethyl-1,1-dimethyl-indan-4-yl)pyridine-3-carboxamide+TX,2-(difluoromethyl)-N-(1,1-dimethyl-3-propyl-indan-4-yl)pyridine-3-carboxamide+TX,2-(difluoromethyl)-N-(3-isobutyl-1,1-dimethyl-indan-4-yl)pyridine-3-carboxamide+TX,2-(difluoromethyl)-N-[(3R)-1,1,3-trimethylindan-4-yl]pyridine-3-carboxamide+TX,2-(difluoromethyl)-N-[(3R)-3-ethyl-1,1-dimethyl-indan-4-yl]pyridine-3-carboxamide+TX,and2-(difluoromethyl)-N-[(3R)-1,1-dimethyl-3-propyl-indan-4-yl]pyridine-3-carboxamide+TX,wherein each of these carboxamide compounds can be prepared according tothe procedures described in WO 2014/095675 and/or WO 2016/139189.

The references in brackets behind the active ingredients, e.g.[3878-19-1] refer to the Chemical Abstracts Registry number. The abovedescribed mixing partners are known. Where the active ingredients areincluded in “The Pesticide Manual” [The Pesticide Manual—A WorldCompendium; Thirteenth Edition; Editor: C. D. S. TomLin; The BritishCrop Protection Council], they are described therein under the entrynumber given in round brackets hereinabove for the particular compound;for example, the compound “abamectin” is described under entry number(1). Where “[CCN]” is added hereinabove to the particular compound, thecompound in question is included in the “Compendium of Pesticide CommonNames”, which is accessible on the internet [A. Wood; Compendium ofPesticide Common Names, Copyright © 1995-2004]; for example, thecompound “acetoprole” is described under the internet addresshttp://www.alanwood.net/pesticides/acetoprole.html.

Most of the active ingredients described above are referred tohereinabove by a so-called “common name”, the relevant “ISO common name”or another “common name” being used in individual cases. If thedesignation is not a “common name”, the nature of the designation usedinstead is given in round brackets for the particular compound; in thatcase, the IUPAC name, the IUPAC/Chemical Abstracts name, a “chemicalname”, a “traditional name”, a “compound name” or a “development code”is used or, if neither one of those designations nor a “common name” isused, an “alternative name” is employed. “CAS Reg. No” means theChemical Abstracts Registry Number.

The active ingredient mixture of the compounds of formula (I) selectedfrom a compound 1.1 to 1.171 described in Table T1 (below) or a compoundof formula (I) described in Tables 1.1 to 1.18 (below), and an activeingredient as described above are preferably in a mixing ratio of from100:1 to 1:6000, especially from 50:1 to 1:50, more especially in aratio of from 20:1 to 1:20, even more especially from 10:1 to 1:10, veryespecially from 5:1 and 1:5, special preference being given to a ratioof from 2:1 to 1:2, and a ratio of from 4:1 to 2:1 being likewisepreferred, above all in a ratio of 1:1, or 5:1, or 5:2, or 5:3, or 5:4,or 4:1, or 4:2, or 4:3, or 3:1, or 3:2, or 2:1, or 1:5, or 2:5, or 3:5,or 4:5, or 1:4, or 2:4, or 3:4, or 1:3, or 2:3, or 1:2, or 1:600, or1:300, or 1:150, or 1:35, or 2:35, or 4:35, or 1:75, or 2:75, or 4:75,or 1:6000, or 1:3000, or 1:1500, or 1:350, or 2:350, or 4:350, or 1:750,or 2:750, or 4:750. Those mixing ratios are by weight.

The mixtures as described above can be used in a method for controllingpests, which comprises applying a composition comprising a mixture asdescribed above to the pests or their environment, with the exception ofa method for treatment of the human or animal body by surgery or therapyand diagnostic methods practised on the human or animal body.

The mixtures comprising a compound of formula (I) selected from one ofTables 1.1 to 1.18 (below), or Table T1 (below), and one or more activeingredients as described above can be applied, for example, in a single“ready-mix” form, in a combined spray mixture composed from separateformulations of the single active ingredient components, such as a“tank-mix”, and in a combined use of the single active ingredients whenapplied in a sequential manner, i.e. one after the other with areasonably short period, such as a few hours or days. The order ofapplying the compounds of formula (I) selected from Tables 1.1 to 1.18(below), or Table T1 (below), and the active ingredient(s) as describedabove, is not essential for working the present invention.

The compositions according to the invention can also comprise furthersolid or liquid auxiliaries, such as stabilizers, for exampleunepoxidized or epoxidized vegetable oils (for example epoxidizedcoconut oil, rapeseed oil or soya oil), antifoams, for example siliconeoil, preservatives, viscosity regulators, binders and/or tackifiers,fertilizers or other active ingredients for achieving specific effects,for example bactericides, fungicides, nematocides, plant activators,molluscicides or herbicides.

The compositions according to the invention are prepared in a mannerknown per se, in the absence of auxiliaries for example by grinding,screening and/or compressing a solid active ingredient and in thepresence of at least one auxiliary for example by intimately mixingand/or grinding the active ingredient with the auxiliary (auxiliaries).These processes for the preparation of the compositions and the use ofthe compounds of formula (I) for the preparation of these compositionsare also a subject of the invention.

Another aspect of the invention is related to the use of a compound offormula (I) or of a preferred individual compound as defined herein, ofa composition comprising at least one compound of formula (I) or atleast one preferred individual compound as above-defined, or of afungicidal or insecticidal mixture comprising at least one compound offormula (I) or at least one preferred individual compound asabove-defined, in admixture with other fungicides or insecticides asdescribed above, for controlling or preventing infestation of plants,e.g. useful plants such as crop plants, propagation material thereof,e.g. seeds, harvested crops, e.g. harvested food crops, or non-livingmaterials by insects or by phytopathogenic microorganisms, preferablyfungal organisms.

A further aspect of the invention is related to a method of controllingor preventing an infestation of plants, e.g., useful plants such as cropplants, propagation material thereof, e.g. seeds, harvested crops, e.g.,harvested food crops, or of non-living materials by insects or byphytopathogenic or spoilage microorganisms or organisms potentiallyharmful to man, especially fungal organisms, which comprises theapplication of a compound of formula (I) or of a preferred individualcompound as above-defined as active ingredient to the plants, to partsof the plants or to the locus thereof, to the propagation materialthereof, or to any part of the non-living materials.

Controlling or preventing means reducing infestation by phytopathogenicor spoilage microorganisms or organisms potentially harmful to man,especially fungal organisms, to such a level that an improvement isdemonstrated.

A preferred method of controlling or preventing an infestation of cropplants by phytopathogenic microorganisms, especially fungal organisms,or insects which comprises the application of a compound of formula (I),or an agrochemical composition which contains at least one of saidcompounds, is foliar application. The frequency of application and therate of application will depend on the risk of infestation by thecorresponding pathogen or insect. However, the compounds of formula (I)can also penetrate the plant through the roots via the soil (systemicaction) by drenching the locus of the plant with a liquid formulation,or by applying the compounds in solid form to the soil, e.g. in granularform (soil application). In crops of water rice such granulates can beapplied to the flooded rice field. The compounds of formula I may alsobe applied to seeds (coating) by impregnating the seeds or tubers eitherwith a liquid formulation of the fungicide or coating them with a solidformulation.

A formulation, e.g. a composition containing the compound of formula(I), and, if desired, a solid or liquid adjuvant or monomers forencapsulating the compound of formula (I), may be prepared in a knownmanner, typically by intimately mixing and/or grinding the compound withextenders, for example solvents, solid carriers and, optionally, surfaceactive compounds (surfactants).

Advantageous rates of application are normally from 5 g to 2 kg ofactive ingredient (a.i.) per hectare (ha), preferably from 10 g to 1 kga.i./ha, most preferably from 20 g to 600 g a.i./ha. When used as seeddrenching agent, convenient dosages are from 10 mg to 1 g of activesubstance per kg of seeds.

When the combinations of the present invention are used for treatingseed, rates of 0.001 g to 50 g of a compound of formula I per kg ofseed, preferably from 0.01 g to 10 g per kg of seed are generallysufficient.

Suitably, a composition comprising a compound of formula (I) accordingto the present invention is applied either preventative, meaning priorto disease development or curative, meaning after disease development.

The compositions of the invention may be employed in any conventionalform, for example in the form of a twin pack, a powder for dry seedtreatment (DS), an emulsion for seed treatment (ES), a flowableconcentrate for seed treatment (FS), a solution for seed treatment (LS),a water dispersible powder for seed treatment (WS), a capsule suspensionfor seed treatment (CF), a gel for seed treatment (GF), an emulsionconcentrate (EC), a suspension concentrate (SC), a suspo-emulsion (SE),a capsule suspension (CS), a water dispersible granule (WG), anemulsifiable granule (EG), an emulsion, water in oil (EO), an emulsion,oil in water (EW), a micro-emulsion (ME), an oil dispersion (OD), an oilmiscible flowable (OF), an oil miscible liquid (OL), a solubleconcentrate (SL), an ultra-low volume suspension (SU), an ultra-lowvolume liquid (UL), a technical concentrate (TK), a dispersibleconcentrate (DC), a wettable powder (WP) or any technically feasibleformulation in combination with agriculturally acceptable adjuvants.

Such compositions may be produced in conventional manner, e.g. by mixingthe active ingredients with appropriate formulation inerts (diluents,solvents, fillers and optionally other formulating ingredients such assurfactants, biocides, anti-freeze, stickers, thickeners and compoundsthat provide adjuvancy effects). Also conventional slow releaseformulations may be employed where long lasting efficacy is intended.Particularly formulations to be applied in spraying forms, such as waterdispersible concentrates (e.g. EC, SC, DC, OD, SE, EW, EO and the like),wettable powders and granules, may contain surfactants such as wettingand dispersing agents and other compounds that provide adjuvancyeffects, e.g. the condensation product of formaldehyde with naphthalenesulphonate, an alkylarylsulphonate, a lignin sulphonate, a fatty alkylsulphate, and ethoxylated alkylphenol and an ethoxylated fatty alcohol.

A seed dressing formulation is applied in a manner known per se to theseeds employing the combination of the invention and a diluent insuitable seed dressing formulation form, e.g. as an aqueous suspensionor in a dry powder form having good adherence to the seeds. Such seeddressing formulations are known in the art. Seed dressing formulationsmay contain the single active ingredients or the combination of activeingredients in encapsulated form, e.g. as slow release capsules ormicrocapsules.

In general, the formulations include from 0.01 to 90% by weight ofactive agent, from 0 to 20% agriculturally acceptable surfactant and 10to 99.99% solid or liquid formulation inerts and adjuvant(s), the activeagent consisting of at least the compound of formula (I) optionallytogether with other active agents, particularly microbiocides orconservatives or the like. Concentrated forms of compositions generallycontain in between about 2 and 80%, preferably between about 5 and 70%by weight of active agent. Application forms of formulation may forexample contain from 0.01 to 20% by weight, preferably from 0.01 to 5%by weight of active agent. Whereas commercial products will preferablybe formulated as concentrates, the end user will normally employ dilutedformulations.

Whereas it is preferred to formulate commercial products asconcentrates, the end user will normally use dilute formulations.

TABLE 1.1 This table discloses 44 specific compounds of the formula(T-1):

(T-1)

wherein n is 1, A¹ is C—R¹, A² is C—R², A³ is C—R³, A⁴ is C—R⁴ and R¹,R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are hydrogen, and R⁹ is as defined belowin Table 1.

Each of Tables 1.2 to 1.18 (which follow Table 1.1) make available 44individual compounds of the formula (T-1) in which n, A¹, A², A³, A⁴,R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are as specifically defined in Tables1.2 to 1.18, which refer to Table 1 wherein R⁹ is specifically defined.

TABLE 1 Compound no. R⁹ 1.001

1.002 —CH₂CH₃ 1.003 —(CH₂)₁₁CH₃ 1.004

1.005

1.006

1.007

1.008 —CH₂CH═CHCl 1.009

1.010

1.011 —CH₂CH═CH₂ 1.012 —CH₂CH═C(CH₃)₂ 1.013 —CH₂CH═C(Cl)₂ 1.014—CH(CH₃)₂ 1.015 —CH(CH₃)C(O)OCH₂CH₃ ((R) and (S)) 1.016 —CH₂CH(CH₃)₂1.017

1.018 —CH₃ 1.019

1.020 —C(CH₃)₃ 1.021

1.022

1.023

1.024 —(CH₂)₅CH₃ 1.025 —CH₂CH═CHCl ((E) and (Z)) 1.026 —CH₂CH₂CH₂CH₃1.027 —CH₂CH₂OH 1.028 —CH₂C(═CH₂)Cl 1.029

1.030

1.031 —CH₂CH₂CH₃ 1.032

1.033

1.034

1.035

1.036 —CH(CH₃)C(O)OH 1.037

1.038

1.039

1.040 —CH₂C≡CH 1.041 —CH₂CF₃ 1.042

1.043

1.044 HTable 1.2:

This table discloses 44 specific compounds of formula (T-1) wherein n is1, A¹ is C—R¹, A² is C—R², A³ is C—R³, A⁴ is C—R⁴ and R², R³, R⁴, R⁵,R⁶, R⁷ and R⁸ are hydrogen, R¹ is fluorine, and R⁹ is as defined abovein Table 1.

Table 1.3:

This table discloses 44 specific compounds of formula (T-1) wherein n is1, A¹ is C—R¹, A² is C—R², A³ is C—R³, A⁴ is C—R⁴ and R¹, R², R⁴, R⁵,R⁶, R⁷ and R⁸ are hydrogen, R³ is fluorine, and R⁹ is as defined abovein Table 1.

Table 1.4:

This table discloses 44 specific compounds of formula (T-1) wherein n is1, A¹ is C—R¹, A² is C—R², A³ is C—R³, A⁴ is C—R⁴ and R², R⁴, R⁵, R⁶, R⁷and R⁸ are hydrogen, R¹ and R³ are fluorine, and R⁹ is as defined abovein Table 1.

Table 1.5:

This table discloses 44 specific compounds of formula (T-1) wherein n is1, A¹ is C—R¹, A² is C—R², A³ is C—R³, A⁴ is C—R⁴ and R³, R⁴, R⁵, R⁶, R⁷and R⁸ are hydrogen, R¹ and R² are fluorine, and R⁹ is as defined abovein Table 1.

Table 1.6:

This table discloses 44 specific compounds of formula (T-1) wherein n is2, A¹ is C—R¹, A² is C—R², A³ is C—R³, A⁴ is C—R⁴ and R¹, R², R³, R⁴,R⁵, R⁶, R⁷ and R⁸ are hydrogen, and R⁹ is as defined above in Table 1.

Table 1.7:

This table discloses 44 specific compounds of formula (T-1) wherein n is2, A¹ is C—R¹, A² is C—R², A³ is C—R³, A⁴ is C—R⁴ and R², R³, R⁴, R⁵,R⁶, R⁷ and R⁸ are hydrogen, R¹ is fluorine, and R⁹ is as defined abovein Table 1.

Table 1.8:

This table discloses 44 specific compounds of formula (T-1) wherein n is2, A¹ is C—R¹, A² is C—R², A³ is C—R³, A⁴ is C—R⁴ and R¹, R², R⁴, R⁵,R⁶, R⁷ and R⁸ are hydrogen, R³ is fluorine, and R⁹ is as defined abovein Table 1.

Table 1.9:

This table discloses 44 specific compounds of formula (T-1) wherein n is1, A¹ is C—R¹, A² is C—R², A³ is C—R³, A⁴ is C—R⁴ and R¹, R², R³, R⁴,R⁵, R⁷ and R⁸ are hydrogen, R⁶ is methyl, and R⁹ is as defined below inTable 1.

Table 1.10:

This table discloses 44 specific compounds of formula (T-1) wherein n is1, A¹ is C—R¹, A² is C—R², A³ is C—R³, A⁴ is C—R⁴ and R², R³, R⁴, R⁵, R⁷and R⁸ are hydrogen, R¹ is fluorine, R⁶ is methyl, and R⁹ is as definedabove in Table 1.

Table 1.11:

This table discloses 44 specific compounds of formula (T-1) wherein n is1, A¹ is C—R¹, A² is C—R², A³ is C—R³, A⁴ is C—R⁴ and R¹, R², R⁴, R⁵, R⁷and R⁸ are hydrogen, R³ is fluorine, R⁶ is methyl, and R⁹ is as definedabove in Table 1.

Table 1.12:

This table discloses 44 specific compounds of formula (T-1) wherein n is1, A¹ is C—R¹, A² is C—R², A³ is C—R³, A⁴ is C—R⁴ and R¹, R², R³, R⁴,R⁵, R⁶ and R⁷ are hydrogen, R⁸ is methyl, and R⁹ is as defined above inTable 1.

Table 1.13:

This table discloses 44 specific compounds of formula (T-1) wherein n is1, A¹ is C—R¹, A² is C—R², A³ is C—R³, A⁴ is C—R⁴ and R², R³, R⁴, R⁵, R⁶and R⁷ are hydrogen, R¹ is fluorine, R⁸ is methyl, and R⁹ is as definedabove in Table 1.

Table 1.14:

This table discloses 44 specific compounds of formula (T-1) wherein n is1, A¹ is C—R¹, A² is C—R², A³ is C—R³, A⁴ is C—R⁴ and R¹, R², R⁴, R⁵, R⁶and R⁷ are hydrogen, R³ is fluorine, R⁸ is methyl, and R⁹ is as definedabove in Table 1.

Table 1.15:

This table discloses 44 specific compounds of formula (T-1) wherein n is0, A¹ is C—R¹, A² is C—R², A³ is C—R³, A⁴ is C—R⁴ and R¹, R², R³, R⁴, R⁵and R⁸ are hydrogen, and R⁹ is as defined above in Table 1.

Table 1.16:

This table discloses 44 specific compounds of formula (T-1) wherein n is0, A¹ is C—R¹, A² is C—R², A³ is C—R³, A⁴ is C—R⁴ and R², R³, R⁴, R⁵ andR⁸ are hydrogen, R¹ is fluorine, and R⁹ is as defined above in Table 1.

Table 1.17:

This table discloses 44 specific compounds of formula (T-1) wherein n is0, A¹ is C—R¹, A² is C—R², A³ is C—R³, A⁴ is C—R⁴ and R¹, R², R⁴, R⁵ andR⁸ are hydrogen, R³ is fluorine, and R⁹ is as defined above in Table 1.

Table 1.18:

This table discloses 44 specific compounds of formula (T-1) wherein n is0, A¹ is C—R¹, A² is C—R², A³ is C—R³, A⁴ is C—R⁴ and R¹, R², R³, R⁴,and R⁵ are hydrogen, R⁸ is methyl, and R⁹ is as defined above in Table1.

EXAMPLES

The Examples which follow serve to illustrate the invention. Thecompounds of the invention can be distinguished from known compounds byvirtue of greater efficacy at low application rates, which can beverified by the person skilled in the art using the experimentalprocedures outlined in the Examples, using lower application rates ifnecessary, for example 50 ppm, 12.5 ppm, 6 ppm, 3 ppm, 1.5 ppm, 0.8 ppm,or 0.2 ppm.

Compounds of Formula (I) may possess any number of benefits including,inter alia, advantageous levels of biological activity for protectingplants against diseases that are caused by fungi or superior propertiesfor use as agrochemical active ingredients (for example, greaterbiological activity, an advantageous spectrum of activity, an increasedsafety profile (including improved crop tolerance), improvedphysico-chemical properties, or increased biodegradability).

Throughout this description, LC/MS means Liquid Chromatography MassSpectrometry and the description of the apparatus and the method(Methods A, B, C and D) is as follows:

The Description of the Apparatus and the Method A is:

SQ Detector 2 from Waters

Ionisation method: Electrospray

Polarity: positive and negative ions

Capillary (kV) 3.0, Cone (V) 30.00, Extractor (V) 2.00, SourceTemperature (° C.) 150, Desolvation Temperature (° C.) 350, Cone GasFlow (L/Hr) 0, Desolvation Gas Flow (L/Hr) 650

Mass range: 100 to 900 Da

DAD Wavelength range (nm): 210 to 500

Method Waters ACQUITY UPLC with the Following HPLC Gradient Conditions

(Solvent A: Water/Methanol 20:1+0.05% formic acid and Solvent B:Acetonitrile+0.05% formic acid)

Time (minutes) A (%) B (%) Flow rate (ml/min) 0 100 0 0.85 1.2 0 1000.85 1.5 0 100 0.85Type of column: Waters ACQUITY UPLC HSS T3; Column length: 30 mm;Internal diameter of column: 2.1 mm; Particle Size: 1.8 micron;Temperature: 60° C.The Description of the Apparatus and the Method B is:SQ Detector 2 from WatersIonisation method: ElectrosprayPolarity: positive ionsCapillary (kV) 3.5, Cone (V) 30.00, Extractor (V) 3.00, SourceTemperature (° C.) 150, Desolvation Temperature (° C.) 400, Cone GasFlow (L/Hr) 60, Desolvation Gas Flow (L/Hr) 700Mass range: 140 to 800 DaDAD Wavelength range (nm): 210 to 400Method Waters ACQUITY UPLC with the Following HPLC Gradient Conditions(Solvent A: Water/Methanol 9:1+0.1% formic acid and Solvent B:Acetonitrile+0.1% formic acid)

Time (minutes) A (%) B (%) Flow rate (ml/min) 0 100 0 0.75 2.5 0 1000.75 2.8 0 100 0.75 3.0 100 0 0.75Type of column: Waters ACQUITY UPLC HSS T3; Column length: 30 mm;Internal diameter of column: 2.1 mm; Particle Size: 1.8 micron;Temperature: 60° C.The Description of the Apparatus and the Method C is:6410 Triple quadrupole Mass Spectrometer from Agilent TechnologiesAgilent 1200 Series HPLCIonisation method: ElectrosprayPolarity: positive and negative polarity switchCapillary (kV) 4.0, Cone (V) 100, Extractor (V) 4.00, DesolvationTemperature (° C.) 300, Cone Gas Flow (psi) 45, Desolvation Gas Flow(L/min.) 11Mass range: 140 to 800 DaDAD Wavelength range (nm): 210 to 400HPLC Gradient Conditions(Solvent A: Water, 0.1% formic acid and Solvent B: Acetonitrile, 0.1%formic acid)

Time (minutes) A (%) B (%) Flow rate (ml/min) 0 90 10 1.8 0.9 0 100 1.801.8 0 100 1.80 2.2 90 10 1.80Type of column: KINETEX EVO C18; Column length: 50 mm; Internal diameterof column: 4.6 mm;Particle Size: 2.6μ; Temperature: 40° C.The Description of the Apparatus and the Method D is:Mass Spectrometer: ACQUITY SQD Mass Spectrometer from WatersIonisation method: ElectrosprayPolarity: Positive and Negative Polarity SwitchCapillary (kV): 3.0, Cone Voltage (V): 41, Source Temperature (° C.)150,Desolvation Gas Flow (L/Hr) 1000, Desolvation Temperature (° C.500, GasFlow @ Cone (L/Hr)50, Mass rangel 110 to 800 Da, PDA Wavelength range(nm) 210 to 400Gradient Conditions:Solvent A: Water with 0.1% formic acid:Acetonitrile 95:5 v/vSolvent B: Acetonitrile with 0.05% formic acid

Time (minutes) A (%) B (%) Flow rate (ml/min) 0 90 10 0.8 0.2 50 50 0.80.7 0 100 0.8 1.3 0 100 0.8 1.4 90 10 0.8 1.6 90 10 0.8Type of column: Waters ACQUITY UPLC HSS T3 C18; Column length: 30 mm;Internal diameter of column: 2.1 mm; Particle Size: 1.8μ; Temperature:40° C.

Where necessary, enantiomerically pure final compounds may be obtainedfrom racemic materials as appropriate via standard physical separationtechniques, such as reverse phase chiral chromatography, or throughstereoselective synthetic techniques, e.g., by using chiral startingmaterials.

FORMULATION EXAMPLES

Wettable powders a) b) c) active ingredient [compound of formula (I)]25%  50% 75% sodium lignosulfonate 5%  5% — sodium lauryl sulfate 3% — 5% sodium diisobutylnaphthalenesulfonate —  6% 10% phenol polyethyleneglycol ether (7-8 mol of —  2% — ethylene oxide) highly dispersedsilicic acid 5% 10% 10% Kaolin 62%  27% —

The active ingredient is thoroughly mixed with the adjuvants and themixture is thoroughly ground in a suitable mill, affording wettablepowders that can be diluted with water to give suspensions of thedesired concentration.

Powders for dry seed treatment a) b) c) active ingredient [compound offormula (I)] 25% 50% 75% light mineral oil  5%  5%  5% highly dispersedsilicic acid  5%  5% — Kaolin 65% 40% — Talcum — — 20%

The active ingredient is thoroughly mixed with the adjuvants and themixture is thoroughly ground in a suitable mill, affording powders thatcan be used directly for seed treatment.

Emulsifiable concentrate active ingredient [compound of formula (I)] 10%octylphenol polyethylene glycol ether (4-5 mol of ethylene oxide)  3%calcium dodecylbenzenesulfonate  3% castor oil polyglycol ether (35 molof ethylene oxide)  4% Cyclohexanone 30% xylene mixture 50%

Emulsions of any required dilution, which can be used in plantprotection, can be obtained from this concentrate by dilution withwater.

Dusts a) b) c) Active ingredient [compound of formula (I)]  5%  6%  4%Talcum 95% — — Kaolin — 94% — mineral filler — — 96%

Ready-for-use dusts are obtained by mixing the active ingredient withthe carrier and grinding the mixture in a suitable mill. Such powderscan also be used for dry dressings for seed.

Extruder granules Active ingredient [compound of formula (I)] 15% sodiumlignosulfonate  2% Carboxymethylcellulose  1% Kaolin 82%

The active ingredient is mixed and ground with the adjuvants, and themixture is moistened with water. The mixture is extruded and then driedin a stream of air.

Coated granules Active ingredient [compound of formula (I)] 8%polyethylene glycol (mol. wt. 200) 3% Kaolin 89% 

The finely ground active ingredient is uniformly applied, in a mixer, tothe kaolin moistened with polyethylene glycol. Non-dusty coated granulesare obtained in this manner.

Suspension concentrate active ingredient [compound of formula (I)] 40%propylene glycol 10% nonylphenol polyethylene glycol ether (15 mol ofethylene oxide)  6% Sodium lignosulfonate 10% Carboxymethylcellulose  1%silicone oil (in the form of a 75% emulsion in water)  1% Water 32%

The finely ground active ingredient is intimately mixed with theadjuvants, giving a suspension concentrate from which suspensions of anydesired dilution can be obtained by dilution with water. Using suchdilutions, living plants as well as plant propagation material can betreated and protected against infestation by microorganisms, byspraying, pouring or immersion.

Flowable concentrate for seed treatment active ingredient [compound offormula (I)] 40%  propylene glycol 5% copolymer butanol PO/EO 2%tristyrenephenole with 10-20 moles EO 2% 1,2-benzisothiazolin-3-one (inthe form of a 20% 0.5%  solution in water) monoazo-pigment calcium salt5% Silicone oil (in the form of a 75% emulsion in water) 0.2%  Water45.3%  

The finely ground active ingredient is intimately mixed with theadjuvants, giving a suspension concentrate from which suspensions of anydesired dilution can be obtained by dilution with water. Using suchdilutions, living plants as well as plant propagation material can betreated and protected against infestation by microorganisms, byspraying, pouring or immersion.

Slow-Release Capsule Suspension

28 parts of a combination of the compound of formula I are mixed with 2parts of an aromatic solvent and 7 parts of toluenediisocyanate/polymethylene-polyphenylisocyanate-mixture (8:1). Thismixture is emulsified in a mixture of 1.2 parts of polyvinylalcohol,0.05 parts of a defoamer and 51.6 parts of water until the desiredparticle size is achieved. To this emulsion a mixture of 2.8 parts1,6-diaminohexane in 5.3 parts of water is added. The mixture isagitated until the polymerization reaction is completed.

The obtained capsule suspension is stabilized by adding 0.25 parts of athickener and 3 parts of a dispersing agent. The capsule suspensionformulation contains 28% of the active ingredients. The medium capsulediameter is 8-15 microns.

The resulting formulation is applied to seeds as an aqueous suspensionin an apparatus suitable for that purpose.

LIST OF ABBREVIATIONS

-   CDCl₃=chloroform-d-   ° C.=degrees Celsius-   d=doublet-   EtOAc=ethyl acetate-   h=hour(s)-   HCl=hydrochloric acid-   M=molar-   min=minutes-   MHz=mega hertz-   mp=melting point-   m=multiplet-   M=molar-   N=normal-   ppm=parts per million-   RT=room temperature-   R_(t)=retention time-   s=singlet-   t=triplet-   TFAA=trifluoroacetic acid anhydride-   LC/MS=Liquid Chromatography Mass Spectrometry (description of the    apparatus and the methods used for LC/MS analysis are given above)

PREPARATION EXAMPLES Example 1: Preparation of2-fluoro-N-(2-methoxyimino-1,1-dimethyl-ethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide(Compound 1.2 of Table T1)

To a stirring solution of 1-methoxyimino-2-methyl-propan-2-aminehydrochloride (0.070 g, 0.46 mmol) in dichloromethane (11.0 mL) under anatmosphere of nitrogen was added triethylamine (0.25 mL, 1.77 mmol) atroom temperature, followed by the addition of2-fluoro-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzoyl chloride(0.13 g, 0.44 mmol). The reaction mixture was allowed to react for 18hours at room temperature. The solvent was removed under reducedpressure and the resultant crude residue was subjected to flashchromatography over silica gel (heptane:ethyl acetate (EtOAc) eluent99:1 to 1:99) to afford 0.093 g of2-fluoro-N-(2-methoxyimino-1,1-dimethyl-ethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamideas an oil. LC-MS method A [1.11 min.; 375 (M+H)].

¹H NMR (400 MHz, CDCl₃) δ ppm: 8.26 (m, 1H), 8.04 (m, 1H), 7.92 (d, 1H),7.71 (d, 1H), 4.51 (s, 1H), 3.91 (s, 3H), 1.68 (s, 6H).

Example 2: Preparation ofN-(2-methoxyimino-1-methyl-ethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide (Compound 1.3 of Table T1)

Step 1: Preparation ofN-(2-hydroxy-1-methyl-ethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide

To a stirring solution of 2-aminopropan-1-ol (0.95 g, 13.0 mmol) indichloromethane (25.0 mL) under an atmosphere of nitrogen was addedtriethylamine (1.50 g, 15.0 mmol) at room temperature, followed by theaddition of 4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl] benzoylchloride (3.70 g, 9.8 mmol) in dichloromethane (5.0 mL). The reactionmixture was allowed to react for 18 hours at room temperature. Thesolvent was removed under reduced pressure and the resultant cruderesidue was subjected to flash chromatography over silica gel(dichloromethane: EtOAc eluent 1:3) to afford 1.61 g ofN-(2-hydroxy-1-methyl-ethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide as a white solid (melting point: 168-169° C.).

Step 2: Preparation ofN-(1-methyl-2-oxo-ethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide

To a stirring solution ofN-(2-hydroxy-1-methyl-ethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide (0.10 g, 0.32 mmol) in dichloromethane (4.0 mL) under anatmosphere of nitrogen was added trichloroisocyanuric acid (0.08 g, 3.3mmol) at 5° C. followed by addition of1-piperidinyloxy-2,2,6,6-tetramethyl (0.05 mg, 0.003 mmol). The reactionmixture was allowed to react for 15 minutes at 5° C., then filtered oversilica gel and evaporated the solvent to afford 0.089 g ofN-(1-methyl-2-oxo-ethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide as a gum.

¹H NMR (400 MHz, CDCl₃) δ ppm: 9.70 (s, 1H), 8.24 (d, 2H), 7.81 (d, 2H),6.95 (m, 1H), 4.75 (m, 1H), 1.53 (d, 3H).

Step 3: Preparation ofN-(2-methoxyimino-1-methyl-ethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide

To a stirring solution ofN-(1-methyl-2-oxo-ethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide (0.10 g, 0.31 mmol) in dichloromethane (6.0 mL) under anatmosphere of nitrogen was added O-methylhydroxylamine chloride (0.03 g,0.30 mmol) followed by triethylamine (0.07 mL, 0.48 mmol) at roomtemperature. The reaction mixture was allowed to react for 16 hours atroom temperature. The reaction mixture was washed with saturated aqueoussodium bicarbonate solution, 1N HCl and water. The organic layer wasdried over sodium sulfate, and filtered. The solvent was removed underreduced pressure and the resultant crude residue was subjected to flashchromatography over silica gel (heptane:ethyl acetate eluent 99:1 to1:99) to afford the desiredN-(2-methoxyimino-1-methyl-ethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamideas an oil.

¹H NMR (400 MHz, CDCl₃) δ ppm: 8.24 (d, 2H), 7.76 (d, 2H), 7.51 (m, 1H),6.85 (d, 1H), 4.88 (m, 1H), 3.89 (s, 3H), 1.48 (d, 3H).

Example 3a: Preparation of(Z)-N-(methoxyiminomethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide (Compound 1.5 of Table T1) Example 3b: Preparation of(E)-N-(methoxyiminomethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide Step 1: PreparationN-(dimethylaminomethylene)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide

To a stirring suspension of 4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide (1.00 g, 3.89 mmol) in toluene (6.2 mL) under an atmosphere ofnitrogen was added dimethylformamide dimethylacetate (0.72 g, 5.84 mmol)at room temperature. The reaction mixture was allowed to react for 16hours at 90° C. whilst the methanol by-product was distilled off. Thesolvent was removed under reduced pressure to afford crudeN-(dimethylaminomethylene)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamideas a beige solid (melting point: 127-132° C.).

¹H NMR (400 MHz, CDCl₃) δ ppm: 8.69 (s, 1H), 8.42 (d, 2H), 8.18 (d, 2H),3.23 (s, 3H), 3.27 (s, 3H).

Step 2: PreparationN-(methoxyiminomethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide

To a stirring suspension of O-methylhydroxylamine chloride (0.35 g, 4.20mmol) in dichloromethane (4.0 mL) under an atmosphere of nitrogen wasadded triethylamine (0.43 g, 4.20 mmol) at room temperature. After 5minutes crudeN-(dimethylaminomethylene)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide (1.3 g, 4.2 mmol) was added. The reaction mixture was allowedto react for 16 hours at room temperature. The crude was washed with 1NNaOH and dried over sodium sulfate. The solvent was removed underreduced pressure. The crude residue was subjected to flashchromatography over silica gel (dichloromethane:diisopropyl ether eluent1:99) to afford an E/Z-mixture ofN-(methoxyiminomethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide.

(Z)-N-(methoxyiminomethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide (melting point: 135-140° C.)—¹H NMR (400 MHz, CDCl₃) δ ppm:8.90 (d, 1H), 8.28 (d, 2H), 8.03 (d, 2H), 7.83 (d, 1H), 3.96 (s, 3H).

(E)-N-(methoxyiminomethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide—¹H NMR (400 MHz, CDCl₃) δ ppm: 8.64 (d, 1H), 8.28 (d, 2H),7.99 (d, 2H), 7.83 (d, 1H), 3.81 (s, 3H).

Example 4a: Preparation ofN-[(Z)-prop-2-ynoxyiminomethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide (Compound 1.6 of Table T1) Example 4b: Preparation ofN-[(E)-prop-2-ynoxyiminomethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide Step 2: PreparationN-[(Z)-prop-2-ynoxyiminomethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide

To a stirring suspension of O-propynylhydroxylamine chloride (0.22 g,1.92 mmol) in dichloromethane (4.0 mL) under an atmosphere of nitrogenwas added triethylamine (0.27 mL, 1.92 mmol) at room temperature. After5 minutes crudeN-(dimethylaminomethylene)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide (0.6 g, 1.92 mmol) was added. The reaction mixture was allowedto react for 16 hours at room temperature. The organic phase was washedwith 1N NaOH (3.5 mL) and dried over sodium sulfate. The solvent wasremoved under reduced pressure. The crude residue was subjected to flashchromatography over silica gel (dichloromethane:diisopropyl ether eluent1:99) to afford a 4:1 E/Z-mixture ofN-[(E/Z)-prop-2-ynoxyiminomethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide.

N-[(Z)-prop-2-ynoxyiminomethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide (melting point: 114-119° C.)—¹H NMR (400 MHz, CDCl₃) δ ppm:8.89 (d, 1H), 8.27 (d, 2H), 8.02 (d, 2H), 7.93 (d, 1H), 4.73 (d, 2H),2.53 (t, 1H).

N-[(E)-prop-2-ynoxyiminomethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide—¹H NMR (400 MHz, CDCl₃) δ ppm: 8.71 (d, 1H), 8.25 (d, 2H),8.01 (d, 2H), 7.93 (d, 1H), 4.60 (d, 2H), 2.51 (t, 1H).

Example 5: Preparation ofN-[3-ethoxyiminopropyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide(Compound 1.153 of Table T1)

Step 1: Preparation ofN-(3-hydroxypropyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide

To a solution of 4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzoicacid (2.5 g, 9.7 mmol) in dichloromethane (29 mL) was added at ambienttemperature, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimidehydrochloride (2.8 g, 15 mmol) followed by trimethylamine (4 mL, 29.1mmol), 1-hydroxybenzotriazole hydrate (0.74 g, 4.8 mmol) and3-amino-1-propanol (0.88 g, 12 mmol). After stirring overnight atambient temperature for 24 hours, water (25 mL) was added and theorganics were extracted using dichloromethane. The solvent was removedunder reduced pressure to afford the title compound (2.3 g, 75% oftheoretical yield) as pale yellow solid. LC/MS (Method C) retention time(R_(t))=1.33 minutes, 316 (M+H).

Step 2: Preparation ofN-(3-oxopropyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide

To a solution ofN-(3-hydroxypropyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide(0.60 g, 1.90 mmol) in chloroform (5.712 mL) was added at 0° C.,Dess-Martin Periodinane (1.22 g, 2.86 mmol). After stirring overnight atambient temperature, saturated sodium thiosulfate (15 mL) was added andthe organics were extracted using dichloromethane. The solvent wasremoved under reduced pressure and the resultant crude material waspurified by flash chromatography over silica gel (cyclohexane:EtOAceluent gradient 1:0 to 1:1) to afford the title compound as a whitesolid. LC/MS (Method C) retention time (R_(t))=1.36 minutes, 313.9(M+H).

Step 3: Preparation ofN-[3-ethoxyiminopropyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide

To a solution ofN-(3-oxopropyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide(150 mg, 0.479 mmol) in ethanol (1.44 mL) was added at room temperatureethoxylamine hydrochloride (140.1 mg 1.44 mmol) and sodiumacetate (117.9mg, 1.44 mmol). The reaction mixture was heated at 80° C. for 16 hours.The mixture was cooled to room temperature, filtered and the filtratewas evaporated under reduced pressure to obtain crude material. Theresultant crude material was purified by flash chromatography oversilica gel (cyclohexane:EtOAc eluent gradient 1:0 to 1:0.5) to affordthe title compound as white solid. LC/MS (Method C) retention time(R_(t))=1.53 minutes, 370.9 (M+H).

Example 6: Preparation of2-fluoro-N-[2-methoxyiminopropyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide(Compound 1.157 of Table T1)

Step 1: Preparation of2-fluoro-N-(2-hydroxypropyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide

To a solution of2-fluoro-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzoic acid (0.600g, 2.173 mmol) in dichloromethane (6.51 mL) was added at ambienttemperature, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimidehydrochloride (0.638 g, 3.26 mmol) followed by trimethylamine (0.91 mL,6.52 mmol), 1-hydroxybenzotriazole hydrate (0.166 g, 1.09 mmol) and1-aminopropan-2-ol (0.196 g 2.61 mmol). After stirring at ambienttemperature for 24 hours, water (25 mL) was added and the organics wereextracted using dichloromethane. The solvent was removed under reducedpressure to give crude material. The resultant crude material waspurified by flash chromatography over silica gel (cyclohexane:EtOAceluent gradient 1:0 to 1:1) to afford the title compound as a whitesolid. LC/MS (Method C) retention time (R_(t))=1.08 minutes, 333.8(M+H).

Step 2: Preparation ofN-acetonyl-2-fluoro-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide

To a solution of2-fluoro-N-(2-hydroxypropyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide(0.460 g, 1.38 mmol) in chloroform (4.14 mL) was added at 0° C.,Dess-Martin Periodinane (0.887 g, 2.07 mmol). After stirring overnightat ambient temperature, saturated sodium thiosulfate (15 mL) was addedand the organics were extracted using dichloromethane. The solvent wasremoved under reduced pressure and the resultant crude material waspurified by flash chromatography over silica gel (cyclohexane:EtOAceluent gradient 1:0 to 1:1) to afford the title compound as white asolid. LC/MS (Method C) retention time (R_(t))=1.54 minutes, 332 (M+H).

Step 3: Preparation ofN-[3-ethoxyiminopropyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide

To a solution ofN-acetonyl-2-fluoro-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide(120 mg, 0.362 mmol) in ethanol (1.1 mL) was added at room temperaturemethoxylamine hydrochloride (93 mg 1.08 mmol) and sodium acetate (89.1mg, 1.09 mmol). The reaction mixture was heated at 80° C. for 16 hours.The mixture was cooled to room temperature, filtered and the filtratewas evaporated under reduced pressure to obtain crude material. Theresultant crude material was purified by flash chromatography oversilica gel (cyclohexane/EtOAc eluent gradient 1:0 to 1:0.5) to affordthe title compound as a white solid. LC/MS (Method C) retention time(R_(t))=1.89 minutes, 361.1 (M+H).

Example 7: Preparation ofN-[3-ethoxyiminopropyl]-3-fluoro-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide(Compound 1.161 of Table T1)

Step 1: Preparation of3-fluoro-N-(3-hydroxypropyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide

To a solution of3-fluoro-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzoic acid (700mg, 2.535 mmol) in dichloromethane (7.6 mL) was added at ambienttemperature, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimidehydrochloride (743.8 mg, 3.802 mmol) followed by triethylamine (1.07 mL,7.605 mmol), 1-hydroxybenzotriazole hydrate (194.1 mg, 1.268 mmol) and3-amino-1-propanol (230.8 mg 3.042 mmol). After stirring at ambienttemperature for 24 hours, water (25 mL) was added and the organics wereextracted using dichloromethane. The solvent was removed under reducedpressure to give crude material. The resultant crude material waspurified by flash chromatography over silica gel (cyclohexane:EtOAceluent gradient 1:0 to 1:1) to afford the title compound as a whitesolid. LC/MS (Method D) retention time (R_(t))=0.79 minutes, 334.25(M+H).

Step 2: Preparation of3-fluoro-N-(3-oxopropyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide

To a solution of3-fluoro-N-(3-hydroxypropyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide(0.800 g, 2.40 mmol) in chloroform (7.20 mL) was added at 0° C.,Dess-Martin Periodinane (1.23 g, 2.88 mmol). After stirring overnight atambient temperature, saturated sodium thiosulfate (15 mL) was added andthe organics were extracted using dichloromethane. The solvent wasremoved under reduced pressure and the resultant crude material waspurified by flash chromatography over silica gel (cyclohexane:EtOAceluent gradient 1:0 to 1:0.5) to afford the title compound as a whitesolid. LC/MS (Method D) retention time (R_(t))=0.86 minutes, 332.27(M+H).

Step 3: Preparation ofN-[3-ethoxyiminopropyl]-3-fluoro-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide

To a solution of3-fluoro-N-(3-oxopropyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide(200 mg, 0.60 mmol) in ethanol (1.81 mL) was added at room temperatureethoxylamine hydrochloride (186 mg 1.81 mmol) and sodium acetate (148.6mg, 1.81 mmol). The reaction mixture was heated at 80° C. for 16 h. Themixture was cooled to room temperature, filtered and the filtrate wasevaporated under reduced pressure to obtain crude material. Theresultant crude material was purified by flash chromatography oversilica gel (cyclohexane:EtOAc eluent gradient 1:0 to 1:0.5) to affordthe title compound as a white solid. LC/MS (Method D) retention time(R_(t))=1.00 minutes, 375.27 (M+H).

Example 8: Preparation ofN-cyclopropyl-N-[(2E)-2-methoxyiminoethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide(Compound 1.170 of Table T1)

Step 1: Preparation of 2-(cyclopropylamino)ethanol

To a solution of 2-bromoethanol (2.19 g, 17.5 mmol,) in ethanol (20 mL)was added at ambient temperature, cyclopropylamine (1 g, 17.5 mmol).After stirring at ambient temperature for 24 hours, the solvent wasremoved under reduced pressure to give crude material. The resultantcrude material was taken to next step without further purification.

Step 2: Preparation ofN-cyclopropyl-N-(2-hydroxyethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide

To a solution of 4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzoicacid (1 g, 3.87 mmol) in dichloromethane (10 mL) was added at ambienttemperature, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimidehydrochloride (0.99 g, 3.80 mmol) followed by triethylamine (1.64 mL,11.6 mmol), 1-hydroxybenzotriazole hydrate (0.30 g, 1.94 mmol) and2-(cyclopropylamino)ethanol (0.47 g, 4.65 mmol). After stirring atambient temperature for 24 hours, water (25 mL) was added and theorganics were extracted using dichloromethane. The solvent was removedunder reduced pressure to give crude material. The resultant crudematerial was purified by flash chromatography over silica gel(cyclohexane:EtOAc eluent gradient 1:0 to 1:1) to afford the titlecompound as a white solid. LC/MS (Method C) retention time (R_(t))=1.34minutes, 341.9 (M+H).

Step 3: Preparation ofN-cyclopropyl-N-(2-oxoethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide

To a solution ofN-cyclopropyl-N-(2-hydroxyethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide(100 mg, 0.29 mmol) in chloroform (0.88 mL) was added at 0° C.,Dess-Martin Periodinane (188 mg, 0.44 mmol). After stirring overnight atambient temperature, saturated sodium thiosulfate (10 mL) was added andthe organics were extracted using dichloromethane. The solvent wasremoved under reduced pressure and the resultant crude material waspurified by flash chromatography over silica gel (cyclohexane:EtOAceluent gradient 1:0 to 1:1) to afford the title compound as a colorlessgummy mass. LC/MS (Method C) retention time (R_(t))=1.32 minutes, 337.7(M−H).

Step 4: Preparation ofN-cyclopropyl-N-[(2E)-2-methoxyiminoethyl]-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide

To a solution ofN-cyclopropyl-N-(2-oxoethyl)-4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]benzamide(60 mg, 0.177 mmol) in ethanol (0.53 mL) was added at room temperaturemethoxyamine hydrochloride (45.2 mg 0.53 mmol) and sodium acetate (43.5mg, 0.55 mmol). The reaction mixture was heated at 80° C. for 2 hours.The mixture was cooled to room temperature, filtered and the filtratewas evaporated under reduced pressure to obtain crude material. Theresultant crude material was purified by flash chromatography oversilica gel (cyclohexane:EtOAc eluent gradient 1:0 to 1:0.5) to affordthe title compound as a white solid. LC/MS (Method C) retention time(R_(t))=1.55 minutes, 369 (M+H).

Where necessary, enantiomerically pure final compounds may be obtainedfrom racemic materials as appropriate via standard physical separationtechniques, such as reverse phase chiral chromatography, or throughstereoselective synthetic techniques, e.g., by using chiral startingmaterials.

TABLE T1 Melting point (mp) and/or LC/MS data for compounds for Formula(I): Compound R_(t) [M + H] Meth- mp Entry name Structure (min)(measured) od (° C.) 1.1 N-(2- methoxyimino- 1,1-dimethyl- ethyl)-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.65 356.11 B 1.2 2-fluoro-N-(2- methoxyimino- 1,1-dimethyl-ethyl)-4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.74 1.11 374.96 375 B A 1.3 N-(2- methoxyimino-1- methyl-ethyl)-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.55 343.1 A 164-165 1.4 2-fluoro-N-[(2E)-2- methoxyimino- ethyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

0.97 347 A 1.5 N-[(Z)- methoxyimino methyl]-4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzamide

1.56 315.2 A 135-140 1.6 N-[(Z)-prop-2- ynoxyimino- methyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.63 339.2 A 114-119 1.7 N-[(2E)-1- methoxy-2- methoxyimino-propyl]-4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.03 373 A 100.7- 106.9 1.8 N-[(2E)-2- ethoxyimino-1- methyl-ethyl]-4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

142-143 1.9 N-[(2Z)-2- ethoxyimino-1- methyl-ethyl]-4- [5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

173-174 1.10 N-(2- methoxyimino- ethyl)-4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzamide

155-157 1.11 N-(2- ethoxyiminoethyl)- 4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzamide

156-158 1.12 N-(2- ethoxyimino- propyl)-4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzamide

135-136 1.13 N-[(2E)-2- methoxyimino- propyl]-4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzamide

145-146 1.14 N-[(2Z)-2- methoxyimino- propyl]-4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzamide

151-152 1.15 N-[2-(2- hydroxyethoxy- imino)-1-methyl- ethyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.29 373.22 B 1.16 N-[1-methyl-2-[(4- nitrophenyl) methoxyimino]ethyl]-4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.78 464.27 B 1.17 N-[2-[(3- methoxyphenyl) methoxyimino]-1-methyl-ethyl]-4- [5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.82 449.28 B 1.18 N-[1-methyl-2-(p- tolylmethoxyimino) ethyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.92 433.28 B 1.19 N-[2-[(4- methoxyphenyl) methoxyimino]-1-methyl-ethyl]-4- [5- (trifluoromethyl)- 1,2,4-oxadiazol-3-yl]benzamide

1.81 449.29 B 1.20 2-[2-[[4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3-yl]benzoyl]amino] propylidene- amino] oxyacetic acid

1.29 387.2 B 1.21 N-[2-(2- aminoethoxy- imino)-1-methyl- ethyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

0.93 372.23 B 1.22 N-[2-[(2- chlorophenyl) methoxyimino]-1-methyl-ethyl]-4- [5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.93 453.24 B 1.23 N-[2-[(2- methoxyphenyl) methoxyimino]-1-methyl-ethyl]-4- [5- (trifluoromethyl)- 1,2,4-oxadiazol-3-yl]benzamide

1.81 449.27 B 1.24 N-[2-[(2- fluorophenyl) methoxyimino]-1-methyl-ethyl]-4- [5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.84 437.26 B 1.25 N-(1-methyl-2- tetrahydropyran- 2-yloxyimino-ethyl)-4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.65 413.26 B 1.26 N-[2-[(2-chloro-4- fluoro- phenyl)methoxy-imino]-1-methyl- ethyl]-5-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3-yl]benzamide

1.96 471.23 B 1.27 N-(1-methyl-2- propoxyimino- ethyl)-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.74 371.24 B 1.28 N-(2- dodecoxyimino-1- methyl-ethyl)-4- [5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

2.57 497.43 B 1.29 (2R)-2-[2-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzoyl]amino] propylideneamino] oxypropanoic acid

1.68 429.26 B 1.30 ethyl (2R)-2-[2- [[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzoyl]amino] propylideneamino] oxypropanoate

1.37 401.23 B 1.31 N-[2-[(4- bromophenyl) methoxyimino]-1-methyl-ethyl]-4- [5- (trifluoromethyl)- 1,2,4-oxadiazol-3-yl]benzamide

1.96 497.2 B 1.32 (2S)-2-[2-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzoyl]amino] propylideneamino] oxypropanoic acid

1.37 401.23 B 1.33 N-[2-(3- chloroallyloxy- imino)-1-methyl-ethyl]-4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.75 403.21 B 1.34 N-[2-(3,3- dichloroallyl- oxyimino)-1-methyl-ethyl]-4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.89 437.19 B 1.35 N-[1-methyl-2-(3- methylbut-2- enoxyimino)ethyl]-4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.85 397.27 B 1.36 N-[2-[(Z)-3- chloroallyloxy] imino-1-methyl-ethyl]-4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.75 403.2 B 1.37 2-[2-[[4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3-yl]benzoyl]amino] propylideneamino] oxypropanoic acid

1.67 429.29 B 1.38 ethyl 2-[2-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzoyl]amino] propylideneamino] oxypropanoate

1.37 401.23 B 1.39 N-[2-[(2,6- dichlorophenyl) methoxyimino]-1-methyl-ethyl]- 4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3-yl]benzamide

2 487.21 B 1.40 N-(2-butoxyimino- 1-methyl-ethyl)-4- [5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.86 385.26 B 1.41 N-(2- hexoxyimino-1- methyl-ethyl)-4- [5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

2.06 413.31 B 1.42 N-[1-methyl-2- [(2,3,4,5,6- pentafluorophenyl)methoxyimino] ethyl]-4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3-yl]benzamide

1.96 509.24 B 1.43 N-(2-ethoxyimino- 1-methyl-ethyl)-4- [5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.62 357.22 B 1.44 N-[1-methyl-2- [(2,4,5- trichlorophenyl)methoxyimino] ethyl]-4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3-yl]benzamide

2.16 521.22 B 1.45 N-(2-tert- butoxyimino-1- methyl-ethyl)-4- [5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.85 385.27 B 1.46 N-(2- allyloxyimino-1- methyl-ethyl)-4- [5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.67 369.23 B 1.47 N-(2- benzyloxyimino- 1-methyl-ethyl)-4- [5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.83 419.26 B 1.48 2-[2-[[2-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzoyl]amino] propylideneamino] oxymethyl]phenyl]acetic acid

1.78 491.34 B 1.49 methyl 2-[2-[[2- [[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzoyl]amino] propylideneamino] oxymethyl]phenyl]acetate

1.58 477.3 B 1.50 N-(2- isopropoxyimino- 1-methyl-ethyl)-4- [5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.73 371.24 B 1.51 N-[1-methyl-2- (2,2,2- trifluoroethoxy-imino)ethyl]-4- [5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.71 411.22 B 1.52 N-[2-[(4- fluorophenyl) methoxyimino]-1-methyl-ethyl]-4- [5- (trifluoromethyl)- 1,2,4-oxadiazol-3-yl]benzamide

1.83 437.27 B 1.53 N-[2-[(3- chlorophenyl) methoxyimino]-1-methyl-ethyl]-4- [5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.94 453.24 B 1.54 N-[1-methyl-2-[[3- (trifluoromethyl) phenyl]methoxy-imino]ethyl-4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.96 487.28 B 1.55 N-[1-methyl-2-[[2- (trifluoromethyl) phenyl]methoxy-imino]ethyl]- 4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.97 487.28 B 1.56 N-[2-(2- chloroallyloxy- imino)-1-methyl-ethyl]-4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.76 403.21 B 1.57 N-[2- (cyclopropyl- methoxyimino)- 1-methyl-ethyl]-4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.73 383.25 B 1.58 N-[1-methyl-2- (oxetan-3- yloxyimino)ethyl]- 4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.42 385.23 B 1.59 N-[2-[(4- chlorophenyl) methoxyimino]-1-methyl-ethyl]-4- [5- (trifluoromethyl)- 1,2,4-oxadiazol-3-yl]benzamide

1.93 453.26 B 1.60 N-[2-(2- hydroxyethoxy- imino)ethyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.2 359.2 B 1.61 N-[2-[(4- nitrophenyl) methoxyimino] ethyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.71 450.26 B 1.62 N-[2-[(3- methoxyphenyl) methoxyimino] ethyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.74 435.27 B 1.63 N-[2-(p- tolylmethoxy- imino)ethyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.84 419.28 B 1.64 N-[2-[(4- methoxyphenyl) methoxyimino] ethyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.72 435.28 B 1.65 2-[2-[[4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3-yl]benzoyl]amino] ethylideneamino] oxyacetic acid

1.21 373.19 B 1.66 N-[2-(2- aminoethoxy- imino)ethyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

0.87 358.23 B 1.67 N-[2-[(2- chlorophenyl) methoxyimino] ethyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.85 439.22 B 1.68 N-[2-[(2- methoxyphenyl) methoxyimino] ethyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.72 435.27 B 1.69 N-[2-[(2- fluorophenyl) methoxyimino] ethyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.76 423.25 B 1.70 N-(2- tetrahydropyran- 2-yloxyiminoethyl)- 4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.56 399.26 B 1.71 N-[2-[(2-chloro-4- fluoro- phenyl)methoxy-imino]ethyl]-4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.88 457.23 B 1.72 N-(2- propoxyiminoethyl)- 4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzamide

1.64 357.23 B 1.73 N-(2- dodecoxyimino- ethyl)-4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzamide

2.51 483.42 B 1.74 (2R)-2-[2-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzoyl]amino] ethylideneamino] oxypropanoic acid

1.6 415.24 B 1.75 ethyl (2R)-2-[2- [[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzoyl]amino] ethylideneamino] oxypropanoate

1.32 387.21 B 1.76 N-[2-[(4- bromophenyl) methoxyimino] ethyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.88 483.19 B 1.77 (2S)-2-[2-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzoyl]amino] ethylideneamino] oxypropanoic acid

1.29 387.21 B 1.78 N-[2-(3- chloroallyloxyimino) ethyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.66 389.19 B 1.79 N-[2-(3,3- dichloroallyloxy- imino)ethyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.8 423.17 B 1.80 N-[2-(3- methylbut-2- enoxyimino)ethyl]- 4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.75 383.24 B 1.81 N-[2-[(Z)-3- chloroallyloxy] iminoethyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.66 389.18 B 1.82 2-[2-[[4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3-yl]benzoyl]amino] ethylideneamino] oxypropanoic acid

1.59 415.25 B 1.83 ethyl 2-[2-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzoyl]amino] ethylideneamino] oxypropanoate

1.32 387.21 B 1.84 N-[2-[(2,6- dichlorophenyl) methoxyimino]ethyl]-4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.91 473.2 B 1.85 N-(2- butoxyiminoethyl)- 4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzamide

1.76 371.25 B 1.86 N-(2- hexoxyiminoethyl)- 4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzamide

1.98 399.29 B 1.87 N-[2-[(2,3,4,5,6- pentafluorophenyl) methoxyimino]ethyl]-4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.88 495.25 B 1.88 N-[2-[(2,4,5- trichlorophenyl) methoxyimino]ethyl]-4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

2.09 507.19 B 1.89 N-(2-tert- butoxyiminoethyl)- 4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.75 371.24 B 1.90 N-(2- benzyloxyimino- ethyl)-4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzamide

1.74 405.24 B 1.91 N-(2- allyloxyiminoethyl)- 4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzamide

1.57 355.2 B 1.92 2-[2-[[2-[[4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3-yl]benzoyl]amino] ethylideneamino] oxymethyl]phenyl] acetic acid

1.71 477.3 B 1.93 methyl 2-[2-[[2- [[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzoyl]amino] ethylideneamino] oxymethyl]phenyl]acetate

1.52 463.29 B 1.94 N-(2- isopropoxyimino- ethyl)-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.63 357.22 B 1.95 N-[2-(2,2,2- trifluoroethoxy- imino)ethyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.63 397.19 B 1.96 N-[2-[(4- fluorophenyl) methoxyimino] ethyl]-4- [5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.75 423.24 B 1.97 N-[2-[(3- chlorophenyl) methoxyimino]ethyl]- 4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.85 439.2 B 1.98 4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3-yl]-N-[2-[[3- (trifluoromethyl) phenyl]methoxy- imino]ethyl] benzamide

1.89 473.25 B 1.99 4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3-yl]-N-[2-[[2- (trifluoromethyl) phenyl]methoxy- imino]ethyl] benzamide

1.9 473.25 B 1.100 N-[2-(2- chloroallyloxy- imino)ethyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.66 389.17 B 1.101 N-[2- (cyclopropyl- methoxyimino)ethyl]- 4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.64 369.22 B 1.102 N-[2-(oxetan-3- yloxyimino)ethyl]- 4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.33 371.2 B 1.103 N-[2-[(4- chlorophenyl) methoxyimino]ethyl]- 4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.85 439.21 B 1.104 N-[2-(2- hydroxyethoxy- imino)propoxy]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.26 373.21 B 1.105 N-[2-[(4- nitrophenyl) methoxyimino] propyl]-4- [5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.78 464.26 B 1.106 N-[2-[(3- methoxyphenyl) methoxyimino] propyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.81 449.28 B 1.107 N-[2-(p- tolylmethoxyimino) propyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.91 433.27 B 1.108 N-[2-[(4- methoxyphenyl) methoxyimino] propyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.79 449.28 B 1.109 2-[[1-methyl-2-[[4- [5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzoyl]amino] ethylidene]amino] oxyacetic acid

1.27 387.19 B 1.110 N-[2-(2- aminoethoxy- imino)propyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

0.89 372.25 B 1.111 N-[2-[(2- chlorophenyl) methoxyimino] propyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.93 453.22 B 1.112 N-[2-[(2- methoxyphenyl) methoxyimino] propyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.8 449.27 B 1.113 N-[2-[(2- fluorophenyl) methoxyimino] propyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.84 437.24 B 1.114 N-(2- tetrahydropyran- 2- yloxyiminopropyl)- 4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.65 413.27 B 1.115 N-[2-[(2-chloro-4- fluoro- phenyl)methoxy-imino]propyl]-4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.96 471.22 B 1.116 N-(2- propoxyimino- propyl)-4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzamide

1.74 371.22 B 1.117 (2R)-2-[[1-methyl- 2-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzoyl]amino] ethylidene]amino] oxypropanoic acid

1.67 429.26 B 1.118 ethyl (2R)-2-[[1- methyl-2-[[4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzoyl]amino]ethylidene]amino] oxypropanoate

1.36 401.2 B 1.119 N-[2-[(4- bromophenyl) methoxyimino] propyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.96 497.18 B 1.120 (2S)-2-[[1-methyl- 2-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzoyl]amino] ethylidene]amino] oxypropanoic acid

1.36 401.22 B 1.121 N-[2-(3- chloroallyloxy- imino)propyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.74 403.2 B 1.122 N-[2-(3,3- dichloroallyloxy- imino)propyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.88 437.17 B 1.123 N-[2-(3- methylbut-2- enoxyimino) propyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.84 397.26 B 1.124 N-[2-[(Z)-3- chloroallyloxy] iminopropyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.74 403.19 B 1.125 2-[[1-methyl-2-[[4- [5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzoyl]amino] ethylidene]amino] oxypropanoic acid

1.66 429.26 B 1.126 ethyl 2-[[1-methyl- 2-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzoyl]amino] ethylidene]amino] oxypropanoate

1.36 401.22 B 1.127 N-[2-[(2,6- dichorophenyl) methoxyimino]propyl]-4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

2.01 487.19 B 1.128 N-(2- butoxyiminopropyl)- 4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzamide

1.85 385.24 B 1.129 N-(2- hexoxyiminopropyl)- 4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzamide

2.06 413.29 B 1.130 N-[2-[(2,3,4,5,6- pentafluorophenyl) methoxyimino]propyl]-4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.95 509.22 B 1.131 N-[2-[(2,4,5- trichlorophenyl) methoxyimino]propyl]-4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

2.16 521.16 B 1.132 N-(2-tert- butoxyiminopropyl)- 4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.87 385.25 B 1.133 N-(2- methoxyimino- propyl)-4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzamide

1.48 343.19 B 1.134 N-(2- benzyloxyimino- propyl)-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.82 419.24 B 1.135 N-(2- allyloxyimino- propyl)-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.65 369.21 B 1.136 2-[2-[[[1-methyl-2- [[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzoyl]amino] ethylidene]amino] oxymethyl]phenyl]acetic acid

1.77 491.3 B 1.137 methyl 2-[2-[[[1- methyl-2-[[4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzoyl]amino] ethylidene]amino] oxymethyl]phenyl]acetate

1.57 477.26 B 1.138 N-(2- isopropoxyimino- propyl)-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.73 371.23 B 1.139 N-[2-(2,2,2- trifluoroethoxy- imino)propyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.69 411.2 B 1.140 N-[2-[(4- fluorophenyl) methoxyimino] propyl]- 4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.82 437.26 B 1.141 N-[2-[(3- chlorophenyl) methoxyimino]propyl]- 4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.93 453.22 B 1.142 4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3-yl]-N-[2-[[3- (trifluoromethyl) phenyl]methoxy- imino]propyl] benzamide

1.96 487.26 B 1.143 4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3-yl]-N-[2-[[2- (trifluoromethyl) phenyl]methoxy- imino]propyl]benzamide

1.97 487.26 B 1.144 N-[2-(2- chloroallyloxy- imino)propyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.75 403.19 B 1.145 N-[2- (cyclopropyl- methoxyimino)propyl]- 4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.72 383.23 B 1.146 N-[2-(oxetan-3- yloxyimino)propyl]- 4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.4 385.21 B 1.147 N-[2-[(4- chlorophenyl) methoxyimino]propyl]- 4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.93 453.21 B 1.148 N-[2-(2- fluoroethoxyimino) ethyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

145-146 1.149 N-[(2E)-2-(2- fluoroethoxy- imino)-1-methyl-ethyl]- 4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

138-139 1.150 N-[(2Z)-2-(2- fluoroethoxyimino)- 1-methyl-ethyl]- 4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

172-173 1.151 N-[2-(2- fluoroethoxyimino) propyl]-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

133-134 1.152 N-(3- methoxyimino- propyl)-4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzamide

136-140 1.153 N-(3- ethoxyiminopropyl)- 4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzamide

132-136 1.154 N-(3- hydroxyimino- propyl)-4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzamide

180-183 1.155 2-fluoro-N-(2- methoxyimino-1- methyl-ethyl)-4- [5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

132-134 1.156 N-(2-ethoxyimino- 1-methyl-ethyl)-2- fluoro-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

113-115 1.157 2-fluoro-N-(2- methoxyimino- propyl)-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

122-124 1.158 N-(2- ethoxyiminopropyl)- 2-fluoro-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

120-122 1.159 3-fluoro-N-(2- methoxyimino-1- methyl-ethyl)-4- [5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

119-121 1.160 3-fluoro-N-(3- methoxyiminopropyl)- 4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

103-108 1.161 N-(3- ethoxyiminopropyl)- 3-fluoro-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

108-110 1.162 N-(3- ethoxyiminopropyl)- 2-fluoro-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

97-99 1.163 2-fluoro-N-(3- methoxyimino- propyl)-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

 98-100 1.164 3-fluoro-N-(2- methoxyimino- propyl)-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

131-134 1.165 N-(2- ethoxyiminopropyl)- 3-fluoro-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

120-124 1.166 3-fluoro-N-(2- methoxyimino- ethyl)-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

120-122 1.167 N-[(3E)-3-prop-2- ynoxyiminopropyl]- 4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

89-91 1.168 N-(3- isopropoxyimino- propyl)-4-[5- (trifluoromethyl)-1,2,4-oxadiazol-3- yl]benzamide

1.527 370.9 C 122-124 1.169 2-fluoro-N-(2- methoxyimino- ethyl)-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.460 346.8 C 116-118 1.170 N-cyclopropyl-N- [(2E)-2-methoxyiminoethyl]- 4-[5- (trifluoromethyl)- 1,2,4-oxadiazol-3-yl]benzamide

1.553 369 C 60-62 1.171 N-[(2E)-2- methoxyiminoethyl]- N-methyl-4-[5-(trifluoromethyl)- 1,2,4-oxadiazol-3- yl]benzamide

1.460 342.9 C

BIOLOGICAL EXAMPLES

General Examples of Leaf Disk Tests in Well Plates:

Leaf disks or leaf segments of various plant species are cut from plantsgrown in a greenhouse. The cut leaf disks or segments are placed inmultiwell plates (24-well format) onto water agar. The leaf disks aresprayed with a test solution before (preventative) or after (curative)inoculation. Compounds to be tested are prepared as DMSO solutions (max.10 mg/ml) which are diluted to the appropriate concentration with 0.025%Tween20 just before spraying. The inoculated leaf disks or segments areincubated under defined conditions (temperature, relative humidity,light, etc.) according to the respective test system. A singleevaluation of disease level is carried out 3 to 14 days afterinoculation, depending on the pathosystem. Percent disease controlrelative to the untreated check leaf disks or segments is thencalculated.

General Examples of Liquid Culture Tests in Well Plates:

Mycelia fragments or conidia suspensions of a fungus prepared eitherfreshly from liquid cultures of the fungus or from cryogenic storage,are directly mixed into nutrient broth. DMSO solutions of the testcompound (max. 10 mg/ml) are diluted with 0.025% Tween20 by a factor of50 and 10 μl of this solution is pipetted into a microtiter plate(96-well format). The nutrient broth containing the fungalspores/mycelia fragments is then added to give an end concentration ofthe tested compound. The test plates are incubated in the dark at 24° C.and 96% relative humidity. The inhibition of fungal growth is determinedphotometrically after 2 to 7 days, depending on the pathosystem, andpercent antifungal activity relative to the untreated check iscalculated.

Example 1: Fungicidal Activity Against Puccinia recondita f. sp.Tritici/Wheat/Leaf Disc Preventative (Brown Rust)

Wheat leaf segments cv. Kanzler were placed on agar in multiwell plates(24-well format) and sprayed with the formulated test compound dilutedin water. The leaf disks were inoculated with a spore suspension of thefungus 1 day after application. The inoculated leaf segments wereincubated at 19° C. and 75% relative humidity (rh) under a light regimeof 12 hours light/12 hours darkness in a climate cabinet and theactivity of a compound was assessed as percent disease control comparedto untreated when an appropriate level of disease damage appears inuntreated check leaf segments (7 to 9 days after application).

The following compounds at 200 ppm in the applied formulation give atleast 80% disease control in this test when compared to untreatedcontrol leaf disks under the same conditions, which show extensivedisease development.

Compounds (from Table T1) 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 1.10, 1.11,1.12, 1.13, 1.14, 1.15, 1.20, 1.21, 1.25, 1.29, 1.30, 1.32, 1.33, 1.36,1.37, 1.38, 1.40, 1.43, 1.45, 1.46, 1.48, 1.49, 1.50, 1.56, 1.58, 1.60,1.61, 1.62, 1.64, 1.65, 1.66, 1.67, 1.68, 1.69, 1.70, 1.71, 1.72, 1.74,1.75, 1.77, 1.78, 1.79, 1.80, 1.81, 1.82, 1.83, 1.89, 1.90, 1.91, 1.92,1.93, 1.94, 1.95, 1.97, 1.100, 1.101, 1.102, 1.103, 1.104, 1.105, 1.106,1.109, 1.110, 1.114, 1.116, 1.117, 1.118, 1.120, 1.121, 1.122, 1.123,1.124, 1.125, 1.126, 1.132, 1.133, 1.135, 1.136, 1.137, 1.138, 1.139,1.144, 1.145, 1.146, 1.148, 1.149, 1.150, 1.151, 1.152, 1.153, 1.154,1.155, 1.157, 1.158, 1.159, 1.160, 1.161, 1.162, 1.163, 1.164, 1.165,1.166, 1.167, and 1.168.

Example 2: Fungicidal Activity Against Puccinia recondita f. sp.Tritici/Wheat/Leaf Disc Curative (Brown Rust)

Wheat leaf segments cv. Kanzler are placed on agar in multiwell plates(24-well format). The leaf segments are then inoculated with a sporesuspension of the fungus. Plates were stored in darkness at 19° C. and75% relative humidity. The formulated test compound diluted in water wasapplied 1 day after inoculation. The leaf segments were incubated at 19°C. and 75% relative humidity under a light regime of 12 hours light/12hours darkness in a climate cabinet and the activity of a compound wasassessed as percent disease control compared to untreated when anappropriate level of disease damage appears in untreated check leafsegments (6 to 8 days after application).

The following compounds at 200 ppm in the applied formulation give atleast 80% disease control in this test when compared to untreatedcontrol leaf disks under the same conditions, which show extensivedisease development.

Compounds (from Table T1) 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9,1.10, 1.11, 1.12, 1.13, 1.14, 1.15, 1.16, 1.17, 1.18, 1.19, 1.20, 1.21,1.29, 1.32, 1.33, 1.36, 1.37, 1.38, 1.43, 1.46, 1.58, 1.60, 1.66, 1.70,1.72, 1.74, 1.77, 1.78, 1.81, 1.82, 1.89, 1.91, 1.94, 1.95, 1.100,1.101, 1.102, 1.104, 1.110, 1.114, 1.116, 1.117, 1.120, 1.125, 1.126,1.133, 1.135, 1.138, 1.145, 1.146, 1.148, 1.149, 1.150, 1.151, 1.152,1.153, 1.154, 1.156, 1.157, 1.158, 1.159, 1.160, 1.161, 1.162, 1.163,1.164, 1.165, 1.166, 1.167, and 1.168.

Example 3: Fungicidal Activity Against Phakopsorapachyrhizi/Soybean/Leaf Disc Preventative (Asian Soybean Rust)

Soybean leaf disks are placed on water agar in multiwell plates (24-wellformat) and sprayed with the formulated test compound diluted in water.One day after application leaf discs are inoculated by spraying a sporesuspension on the lower leaf surface. After an incubation period in aclimate cabinet of 24-36 hours in darkness at 20° C. and 75% rh leafdisc are kept at 20° C. with 12 hours light/12 hours and 75% rh. Theactivity of a compound is assessed as percent disease control comparedto untreated when an appropriate level of disease damage appears inuntreated check leaf disks (12 to 14 days after application).

The following compounds at 200 ppm in the applied formulation give atleast 80% disease control in this test when compared to untreatedcontrol leaf disks under the same conditions, which show extensivedisease development.

Compounds (from Table T1) 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 1.10,1.11, 1.12, 1.13, 1.14, 1.15, 1.16, 1.17, 1.19, 1.21, 1.22, 1.23, 1.24,1.25, 1.27, 1.30, 1.33, 1.34, 1.36, 1.40, 1.43, 1.45, 1.46, 1.47, 1.48,1.50, 1.51, 1.52, 1.56, 1.57, 1.58, 1.59, 1.60, 1.61, 1.62, 1.63, 1.64,1.65, 1.66, 1.67, 1.68, 1.69, 1.70, 1.71, 1.72, 1.73, 1.74, 1.75, 1.78,1.79, 1.80, 1.81, 1.82, 1.83, 1.84, 1.85, 1.89, 1.90, 1.91, 1.92, 1.94,1.95, 1.100, 1.101, 1.102, 1.104, 1.110, 1.114, 1.116, 1.118, 1.121,1.122, 1.123, 1.124, 1.126, 1.128, 1.132, 1.133, 1.134, 1.135, 1.138,1.139, 1.144, 1.145, 1.146, 1.148, 1.149, 1.150, 1.151, 1.152, 1.153,1.154, 1.155, 1.156, 1.157, 1.158, 1.159, 1.160, 1.161, 1.162, 1.163,1.164, 1.165, 1.166, 1.167, and 1.168.

Example 4: Fungicidal Activity Against Glomerella lagenarium(Colletotrichum lagenarium) Liquid Culture/Cucumber/Preventative(Anthracnose)

Conidia of the fungus from cryogenic storage are directly mixed intonutrient broth (PDB—potato dextrose broth). After placing a (DMSO)solution of test compound into a microtiter plate (96-well format), thenutrient broth containing the fungal spores is added. The test platesare incubated at 24° C. and the inhibition of growth is measuredphotometrically 3 to 4 days after application.

The following compounds at 20 ppm in the applied formulation give atleast 80% disease control in this test when compared to untreatedcontrol under the same conditions, which show extensive diseasedevelopment.

Compounds (from Table T1) 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9,1.10, 1.11, 1.12, 1.13, 1.14, 1.15, 1.17, 1.20, 1.22, 1.24, 1.25, 1.27,1.29, 1.30, 1.32, 1.33, 1.34, 1.36, 1.37, 1.38, 1.40, 1.43, 1.45, 1.46,1.47, 1.48, 1.49, 1.50, 1.51, 1.52, 1.56, 1.57, 1.58, 1.60, 1.62, 1.64,1.65, 1.66, 1.67, 1.68, 1.69, 1.70, 1.71, 1.72, 1.74, 1.75, 1.77, 1.78,1.79, 1.80, 1.81, 1.82, 1.83, 1.85, 1.89, 1.90, 1.91, 1.92, 1.93, 1.94,1.95, 1.96, 1.100, 1.101, 1.102, 1.104, 1.106, 1.108, 1.109, 1.110,1.112, 1.114, 1.116, 1.117, 1.118, 1.120, 1.121, 1.122, 1.123, 1.124,1.125, 1.126, 1.128, 1.132, 1.133, 1.134, 1.135, 1.136, 1.137, 1.138,1.139, 1.140, 1.144, 1.145, 1.146, 1.148, 1.149, 1.150, 1.151, 1.152,1.153, 1.154, 1.155, 1.156, 1.157, 1.158, 1.159, 1.160, 1.161, 1.162,1.163, 1.164, 1.165, 1.166, 1.167, and 1.168.

Example 5: Fungicidal Activity Against Uromyces viciae-fabae/FieldBean/Leaf Disc Preventative (Faba-Bean Rust)

Field bean leaf discs are placed on water agar in multiwell plates(96-well format) and 10 μl of the formulated test compound diluted inacetone and a spreader pipetted onto the leaf disc. Two hours afterapplication leaf discs are inoculated by spraying a spore suspension onthe lower leaf surface. The leaf discs are incubated in a climatecabinet at 22° C. with 18 hour day and 70% relative humidity. Theactivity of a compound is assessed as percent disease control comparedto untreated when an appropriate level of disease damage appears inuntreated check leaf disks (12 days after application).

The following compounds at 100 ppm in the applied formulation give atleast 80% disease control in this test when compared to untreatedcontrol leaf discs under the same conditions, which show extensivedisease development.

Compounds (from Table T1) 1.1, 1.2, 1.3, and 1.4.

The invention claimed is:
 1. A compound of formula (I)

wherein n is 0; each of A², A³ and A⁴ represents C—H, and A¹ representsCR¹, wherein R¹ is fluoro; R⁵ is hydrogen; R⁸ represents C₁₋₆alkyl; R⁹represents hydrogen, C₁₋₁₂alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,C₁₋₄haloalkyl, C₂₋₄haloalkenyl, hydroxyC₁₋₄alkyl, cyanoC₁₋₄alkyl,C₁₋₄alkoxyC₁₋₄alkyl, hydroxycarbonylC₁₋₄alkyl,C₁₋₄alkoxycarbonylC₁₋₄alkyl, aminoC₁₋₄alkyl, C₃-scycloalkyl,C₃₋₈cycloalkylC₁₋₃alkyl, phenyl, phenylC₁₋₄alkyl, heterocyclyl orheterocyclylC₁₋₄alkyl wherein the heterocyclyl moiety is a 4- to6-membered non-aromatic ring which comprises 1, 2 or 3 heteroatomsindividually selected from N, O and S, and wherein C₃₋₈cycloalkyl,phenyl and heterocyclyl moieties are optionally substituted by 1, 2, or3 substituents, which may be the same or different, selected from R¹⁰,or 1, 2, 3, 4 or 5 substituents, which may be the same or different,selected from R¹¹; R¹⁰ represents cyano, nitro, C₁₋₆alkyl, C₂₋₆alkenyl,C₂₋₆alkynyl, C₁₋₆haloalkyl, C₁₋₆alkoxy, C₁₋₆haloalkoxy, C₁₋₆alkylthio,C₁₋₄alkoxycarbonylC₁₋₄alkyl, hydroxycarbonylC₁₋₄alkyl, orC₃₋₈cycloalkyl; and R¹¹ represents halogen; or a salt or an N-oxidethereof.
 2. A compound of formula (I):

wherein n is 1; each of A², A³ and A⁴ represents C—H, and A¹ representsCR¹, wherein R¹ is fluoro; R⁵ is hydrogen; R⁶ is hydrogen and R⁷ isselected from methyl and methoxy; R⁸ represents hydrogen; R⁹ representshydrogen, C₁₋₁₂alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₄haloalkyl,C₂₋₄haloalkenyl, hydroxyC₁₋₄alkyl, cyanoC₁₋₄alkyl, C₁₋ ₄alkoxyC₁₋₄alkyl,hydroxycarbonylC₁₋₄alkyl, C₁₋₄alkoxycarbonylC₁₋₄alkyl, aminoC₁₋₄alkyl,C₃-scycloalkyl, C₃₋₈cycloalkylC₁₋₃alkyl, phenyl, phenylC₁₋₄alkyl,heterocyclyl or heterocyclylC₁₋₄alkyl wherein the heterocyclyl moiety isa 4- to 6-membered non-aromatic ring which comprises 1, 2 or 3heteroatoms individually selected from N, O and S, and whereinC₃₋₈cycloalkyl, phenyl and heterocyclyl moieties are optionallysubstituted by 1, 2, or 3 substituents, which may be the same ordifferent, selected from R¹⁰, or 1, 2, 3, 4 or 5 substituents, which maybe the same or different, selected from R¹¹; R¹⁰ represents cyano,nitro, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, C₁₋₆alkoxy,C₁₋₆haloalkoxy, C₁₋₆alkylthio, C₁₋₄alkoxycarbonylC₁₋₄alkyl,hydroxycarbonylC₁₋₄alkyl, or C₃₋₈cycloalkyl; and R¹¹ represents halogen;or a salt or an N-oxide thereof.
 3. A compound of formula (I):

wherein n is 2; each of A², A³ and A⁴ represents C—H, and A¹ representsCR¹, wherein R¹ is fluoro; R⁵ is hydrogen; R⁶ and R⁷ are independentlyselected from hydrogen, cyano, C₁₋₄alkyl, C₁₋₄haloalkyl, C₃₋₆cycloalkyland C₁₋₄alkoxy; R⁸ represents hydrogen; R⁹ represents hydrogen,C₁₋₁₂alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₄haloalkyl, C₂₋₄haloalkenyl,hydroxyC₁₋₄alkyl, cyanoC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkyl,hydroxycarbonylC₁₋₄alkyl, C₁₋₄alkoxycarbonylC₁₋₄alkyl, aminoC₁₋₄alkyl,C₃₋₈cycloalkyl, C₃₋₈cycloalkylC₁₋₃alkyl, phenyl, phenylC₁₋₄alkyl,heterocyclyl or heterocyclylC₁₋₄alkyl wherein the heterocyclyl moiety isa 4- to 6-membered non-aromatic ring which comprises 1, 2 or 3heteroatoms individually selected from N, O and S, and whereinC₃₋₈cycloalkyl, phenyl and heterocyclyl moieties are optionallysubstituted by 1, 2, or 3 substituents, which may be the same ordifferent, selected from R¹⁰, or 1, 2, 3, 4 or 5 substituents, which maybe the same or different, selected from R¹¹; R¹⁰ represents cyano,nitro, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, C₁₋₆alkoxy,C₁₋₆haloalkoxy, C₁₋₆alkylthio, C₁₋₄alkoxycarbonylC₁₋₄alkyl,hydroxycarbonylC₁₋₄alkyl, or C₃₋₈cycloalkyl; and R¹¹ represents halogen;or a salt or an N-oxide thereof.
 4. The compound according to claim 3,wherein R⁶ and R⁷ are independently selected from hydrogen, C₁₋₄alkyland C₁₋₄alkoxy.
 5. The compound according to claim 3, wherein R⁶ and R⁷are independently selected from hydrogen, methyl and methoxy.
 6. Thecompound according to any one of claims 1, 2, and 3, wherein R⁹ ishydrogen, C₁₋₁₂alkyl, C₁₋₄haloalkyl, hydroxyC₁₋₄alkyl, C₂₋₆alkenyl,C₂₋₆alkynyl, C₂₋₄haloalkenyl, C₁₋₄alkoxycarbonylC₁₋₄alkyl,C₃₋₈cycloalkylC₁₋₃alkyl, phenyl, benzyl, oxetanyl, tetrahydrofuranyl ortetrahydropyranyl, wherein phenyl moieties are optionally substituted by1, 2 or 3 substituents, which may be the same or different, selectedfrom R¹⁰, or 1, 2, 3, 4 or 5 substituents, which may be the same ordifferent, selected from R¹¹.
 7. The compound according to claim 6,wherein R¹⁰ is selected from methyl, nitro, methoxy,methoxycarbonylmethyl and trifluoromethyl and R¹¹ is selected fromfluoro, chloro and bromo.
 8. The compound according to any one of claims1, 2, and 3, wherein R⁹ is hydrogen, C₁₋₆alkyl, C₁₋₄haloalkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, or C₃₋₈cycloalkylC₁₋₃alkyl.
 9. The compoundaccording to claim 8, wherein R⁹ is methyl, ethyl, isopropyl, t-butyl,2,2,2-trifluoroethyl, or cyclopropylmethyl.
 10. An agrochemicalcomposition comprising a fungicidally effective amount of a compound offormula (I) according to any one of claims 1, 2, and
 3. 11. Thecomposition according to claim 10, further comprising at least oneadditional active ingredient and/or an agrochemically-acceptable diluentor earner.
 12. A method of controlling infestation of useful plants byphytopathogenic microorganisms, comprising, applying a fungicidallyeffective amount of a compound of formula (I) according to any one ofclaims 1, 2, and 3, or a composition comprising this compound as activeingredient, is applied to the plants, to parts thereof or the locusthereof.
 13. The compound according to any one of claims 1, 2, and 3,wherein R⁹ represents C₃₋₈cycloalkyl, C₃₋₈cycloalkylC₁₋₃alkyl, phenyl,phenylC₁₋₄alkyl, heterocyclyl or heterocyclylC₁₋₄alkyl wherein theheterocyclyl moiety is a 4- to 6-membered non-aromatic ring whichcomprises 1, 2 or 3 heteroatoms individually selected from N, O and S,and wherein C₃₋₈cycloalkyl, phenyl and heterocyclyl moieties areoptionally substituted by 1, 2, or 3 substituents, which may be the sameor different, selected from R¹⁰, or 1, 2, 3, 4 or 5 substituents, whichmay be the same or different, selected from R¹¹; R¹⁰ represents cyano,nitro, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆haloalkyl, C₁₋₆alkoxy,C₁₋₆haloalkoxy, C₁₋₆alkylthio, C₁₋₄alkoxycarbonylC₁₋₄alkyl,hydroxycarbonylC₁₋₄alkyl, or C₃₋₈cycloalkyl; and R¹¹ represents halogen.14. The compound according to any one of claims 1, 2, and 3, wherein R⁹represents hydroxyC₁₋₄alkyl, cyanoC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkyl,hydroxycarbonylC₁₋₄alkyl, C₁₋₄alkoxycarbonylC₁₋₄alkyl, oraminoC₁₋₄alkyl.
 15. A compound selected from the group consisting of:


16. The compound of claim 15, wherein the compound is selected from thegroup consisting of:


17. The compound of claim 15, wherein the compound is selected from thegroup consisting of: